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ABSTRACT	  DNA	   resection	   is	   a	   highly	   conserved	   biological	   process	   that	   protects	   the	  genome.	   	   It	   links	   DNA	   damage	   to	   checkpoint	   activation	   and	   is	   required	   for	   the	  homologous	  recombination	  (HR)	  pathway.	   	  The	  relatively	  recent	  discovery	  of	  CtIP,	  EXO1,	  and	  DNA2	  as	  the	  nucleases	  responsible	  for	  DNA	  resection	  in	  the	  HR	  pathway,	  has	  generated	  significant	  interest	  in	  this	  field	  of	  DNA	  repair.	  	  The	  majority	  of	  studies	  depend	   upon	   “knockdowns”	   via	   the	   use	   of	   siRNA	   to	   address	   the	   function	   of	   CtIP,	  EXO1,	  and	  DNA2,	  and	  then	  usually	  only	  in	  the	  presence	  of	  exogenous	  DNA	  damage.	  	  With	  our	  conditionally-­‐null	  knockout	  human	  cell	  lines,	  we	  find	  that	  CtIP,	  EXO1,	  and	  DNA2	   are	   essential	   in	   human	   somatic	   cells	   and	   that	   they	   are	   required	   for	   normal	  DNA	   replication	   fork	  progression	   even	   in	   the	   absence	   of	   exogenous	  DNA	  damage.	  	  Furthermore,	   we	   find	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	   co-­‐regulated	   and	   that	   they	  coordinately	   regulate	   the	   stability	   of	   FANCD2,	  BRCA2,	  Rad51,	   and	  CHK1.	   	   Current	  chemotherapeutic	  drugs	  work	  by	   inhibiting	  DNA	  replication.	   	  Since	  HR	  is	  required	  for	   the	   repair	   of	   damaged	   replication	   forks,	   the	   process	   of	   DNA	   resection	   is	   a	  promising	  drug	  target,	  either	  alone	  or	   in	  combination	  in	  combination	  with	  current	  chemotherapeutic	   drugs.	   	   Therefore,	   it	   is	   important	   that	   we	   understand	   the	  mechanisms	  and	  regulation	  of	  CtIP,	  EXO1,	  and	  DNA2.	  	   The	  nonhomologous	   end-­‐joining	  pathway	   (NHEJ)	   is	   subdivided	   into	   a	  Ku	   –dependent	  pathway	   {Classical	  NHEJ	   (C-­‐NHEJ)}	   and	  a	  Ku-­‐independent,	   {Alternative	  NHEJ	  (A-­‐NHEJ)}.	  	  C-­‐NHEJ	  repair	  normally	  dominates	  in	  human	  cells	  but	  how	  or	  why	  this	  happens	  has	  remained	  obscure.	  	  Using	  C-­‐	  NHEJ	  loss-­‐of-­‐function	  mutant	  cell	  lines	  for	   Ku86,	   LIGIV,	   DNA-­‐PKcs,	   and	   XLF,	   we	   found	   that	   Ku86	   uniquely	   and	   strongly	  represses	   the	  A-­‐NHEJ	  pathway,	  which	  suggests	   that	  Ku86	  regulates	  DSB	  repair	  by	  controlling	  pathway	  choice	  decisions.	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Introduction	  The	  human	  genome	  has	  been	  determined	  to	  be	  3	  billion	  base	  pairs	  in	  length	  and	  it	  encodes	  20,000	  genes	  that	  reside	  in	  23	  pairs	  of	  chromosomes.	  	  Impressively,	  all	   this	   DNA	   is	   contained	  within	   each	   and	   every	   one	   of	   the	   3.7	   x	   1013	  cells1-­‐6	   that	  make	   up	   a	   human	   body.	   	   Ironically	   (and	   tragically),	   it	   only	   takes	   as	   little	   as	   one	  mutation	  of	  one	  gene	  in	  one	  cell	  to	  take	  life	  away.	  	  In	  a	  multi-­‐cellular	  organism,	  cells	  are	  organized	  into	  tissues	  and	  organs	  such	  that	  they	  regulate	  each	  other’s	  growth	  and	  proliferation.	  	  In	  an	  environment	  where	  cells	   are	   required	   to	   proliferate,	   mitogens	   are	   secreted	   to	   signal	   cells	   in	   a	   G0	  quiescent	  state	  to	  enter	  the	  cell	  cycle1,7.	  	  The	  active	  phases	  of	  the	  cell	  cycle	  consist	  of	  G1-­‐,	   S-­‐,	   G2-­‐	   and	  M-­‐phases1.	   	   In	   general,	   G1	   cells	   prepare	   the	   cell	   to	   enter	   S-­‐phase	  where	   DNA	   replication	   occurs	   to	   copy	   the	   genome	   only	   once8.	   	   When	   DNA	  replication	  is	  complete	  in	  S-­‐phase,	  the	  cell	  enters	  the	  G2-­‐phase	  where	  it	  ensures	  that	  replication	   and	   repair	   is	   complete	   before	   entering	   M-­‐phase.	   	   In	   M-­‐phase,	   the	  duplicated	  genome	  is	  first	  segregated	  equally	  into	  two	  portions	  that	  will	  eventually	  be	  transmitted	  to	  the	  two	  daughter	  cells8.	  DNA	  damage	  can	  occur	  in	  all	  phases	  of	  the	  cell	  cycle.	  	  Of	  the	  various	  forms	  of	  DNA	  damage,	  DNA	  double-­‐stranded	  breaks	   (DSBs)	  pose	   the	   greatest	   threat	   to	   the	  cellular	   genome	   because	   they	   are	   lethal	   or	   mutagenic	   when	   unrepaired	   or	  misrepaired,	   respectively1.	   	   DSBs	   can	   arise	   exogenously	   from	   factors	   such	   as	  ionizing	   radiation	   (IR)	   exposure.	   	   Alternatively,	   DSBs	   can	   also	   arise	   from	  endogenous	  metabolic	  processes.	  	  One	  such	  process	  is	  DNA	  replication.	  	  When	  DNA	  replication	   forks	   stall	   for	   long	  periods	  of	   time	   they	   can	   collapse	   into	  DSBs9,10.	   	   To	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manage	   such	   threats,	   the	   cell	   has	   evolved	   checkpoint	  mechanisms	   that	   arrest	   cell	  cycle	   progression	   to	   provide	   sufficient	   time	   to	   repair	   the	   DSBs.	   	   When	   these	  checkpoints	  fail,	  cell	  cycle	  progression	  with	  incomplete	  repair	  results	   in	  mutations	  and	  genomic	  instability1,9,10.	  	  Importantly,	  the	  cell	  is	  equipped	  with	  at	  least	  two	  DSB	  repair	   mechanisms:	   homologous	   recombination	   (HR)	   and	   nonhomologous	   end-­‐joining	  (NHEJ)	  pathways.	  	  The	  HR	  pathway	  requires	  an	  intact	  template	  homologous	  to	   the	  broken	  chromosome	   for	  error-­‐free	   repair11.	   	   In	   contrast,	   the	  NHEJ	  pathway	  does	  not	  require	  a	  homologous	  template	  but	  simply	  rejoins	  two	  ends	  of	  broken	  DNA	  together;	   however,	   unfortunately	   NHEJ	   is	   often	   error	   prone,	   which	   can	   result	   in	  mutagenesis12.	  	   One	  of	   the	  major	  mechanistic	  distinctions	  between	  HR	  and	  NHEJ	   is	   that	  HR	  generally	   requires	   extensive	   resection	   of	   the	   DNA	   ends	  whereas	   C-­‐NHEJ	   requires	  little	  or	  no	   resection.	   	  DNA	  resection	   is	  a	   conserved	  biological	  process	   that	   is	  also	  linked	   to	   checkpoint	   activation.	   	   A	   trio	   of	   nucleases	   CtIP,	   EXO1,	   and	   DNA2	   are	  implicated	  in	  DNA	  resection	  and	  are	  presumed	  to	  generate	  the	  single-­‐stranded	  DNA	  (ssDNA)	   ends	   that	   are	   required	   for	   the	   HR	   repair	   of	   DSBs13-­‐16.	   	   Besides	   being	  required	  for	  DSB	  repair,	  the	  essential	  function(s)	  and	  regulation	  of	  these	  nucleases	  has	  not	  been	   thoroughly	   investigated	   in	  human	  cells	  and	  will	  be	  addressed	   in	   this	  study.	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The	  Most	  Lethal	  Form	  Of	  DNA	  Damage:	  DNA	  Double-­‐Stranded	  Breaks	  (DSBs)	  
	   	  On	  a	  daily	  basis,	  a	  cell	  is	  confronted	  by	  numerous	  exogenous	  and	  endogenous	  events	  that	  cause	  DNA	  damage	  that	  includes	  ssDNA	  breaks,	  the	  formation	  of	  bulky	  adducts,	  mismatched	  base	  pairing,	  and	  DNA	  DSBs.	  	  DSBs	  hold	  the	  greatest	  threat	  to	  cellular	   survival	   and	   fitness	  because	   they	   can	   trigger	   either	   cell	   death	  or	   genomic	  instability,	   respectively1.	   	   Reactive	   oxidative	   species	   (ROS)	   from	   endogenous	  metabolites	   or	   exogenous	   sources,	   such	   as	   IR,	   randomly	   breaks	   sugar-­‐phosphate	  bonds	  on	  the	  backbones	  of	  both	  DNA	  strands.	  	  When	  the	  breaks	  occur	  close	  enough	  to	  each	  other,	   the	  strands	  can	  separate	   into	   two	   free	  ends,	  which	   is	  classified	  as	  a	  DSB17.	  	  	  Not	  all	  DSBs	  are	  random,	  nor	  harmful	  however.	  	  Thus,	  programmed	  DSBs	  are	  also	   produced	   during	   V(D)J	   recombination	   which	   is	   required	   for	   antibody	  diversification	  in	  developing	  T-­‐	  and	  B-­‐	  cells	  of	  our	  immune	  system18.	  	  Programmed	  DSBs	  in	  the	  immune	  system	  rely	  on	  the	  C-­‐NHEJ	  pathway	  for	  repair,	  and	  mutations	  in	  any	  of	  the	  genes	  that	  compromise	  the	  C-­‐NHEJ	  pathway	  result	  in	  patients	  with	  severe	  combined	  immunodeficiency	  syndromes	  (SCID)19.	  DNA	  replication	  is	  a	  major	  source	  of	  endogenous	  (and	  decidedly	  unwanted)	  DSBs9,10.	   	  Replication	  forks	  can	  spontaneously	  stall	  when	  they	  encounter	  lesions	  or	  regions	   that	   are	   difficult	   to	   replicate.	   	   Highly	   repetitive	   regions	   in	   the	   human	  genome	  are	  often	  difficult	  to	  replicate.	  	  These	  include	  trinucleotide	  repeats	  (TNRs),	  telomeres,	   LINE,	   or	   ALU	   repeat	   elements	   that	   can	   transiently	   form	   complex	   DNA	  structures	   at	   periods	   when	   they	   become	   single-­‐stranded20-­‐22.	   	   During	   DNA	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replication,	   these	   transient	   complex	   DNA	   structures,	   such	   as	   hairpins,	   triplex	   and	  quadruplex	   DNA	   can	   trigger	   replication	   fork	   stalling2,4-­‐6.	   	   During	   DNA	   replication,	  these	   transient	   complex	  DNA	   structures,	   such	   as	   hairpins,	   triplex	   and	   quadruplex	  DNA	   can	   trigger	   replication	   fork	   stalling2-­‐6.	   	   Stalled	   forks	   are	   stabilized	   and	   then	  restarted	   by	   the	   ATR-­‐CHK1	   signaling	   pathway9-­‐11,23,	   which	   involve	   the	   HR	   and	  Fanconi	  anemia	  pathways24,25.	   	   Importantly,	   if	   the	  stalled	  forks	  are	  not	  repaired	  or	  restarted	   in	  a	   timely	   fashion,	  endonucleases	  can	  cleave	  exposed	  ssDNA	  replication	  forks,	  which	  results	  in	  the	  formation	  of	  a	  DSB9,10,26,27.	  Regardless	   of	   the	   source,	   DSBs	   must	   be	   repaired;	   otherwise,	   they	   lead	   to	  mutations,	   genomic	   instability	   or	   cell	   death28.	   	   To	   counter	   this	   threat,	   organisms	  have	  evolved	  specialized	  DNA	  repair	  pathways	  to	  fix	  the	  damaged	  DNA.	  	  DSB	  repair	  is	  a	  challenging	  process	  because	  it	  is	  no	  simple	  task	  to	  accurately	  rejoin	  two	  ends	  of	  DNA	   that	   are	   in	   motion.	   	   Metaphorically	   speaking,	   DSB	   repair	   would	   be	   as	  challenging	  as	  accurately	  joining	  two	  ends	  of	  a	  broken	  thread,	  without	  using	  knots.	  	  In	  human	  cells,	  DSBs	  are	  repaired	  by	  the	  NHEJ12,29	  or	  the	  HR	  pathways11.	  	  These	  two	  DSB	   repair	   pathways	   are	   mechanistically	   distinct.	   	   NHEJ	   directly	   re-­‐ligates	   the	  broken	  ends	  of	  DNA	  in	  a	  manner	  that	  can	  be	  error	  prone2,12	  thus	  leading	  to	  the	  loss	  of	   genetic	   information.	   	   In	   contrast,	   HR	   repairs	   DSBs	   by	   “copying”	   genetic	  information	   that	  was	   lost	   at	   the	   site	   of	   the	  DSB	   from	   an	   undamaged	   homologous	  template	  for	  repair.	  	  As	  a	  result,	  HR	  repair	  is	  generally	  an	  error-­‐free	  repair	  pathway	  that	  restores	  genetic	  information11.	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Cell	  Cycle	  Checkpoints	  	  	   Since	   the	   genome	   is	   constantly	   challenged	   with	   DNA	   damage,	   cells	   are	  equipped	   with	   G1-­‐,	   S-­‐,	   and	   G2-­‐checkpoints	   to	   sense	   DNA	   damage	   and	   delay	   the	  progression	  of	   the	  cell	  cycle30.	   	  Checkpoints	  essentially	  extend	  the	  cell	  cycle	  phase	  where	  DNA	  damage	  has	  occurred	  and	  hence	  they	  provide	  the	  cell	  with	  a	  window	  of	  time	  to	  repair	  the	  damaged	  DNA	  before	  moving	  on	  to	  the	  next	  cell	  cycle	  phase1,9,31	  	  .	  	  A	  cell	   that	  proceeds	   to	   the	  next	  cell	   cycle	  phase	  with	   incomplete	  repair	  will	   suffer	  from	   genomic	   instability,	   mutations,	   and	   even	   apoptosis30.	   	   The	   ATM-­‐CHK2	   and	  ATR-­‐CHK1	   pathways	   primarily	   govern	   cell	   cycle	   checkpoints	   by	   sensing	   the	   DNA	  damage,	   transmitting	   the	   signal	   to	   arrest	   the	   cell	   cycle	   and	   then	   facilitating	   DNA	  repair1,32.	  	  The	  ATM-­‐CHK2	  pathway	  is	  primarily	  responsive	  to	  DSBs	  while	  the	  ATR-­‐CHK1	   pathway	   is	   extremely	   responsive	   to	   DNA	   damage	   with	   exposed	   tracts	   of	  ssDNA	  such	  as	  occurs	  at	  stalled	  DNA	  replication	  forks9.	  	  	  DNA	  damage	   in	  G1	   triggers	  G1	  checkpoint	  activation.	   	  How	  DNA	  damage	   is	  sensed	  is	  still	  biochemically	  vague.	  	  What	  is	  clear,	  however,	  is	  that	  sensing	  activates	  ATM,	  which,	  in	  turn	  phosphorylates	  and	  activates	  p53.	  	  The	  phosphorylation	  of	  p53,	  an	   established	   tumor	   suppressor,	   extends	   the	   half-­‐life	   of	   the	   p53	   protein	   and	  increases	   its	   transcriptional	   activity	   for	   various	   target	   genes30.	   	   To	   arrest	   the	   cell	  cycle,	  p53	  increases	  the	  transcription	  of	  p21/CIP130.	  	  As	  p21/CIP1	  levels	  increase	  in	  the	   cell,	   it	   deactivates	   Cdk2/Cylin	   E	   to	   arrest	   the	   cells	   in	   G1	   and	   prevent	   the	  transition	   into	   S-­‐phase.	   	   NHEJ	   repairs	   the	   majority	   of	   G1-­‐phase	   DSBs	   by	   default	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because	  there	  are	  no	  sister	  chromatids	  for	  the	  HR	  pathway12,33.	  	  Once	  the	  damage	  is	  repaired,	  the	  cell	  resumes	  its	  cell	  cycle	  progression.	  The	   S-­‐phase	   checkpoint	   is	   considerably	   more	   complicated	   than	   the	   G1-­‐checkpoint.	  	  Safeguarding	  a	  genome	  that	  is	  actively	  doubling	  in	  size	  is	  intuitively,	  a	  complex	  process.	   	   In	  S-­‐phase,	  an	  estimated	  30,000	  to	  50,000	  origins	  of	   replication	  are	  initiated,	  which	  translates	  to	  60,000	  to	  100,000	  replication	  forks34.	  	  Damaged	  or	  stalled	  replication	  forks	  are	  complex	  DNA	  structures	  with	  vulnerable,	  naked	  ssDNA,	  which	   can	   collapse	   into	   dangerous	   DSBs	   if	   these	   structures	   continue	   to	   persist9.	  	  Clearly,	   it	   is	   in	   the	   cell’s	  best	   interest	   to	   repair	   and	   restart	   these	   forks	   in	  a	   timely	  fashion.	   	  Furthermore,	   if	   the	  cell	   transitions	   into	   the	  G2/M	  phase	  with	   incomplete	  DNA	   repair	   and/or	   replication,	   the	   cell	  will	   suffer	   from	  mutations,	   loss	   of	   genetic	  information	   and	   genomic	   instability.	   	   The	   S-­‐phase	   checkpoint	   safeguards	   the	   cell	  genome	  by	  providing	  the	  cell	  time	  to	  repair	  and	  complete	  replication	  by	  delaying	  S-­‐phase	  progression23,35.	  Although	   the	   details	   of	   fork	   re-­‐start/repair	   need	   to	   be	   elucidated,	  many	   of	  the	  general	  steps	  are	  already	  known.	  	  At	  stalled	  replication	  forks,	  stretches	  of	  naked	  ssDNA	  are	  exposed	  and	   subsequently	   coated	  by	  RPA.	   	  RPA-­‐coated	   ssDNA,	   in	   turn,	  recruits	   TOPBP1,	   Rad17,	   and	   the	   9-­‐1-­‐1	   complex,	   whose	   job	   it	   is	   to	   mediate	   the	  recruitment	   of	  ATR-­‐ATRIP9,35.	   	   Claspin,	  which	   is	   normally	   associated	  with	  moving	  replication	   forks,	   mobilizes	   from	   stalled	   forks	   to	   interact	   with	   ATR-­‐ATRIP	   and	  mediate	  the	  phosphorylation	  of	  the	  CHK1	  kinase	  at	  serine	  345	  and	  serine	  31736-­‐38.	  	  Phosphorylated	  CHK1	   is	   the	  direct	  activator	  of	   the	  S-­‐phase	  checkpoint.	   	   Similar	   to	  the	   G1-­‐checkpoint,	   S-­‐phase	   checkpoint	   prevents	   progression	   into	   G2/M-­‐phase	   by	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inhibiting	  S-­‐	   to	  G2-­‐phase	  promoting	   factors.	   	   In	   this	   case,	  Cdc25A	  and	  Cdc25C	  are	  phosphorylated	   by	   CHK1,	   which	   signals	   them	   for	   protein	   degradation	   and	  sequestration	  by	  14-­‐3-­‐3,	  respectively32.	  	  In	  a	  situation	  where	  stalled	  forks	  collapses	  into	  DSBs,	   the	  ATM-­‐CHK2	  pathway	   is	  also	  activated	  which	   further	  prolongs	   the	  S-­‐phase	  delay9.	  After	   DNA	   replication	   is	   complete,	   the	   cell	   enters	   the	   G2-­‐phase	   where	   it	  prepares	   itself	   for	   cell	   division	   in	   the	   mitotic	   (M-­‐)	   phase.	   	   In	   M-­‐phase,	   the	   cell	  segregates	   its	   newly	   duplicated	   genome	   and	   physically	   pinches	   itself	   in	   two,	  producing	   a	   daughter	   cell	   with	   an	   identical	   set	   of	   genes.	   	   The	   G2/M-­‐checkpoint	  surveys	   the	   genome	   one	   final	   time	   for	   any	   unrepaired	   damage31.	   	   Both	   the	   ATR-­‐CHK1	   and	   ATM-­‐CHK2	   pathways	   activate	   the	   G2/M	   checkpoints	   by	   upregulating	  factors	  that	  deactivate	  the	  Cdc25	  family	  of	  phosphatases,	  which	  promote	  cell	  cycle	  progression	   as	  described	   above.	   	  As	   a	   result,	   Cdk1/Cyclin	  B,	   the	   cyclin-­‐dependent	  kinase,	   which	   promote	   G2/M	   progression	   remains	   inactive,	   thereby	   arresting	   the	  cell	   in	  G232.	   	  When	  cells	  arrest	   in	  either	  S-­‐	  or	  G2/M-­‐phases	   the	  HR	  pathway	   is	   the	  preferred	   mechanism	   to	   repair	   damaged	   DNA	   because	   sister	   chromatids	   are	  available	  after	  DNA	  replication33.	   	  Moreover,	  damaged	  and	  stalled	  DNA	  replication	  forks	  are	  complex	  structures	  that	  require	  the	  precision	  of	  HR	  to	  repair	  and	  restart,	  without	  losing	  any	  genetic	  information26.	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DNA	  Replication:	  How	  The	  Cell	  Copies	  And	  Protects	  Its	  Genome	  
	   When	  a	  cell	   is	  prompted	  to	  enter	  the	  active	  cell	  cycle	  to	  proliferate,	   it	  must	  duplicate	  all	  3	  billion	  base	  pairs	  of	  genetic	  material,	  through	  DNA	  replication.	  	  DNA	  replication	  is	  a	  critical	  biological	  process	  that	  occurs	  in	  the	  S-­‐phase	  of	  cell	  cycle	  with	  the	  purpose	  of	  making	  a	  “copy”	  of	  its	  genome.	  	  The	  genome	  must	  be	  copied	  with	  the	  highest	   fidelity;	   otherwise,	   harmful	   mutations	   may	   be	   passed	   on	   to	   the	   future	  generations8,39.	  	  In	   the	  G1-­‐phase,	   the	  cell	  prepares	   for	  DNA	  replication.	   	   It	   is	  during	  G1	   that	  ORCS,	   Cdt1	   and	   Cdc6	   proteins	   load	   the	  MCM2-­‐7	   helicase	   complexes	   on	   to	   unique	  sequences	   called	   replication	   origins.	   	   Together,	  ORC,	   Cdt1,	   Cdc6,	   and	  MCM2-­‐7	   are	  called	   the	   pre-­‐replication	   complex	   (or	   PreRC)	   and	   any	   origin	   bound	   by	   preRC	   is	  considered	  licensed8.	   	  The	  purpose	  of	   licensing	   is	  to	  ensure	  that	  chromosomes	  are	  replicated	   once	   and	   only	   once	   per	   cell	   cycle	   and	   to	   potentiate	   the	   origins	   for	   the	  initiation	  of	  DNA	  replication.	  	  As	  the	  cell	  enters	  S-­‐phase,	  the	  Dbf4-­‐dependent	  kinase	  (DDK)	   is	  activated,	  which	   in	   turn	  phosphorylates	   the	  MCM	  subunits	   to	   load	  Cdc45	  and	  Treslin.	  	  Next,	  activated	  cyclin-­‐dependent	  kinase	  (CDK)	  phosphorylates	  Treslin	  and	  RecQ4	  facilitating	  the	  binding	  of	  TopBP1	  which	  then	  recruits	  the	  Go-­‐ichi-­‐ni-­‐san	  (GINS)	  helicase	  complex	  and	  polymerase-­‐ε,	   the	  DNA	  polymerase	  that	  extends	  RNA	  primers	   on	   the	   leading	   strand40.	   	   Finally,	   polymerase-­‐α:primase,	   the	   polymerase	  that	   synthesizes	   RNA	   primers	   on	   template;	   and	   pol-­‐δ,	   the	   lagging	   strand	   DNA	  polymerase	   that	   extends	   the	  RNA	  primers40,	   arrive	   at	   the	  origin.	   	  DNA	   replication	  initiates	  when	  two	  replisomes	  emerge	  and	  travel	  away	  from	  each	  other	  8,39,41.	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DNA	  Replication	  Barriers:	  Repetitive	  Regions	  	  	   The	   genomic	   landscape	   of	   a	   human	   cell	   is	   wrought	   with	   obstacles	   for	   a	  traveling	  replication	  fork.	  	  Highly	  repetitive	  regions	  in	  the	  human	  genome,	  including	  trinucleotide	   repeats	   (TNRs),	   telomeres,	   LINEs,	   SINEs,	  DNA	   transposons,	   and	  ALU	  repeat	   elements	   transiently	   form	   complex	   DNA	   structures	   when	   they	   become	  single-­‐stranded20-­‐22.	  	  During	  DNA	  replication,	  these	  complex	  DNA	  structures,	  such	  as	  hairpins,	   triplex	   and	   quadruplex	   DNA	   become	   barriers	   to	   DNA	   replication	   and	  trigger	  replication	  fork	  stalling2,4-­‐6.	  	  In	  addition,	  common	  fragile	  sites	  (CFS)	  are	  late	  replicating,	   AT	   rich	   regions	   that	   are	   prone	   to	   breakage	   when	   cells	   are	   under	  replication	   stress	   or	  when	   ATR	   function	   is	   compromised42-­‐44.	   	   Recently,	   a	   second	  class	  of	  CFS	  termed	  early	  replicating	  common	  fragile	  sites	  (ERCFs)	  was	  discovered.	  	  As	   their	   name	   implies,	   ERCFs	   are	   early	   replicating	   regions	   that	   are	   GC-­‐enriched	  regions	  (including	  LINEs,	  SINEs,	  ALUs	  and	  tRNAs)	  that	  are	  prone	  to	  breakage	  during	  DNA	   replication45.	   	   Similar	   to	   CFSs,	   ERCFs	   are	   more	   prone	   to	   break	   if	   ATR	   is	  inhibited42-­‐44.	  	  The	  presence	  of	  these	  fragile	  sites	  strongly	  suggest	  that	  the	  volatility	  of	  DNA	  replication	  is	  currently	  underestimated.	  Importantly,	  stalled	  replication	  forks	  are	  detrimental	  to	  the	  cell.	   	  They	  must	  be	  repaired	  and	  restarted	  in	  a	  timely	  manner;	  otherwise,	  the	  prolonged	  stalling	  will	  lead	  to	  collapse	  of	  a	  fork	  into	  a	  dangerous	  DSB.	  	  At	  stalled	  replication	  forks,	  stretches	  of	   naked	   ssDNA	   are	   exposed	   and	   are	   subsequently	   coated	   by	   RPA,	  which	   in	   turn	  recruits	  TOPBP1,	  Rad17,	  and	  the	  9-­‐1-­‐1	  complex	  to	  mediate	  the	  recruitment	  of	  ATR-­‐ATRIP9,35.	   	   Claspin,	   which	   is	   normally	   associated	   with	   an	   active	   replication	   fork,	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detaches	   from	   stalled	   forks	   and	   localizes	   with	   ATR-­‐ATRIP	   to	   mediate	   the	  phosphorylation	  of	  the	  CHK1	  kinase	  at	  serine	  345	  and	  serine	  31736-­‐38,	  which	  directly	  activates	  the	  S-­‐phase	  checkpoint.	  Stalled	   forks	  are	  stabilized	  and	   then	  restarted	  by	  ATR-­‐CHK1	  signaling9-­‐11,23,	  which	  activates	  the	  HR	  and	  FA	  pathways24,25.	  	  	  	  
Homologous	  Recombination	  (HR)	  	   In	  contrast	  to	  NHEJ,	  which	  can	  simply	  fuse	  the	  ends	  of	  DSB	  together,	  the	  HR	  pathway	   requires	   an	   undamaged	   template	   that	   is	   homologous	   to	   the	   site	   of	  damaged	   DNA	   in	   order	   to	   enact	   repair.	   	   Not	   surprisingly,	   the	   HR	   pathway	   is	  upregulated	   in	   the	   late	   S	   and	  G2	  phases	  of	   the	  mammalian	   cell	   cycle	  where	   sister	  chromatids	  are	  available33,46.	  	  HR	  repair	  normally	  occurs	  with	  high	  fidelity	  such	  that	  it	  can	  restore	  any	  genetic	  information	  that	  might	  be	  lost	  at	  the	  site	  of	  DNA	  damage.	  	  The	  HR	  pathway	  was	  originally	  identified	  in	  yeast	  (S.	  cerevisiae)	  and	  it	  is	  well	  conserved	   in	   higher	   organisms.	   	   The	   RAD50	   epistasis	   group	   -­‐	   RAD50,	   RAD51,	  RAD52,	  RAD54,	  RAD55,	  RAD57,	  RAD59,	  MRE11,	  and	  XRS2	  -­‐	  whose	  products	  are	  the	  core	  components	  of	  the	  HR	  machinery,	  was	  found	  through	  a	  reverse	  genetic	  screen	  for	  radiosensitive	  mutants47.	   	   In	  humans,	  the	  HR	  pathway	  is	  more	  complicated	  but	  nonetheless	  orthologs	  of	  the	  RAD50	  epistasis	  group	  have	  been	  identified.	  	  However,	  additional	   factors	   such	   as	   BRCA1,	   BRCA2,	   Rad51	   homologs	   (Rad51C,	   Rad51B,	  Rad51D,	   and	   DMC1),	   and	   Rad54	   homologs	   (Rad54B,	   and	   Rad54L)	   expand	   the	  repertoire	  of	  the	  human	  HR	  machinery11,33.	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HR	  repair	  begins	  with	  an	  essential	  5’>3’	  DNA	  resection	  step	  of	  the	  ends	  of	  a	  DSB,	   facilitated	   by	   the	  MRN	   (Mre11,	   Rad50,	   and	  Nbs1)	   complex	   that	   generate	   3’-­‐	  ssDNA33.	   	  RPA	   is	   then	   recruited	   to	   coat	   the	   ssDNA,	  which	   simultaneously	  protects	  the	   ssDNA	   from	   degradation	   and	   activates	   the	   DNA	   damage	   checkpoint	   via	   ATR-­‐ATRIP	   recruitment	   as	   described	   above.	   	   BRCA2	   is	   then	   recruited	   to	   the	   site	   of	  damage	  where	  it	  displaces	  RPA	  for	  Rad51,	  forming	  a	  nucleoprotein	  filament11.	  	  The	  nucleoprotein	   filament	   (Rad51-­‐ssDNA)	   is	   stabilized	   by	   Rad54,	   which	   also	  subsequently	   aids	   the	   homology	   search	   for	   an	   undamaged	   homologous	   template	  correct	   template48.	   	   Rad54	   facilitates	   the	   nucleoprotein	   filament’s	   invasion	   of	   the	  undamaged	  homologous	  template,	  and	  displaces	  one	  of	  the	  template	  strands	  to	  form	  a	  D-­‐loop	  heteroduplex48.	   	  Here,	  DNA	  polymerases	   extend	   the	   invading	   strand	   and	  via	   DNA	   replication	   recover	   any	   lost	   genetic	   information	   suffered	   at	   the	   DSB40.	  	  When	  extension	  of	  the	  invading	  strand	  is	  complete,	  the	  newly	  synthesized	  (nascent)	  DNA	  strand	  is	  ligated	  back	  to	  the	  native	  strand	  where	  the	  break	  originally	  occurred	  by	  DNA	  Ligase	  I(LIGI)11.	  	  	  
DNA	  End	  Resection	  
	   DNA	  resection	  is	  a	  highly	  conserved	  biological	  process	  that	  generates	  ssDNA	  from	  dsDNA	  and	  is	  catalyzed	  by	  nucleases.	   	  DNA	  resection	  is	  a	  critical	  process	  that	  links	  DNA	  damage	   to	   cell	   cycle	   checkpoint	   activation,	  which	   is	   key	   to	   the	   survival	  and	  fitness	  of	  an	  organism15,16,49-­‐67.	  	  Furthermore,	  DNA	  resection	  is	  required	  for	  HR	  and	   for	   generating	   ssDNA	   that	   forms	   protective	   t-­‐loops	   at	   the	   ends	   of	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chromosomes68.	   	   The	  mechanism	  of	  DNA	   resection	   at	   the	   ends	   of	   a	  DSB,	   the	   first	  step	  of	  HR,	  had	  been	  unclear	   for	  a	   long	  period	  of	   time.	   	  Within	   the	  past	  6	  years,	  a	  plethora	  of	  studies	  have	  emerged,	  identifying	  CtIP	  (SAE2	  in	  yeast),	  EXO1	  and	  DNA2	  as	  the	  trio	  of	  nucleases	  involved	  in	  the	  DNA	  resection	  of	  DSBs15,16,49-­‐67.	  The	  resection	  pathway	  was	  initially	  delineated	  in	  yeast	  as	  a	  2-­‐tiered	  process.	  	  At	   a	   DSB	   SAE2	   (CtIP	   in	   humans)	   and	   the	   MRX	   complex	   (the	   MRN	   complex	   in	  humans)	  begins	  the	  resection	  process	  by	  minimally	  resecting	  the	  ends	  by	  100bp56,58.	  	  This	   minimal	   processing	   is	   followed	   by	   long-­‐range	   resection	   facilitated	   either	   by	  EXO1	   or	   DNA2	   and	   it	   can	   extend	   over	   kb	   lengths54,55,66.	   	   As	   a	   result,	   long	   3’-­‐overhangs	   of	   ssDNA	   are	   generated	   that	   can	   be	   utilized	   by	   the	   HR	   machinery	   to	  complete	  the	  repair.	  Importantly,	  the	  impairment	  of	  DNA	  resection	  results	  in	  human	  disease	  and	  cancer.	   	   Mutations	   in	   human	   CtIP	   were	   found	   in	   Seckel	   and	   Jawad	   syndrome	  patients	   that	   suffer	   from	   microcephaly	   and	   various	   developmental	   disorders69.	  	  Additionally,	   CtIP	   is	   overexpressed	   in	   several	   breast	   cancer	   cell	   lines70	   suggesting	  that	  DNA	   resection	  may	  have	   a	   role	   in	   cancer	   cells.	   	   Consequently,	  DNA	   resection	  appears	   to	  be	   important	   for	  human	  health	  and	  more	   investigation	  on	   this	  process	  seems	   warranted.	   	   Importantly,	   these	   nucleases	   could	   potentially	   serve	   as	   novel	  cancer	   drug	   targets,	   in	   strategies	   that	   could	   augment	   current	   chemotherapeutic	  treatments.	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CtIP	  
	   Human	  CtIP	  (C-­‐terminal	  interacting	  protein)	  was	  originally	  identified	  from	  a	  yeast-­‐2-­‐hybrid	   screen	   for	   genes	   that	   interact	   with	   CtBP	   (C-­‐terminal	   binding	  protein),	  which	  binds	  to	  the	  human	  adenovirus	  E1A	  transforming	  factor71.	  	  Thus,	  the	  function	   of	   CtIP	   was	   first	   described	   to	   likely	   be	   be	   that	   of	   a	   transcription	   factor.	  	  Subsequently,	   however,	   it	   has	   been	   shown	   to	   have	   a	   role	   in	   regulating	   the	   cell	  cycle72-­‐74.	  It	  was	  first	  associated	  with	  the	  HR	  repair	  pathway	  when	  it	  was	  reported	  that	   CtIP	   binds	   to	   BRCA1	   (a	   key	   HR	   factor),	   and	   that	   it	   is	   phosphorylated	   by	  ATM75,76.	   	   The	   current	  understanding	  of	  CtIP	   as	   a	  nuclease	  was	  only	  discovered	  6	  years	   ago	   when	   Sartori	   et	   al.	   reported	   that	   CtIP	   localizes	   to	   sites	   of	   DSBs	   and	   is	  required	  for	  resection.	   	  Furthermore,	  detailed	  studies	  of	  DNA	  resection	  by	  SAE2	  in	  yeast	  corroborated	  the	  findings	  that	  CtIP	  is	  a	  factor	  required	  for	  DNA	  resection.	  	  The	   human	   CtIP	   locus	   is	   located	   on	   Chromosome	   18,	   and	   the	   protein	   is	  encoded	   by	   19	   exons.	   	   The	   first	   codon	   is	   non-­‐coding	   but	   the	   remaining	   18	   exons	  encode	   for	   the	   ~100	   kDa,	   full-­‐length	   CtIP	   protein	   of	   897	   amino	   acids	   (a.a).	   	   CtIP	  dimerizes	  into	  a	  functional	  dimer	  through	  a	  coiled-­‐coil	  (CC)	  domain	  located	  at	  its	  N-­‐terminus77.	   	   Yeast	   CtIP,	   SAE2,	   is	   reported	   to	   be	   an	   endonuclease	   and	   its	   nuclease	  domain	   resides	   in	   the	   C-­‐terminus.	   	   Human	   CtIP	   is	   weakly	   conserved	   with	   SAE2;	  however,	  the	  C-­‐termini	  of	  CtIP	  and	  SAE2	  do	  share	  significant	  homology16.	  	  In	  spite	  of	  this	  homology,	   it	   is	  still	  unclear	  whether	  CtIP	  possesses	   intrinsic	  nuclease	  activity.	  	  What	   is	   clear	   is	   that	   its	   interaction	  with	   the	  MRN	   complex	   stimulates	   resection57.	  	  Furthermore,	   the	   significant	   divergence	   of	   the	   N-­‐terminal	   domains	   of	   CtIP	   from	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SAE2	  suggests	  that	  CtIP	  has	  evolved	  to	  adopt	  more	  specialized	  functions	  in	  order	  to	  manage	  the	  larger	  and	  more	  complicated	  genomes	  of	  higher	  organisms.	  CtIP	   interacts	   with	   the	   MRN	   complex14,57	   and	   localizes	   to	   sites	   of	  DSBs14,52,53,57	  to	  mediate	  further	  resection	  by	  EXO151	  and	  DNA251,63.	  	  However,	  CtIP	  appears	   to	   have	   additional	   functions	   apart	   from	   facilitating	   DSB	   resection.	   	   Thus,	  CtIP	   has	   been	   reported	   to	   interact	   with	   BRCA173,74,78,	   Rb72,	   PCNA79,	   CDK250,	   and	  ATM14,73;	   indicating	   a	   role	   for	   CtIP	   in	   the	   DNA	   damage	   response	   (DDR)	   signaling	  pathway	  and	  checkpoint	  regulation.	  	  	  CtIP	   is	   an	   essential	   gene	   in	   mice	   and	   it	   has	   been	   suggested	   to	   carry	   out	  essential	  functions	  in	  cells	  cycle	  regulation	  with	  Rb80.	  	  In	  a	  recent	  study,	  two	  human	  CtIP	  mutations	   that	   result	   in	  CtIP	  C-­‐terminal	   truncations	  were	   identified	   in	  Seckel	  (SCKL2)	   and	   Jawad	   (J)	   syndrome	   patients69	   (characterized	   by	   mirocephaly	   and	  developmental	   defects).	   	   The	   SCKL2	   and	   J	   mutations	   are	   presumed	   to	   be	  hypormorphic	   in	  mediating	   DNA	   resection.	   	   However,	   they	   still	   possess	   their	   Rb-­‐interacting	   domain	   at	   the	   N-­‐terminus52,72	   strongly	   suggesting	   that	   CtIP	   may	   be	  essential	  in	  humans,	  similar	  to	  mice.	  	  
EXO1	  
	  
	   Human	  EXO1	  is	  highly	  conserved	  with	  yeast	  EXO1.	   	  Human	  EXO1	  is	   located	  on	  Chromosome	  1	  and	  consists	  of	  13	  coding	  (from	  a	  total	  of	  15)	  exons.	   	  The	  EXO1	  locus	  encodes	   for	   two	   isoforms,	  EXO1b	  and	  EXO1a.	   	  EXO1b	   is	  803	  a.a.	   long	  with	  a	  molecular	  weight	  of	  ~100	  kDa.	   	   EXO1a	   is	   the	  product	  of	   an	   alternative	   splice	   site	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located	   in	   the	   boundary	   of	   exons	   14	   and	   15.	   	   The	   variant	   transcript	   results	   in	   a	  frameshift	  and	  uses	  an	  upstream	  stop	  codon	  resulting	  in	  the	  EXO1a	  isoform,	  which	  is	  43	  a.a.	  shorter	  than	  EXO1b.	  	  The	  EXO1	  isoforms	  have	  not	  been	  reported	  to	  carry	  out	  separate	  functions;	  however,	  more	  investigation	  is	  warranted.	  The	   human	   EXO1	   is	   a	   member	   of	   the	   Rad2	   structure-­‐specific	   family	   of	  nucleases	   that	   possess	   5’-­‐3’	   endonucleolytic	   and	   exonucleolytic	   activities81.	   	   The	  endonucleolytic	  activity	  of	  EXO1	  is	  capable	  of	   incising	  5’-­‐flap	  structures	  by	  using	  a	  common	  nuclease	  mechanism	   that	   bends	  DNA	  at	   nicks	   or	   gaps	   to	   expose	   the	   flap	  structures82,	   whereas	   its	   5’-­‐3’	   exonucleolytic	   activity	   is	   highly	   processive	   and	   is	  capable	   of	   to	   generating	   kb	   long	   stretches	   of	   ssDNA60,83,84.	   	   Moreover,	   EXO1	   is	   a	  multitasking	  nuclease85;	   it	  was	   originally	   described	   as	   the	  nuclease	  utilized	   in	   the	  mismatch	   repair	   pathway	   to	   excise	   patches	   of	   mismatched	   DNA86-­‐90.	   	   However,	  multiple	  subsequent	  studies	  demonstrate	   the	   far-­‐reaching	   involvement	  of	  EXO1	   in	  DNA	  replication91,	  HR51,	  checkpoint	  activation92,	  nucleotide	  excision	  repair	  (NER)92	  and	  telomere	  maintenance68.	  	  	  The	  involvement	  of	  EXO1	  in	  DDR	  was	  demonstrated	  in	  studies	  showing	  tight	  coordinate	   regulation	   of	   EXO1	   during	   replication	   stress11,67,93,94.	   	   When	   DNA	  replication	   is	   inhibited	   by	   hydroxyurea	   or	   aphidicolin	   treatment,	   EXO1b	   is	  phosphorylated	   by	   ATR,	   which	   signals	   for	   its	   ubiquitylation	   and	   proteasomal	  degradation;	   a	   process	   mediated	   by	   14-­‐3-­‐3	   proteins	   that	   specifically	   recognize	  phosphorylated	  EXO194,95.	  	  The	  degradation	  of	  EXO1	  in	  response	  to	  DNA	  damage	  is	  postulated	  to	  prevent	  extensive	  DNA	  resection	  at	  the	  damage	  site.	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EXO1	  is	  an	  important	  player	  in	  DSB	  repair	  and	  is	  required	  for	  IR	  resistance	  and	  genomic	   stability.	   	  Currently,	  EXO1	   is	  heavily	   studied	   for	   its	  direct	   role	   in	   the	  long-­‐range	  resection	  of	  DSBs,	  a	  process	  which	   is	  essential	   for	   the	  HR	  pathway.	   	   In	  
vitro	   studies	   have	   shown	   that	   EXO1	   is	   involved	   with	   two	   distinct	   DNA	   resection	  machineries.	   	   EXO1	  can	   resect	  DNA	   in	   complexes	  with	  BLM,	  MRN	  and	  either	  with	  RPA	  or	  hSSB1	  (SOSS1)60,83,84.	   	  hSSB1	   is	  a	  newly	  discovered	  ssDNA	  binding	  protein	  that	  is	  required	  for	  IR	  resistance	  and	  genomic	  stability96.	  	  It	  has	  similar	  functions	  to	  RPA	  except	   that	   hSSB1	  binds	   and	   stabilizes	  DNA	  with	  distinct	   kinetics97	   and	  does	  not	  co-­‐localize	  with	  RPA96.	   	  hSSB1	  was	  shown	   to	  enhance	   (in	  comparison	   to	  RPA)	  the	   exonucleolytic	   activity	   of	   EXO1	   and	   the	   affinity	   of	   EXO1	   for	   DNA	   ends.	   	   The	  different	  ssDNA	  structures	  stabilized	  by	  RPA	  or	  hSSB1	  are	   thought	   to	  regulate	   the	  kinetics	  of	  resection	  by	  EXO184.	  	  This	  suggests	  that	  the	  recruitment	  of	  RPA	  or	  SSB1	  to	  the	  damage	  site	  may	  constitute	  a	  new	  mechanism	  to	  tailor	  resection	  products	  in	  response	  to	  the	  various	  types	  of	  DNA	  damage	  and	  repair.	  	  	  In	  addition	  to	  DNA	  resection,	  EXO1	  has	  been	  gaining	  attention	  as	  a	  key	  player	  in	  the	  process	  of	  DNA	  replication.	  	  Very	  recently,	  it	  was	  reported	  to	  travel	  intimately	  with	   the	   replication	   fork	   in	   study	   that	   isolated	   proteins	   on	   nascent	  DNA	   by	  mass	  spectrometry	  (iPOND-­‐MS)	  91.	   	  Furthermore,	  EXO1	  physically	  associates	  with	  PCNA	  through	  its	  (PCNA	  interacting	  protein	  motif)	  PIP	  box	  domain.	  	  The	  exact	  function	  of	  EXO1	  in	  DNA	  replication	  is	  unclear	  and	  further	  investigation	  is	  warranted.	  In	   mice,	   EXO1	   was	   reported	   to	   play	   a	   significant	   role	   in	   telomere	  maintenance;	  murine	  EXO1	   tailors	   ssDNA	  or	  G-­‐overhangs	  such	   that	   they	  can	   form	  
	   18	  
the	  t-­‐loop	  structures68	  that	  protect	  telomeres.	  	  EXO1	  knockout	  mice	  are	  viable2,98,99;	  however,	  it	  is	  not	  known	  if	  this	  is	  also	  the	  case	  for	  humans.	  	  	  	  
DNA2	  
	   The	  human	  DNA2	  locus	  is	  located	  on	  chromosome	  10	  and	  encodes	  21	  coding	  exons.	   	   The	   full-­‐length	   protein	   is	   1060	   a.a.	   with	   a	  mass	   of	   ~140	   kDa,	   and	   it	   is	   a	  member	  of	   the	  helicase	   and	  nuclease	   family	  of	   proteins	   that	   are	  highly	   conserved	  among	   various	   species100.	   	   The	   helicase	   domain	   of	   hDNA2	   is	   located	   in	   the	   N-­‐terminus,	   while	   the	   endonuclease	   domain	   is	   found	   on	   the	   C-­‐terminus	   of	   the	  protein100.	   	  Human	  DNA2	  has	  not	  been	  very	  well	  characterized;	  however	  much	  has	  been	   learned	   from	   yeast	   models.	   	   Yeast	   DNA2	   was	   initially	   described	   as	   a	   flap	  endonuclease	  that	  excises	  5’-­‐flap	  ssDNA	  structures	  resulting	  from	  the	  displacement	  of	  Okazaki	   fragments	   during	  Polymerase	   δ	   extension101,102.	   	   The	   excision	  by	   yeast	  DNA2	   leaves	   behind	   ~6	   nt	   long	   flaps,	   which	   are	   further	   processed	   by	   FEN-­‐1	   to	  create	  ligatable	  nicks	  to	  be	  sealed	  by	  LIGI101,102.	  	  More	  recently,	  studies	  have	  shown	  that	   yeast	   DNA2	   functions	   synergistically	   with	   EXO1	   in	   DNA	   resection	   of	   DSBs	  (downstream	  of	  SAE2)55.	  	  	  	   DNA2	   is	   an	   essential	   gene	   in	   yeast	   due	   to	   its	   requirement	   in	   DNA	  replication103	  but	   it	   is	  not	  known	  if	   it	   is	  essential	   for	  human	  cells	  or	  mice.	   	  Human	  DNA2	   also	   has	   helicase	   and	   endonuclease	   domains	   in	   the	   N-­‐	   and	   C-­‐termini,	  respectively;	   confusingly	   however,	   human	   DNA2	   in	   vitro	   is	   devoid	   of	   helicase	  activity	   and	   only	   has	   active	   endonucleolytic	   activity100.	   	   In	   human	   cells,	   DNA2	   is	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found	   in	   the	  mitochondria,	  where	   it	  maintains	  mitochondrial	  DNA	  stability,	  and	   in	  the	  nucleus,	  where	  it	  is	  required	  for	  genomic	  stability104.	  	  	  	   In	   vitro	   studies	   have	   reported	   that	   human	   DNA2	   makes	   up	   a	   third	   DNA	  resection	  machinery.	   	   hDNA2	   resects	  DNA	   in	   a	   complex	  with	  RPA,	  BLM	  and	  MRN	  and	  processively	  clips	  off	  30-­‐40	  nt	  pieces	  of	  ssDNA60,97.	  	  Interestingly,	  RPA	  serves	  to	  guide	   the	  DNA	  resection	  of	  hDNA2	   in	   the	  5’-­‐3’	  direction;	   and	   in	   contrast	   to	  EXO1,	  hDNA2	   is	   not	   stimulated	   by	   hSSB197.	   	   Furthermore,	   human	   DNA2	   was	   recently	  reported	  to	  be	  involved	  in	  HR-­‐mediated	  repair	  of	  damaged	  replication	  forks63.	  	  The	  regulation	   of	   these	   resection	  machines	   and	   their	   preferences	   for	   various	   types	   of	  DNA	  damage	  requires	  further	  investigation.	  The	   vast	   majority	   of	   studies	   on	   CtIP14,24,25,52,53,57,	   EXO19,10,26,51,67,93,105,	   and	  DNA211,16,51,63,106	   function	  are	  based	  on	  transiently	  knocking	  down	  CtIP,	  EXO1,	  and	  DNA2,	   followed	   by	   examining	   the	   cell’s	   responses	   to	   DNA	   damaging	   agents.	  	  Inasmuch	   information	   that	   these	   studies	  provide,	  we	  still	  do	  not	  know	   if	  CtIP	  and	  EXO1	  are	  essential	  genes	  in	  human	  cells.	  	  It	  is	  important	  to	  know	  whether	  CtIP	  and	  EXO1	  are	  essential	  in	  humans	  because	  if	  they	  are	  essential,	  it	  would	  most	  certainly	  mean	   they	   have	   essential	   functions	   in	   addition	   to	   responding	   and	   repairing	  artificially-­‐induced	  DNA	  damage.	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The	  Fanconi	  Anemia	  (FA)	  Pathway	  
	   The	   cellular	   genome	   is	   susceptible	   to	   DNA	   modifications	   resulting	   from	  exposure	   to	   various	   environmental	   factors,	   chemotherapeutic	   agents,	   or	   reactive	  metabolic	   products	   produced	   endogenously.	   	   Interstrand	   crosslinks	   (ICLs)	   are	   a	  modification	  where	  covalent	  bonds	  are	  formed	  between	  bases	  of	  both	  strands.	  	  DNA	  replication	   forks	   stall	   when	   they	   encounter	   ICLs107.	   	   The	   replication	   machinery	  cannot	  separate	  the	  covalently	  linked	  DNA	  and	  requires	  the	  FA	  pathway	  to	  resolve	  the	   ICLs	   and	   restart	   the	   stalled	   fork;	   otherwise,	   ICLs	   are	   lethal	   if	   left	   unresolved.	  	  The	  FA	  pathway	  was	  discovered	  in	  FA	  patients	  who	  suffer	  from	  bone	  marrow	  failure	  and	   cancer	   predisposition.	   	   Unfortunately,	   FA	   is	   a	   heritable,	   recessive,	   genomic	  instability	  syndrome	  and	  FA	  patients	  begin	  suffering	  at	  very	  young	  ages.	  	  FA	  patient	  cells	   are	   highly	   sensitive	   to	  DNA	   replication	   inhibitors	   such	   as	   hydroxyurea	   (HU),	  and	  aphidicolin	   (APH)	  and	  especially	   sensitive	   to	   ICL	  agents	   such	  as	   cisplatin	   and	  mitomycin	  C	  (MMC).	   	  When	  challenged	  with	  these	  compounds,	  FA	  patient	  cells	  are	  highly	   susceptible	   to	   chromosomal	   aberrations	   that	   are	   mediated	   by	   the	   NHEJ	  pathway108,109.	  	  Residing	   upstream	   in	   the	   FA	   pathway	   is	   an	   8-­‐membered,	   core	   complex	  comprised	  of	   FANCA,	  B,	   C,	   E,	   F,	  G,	   L,	   and	  M,	  which	   functions	   as	   a	  ubiquitin	   ligase.	  	  When	  a	  replication	   fork	  encounters	  an	   ICL,	   it	   stalls	  and	   the	  ATR-­‐CHK1	  pathway	   is	  activated.	   	   ATR	   subsequently	   phosphorylates	   the	   core	   complex,	   which	   in	   turn	  monoubiquitylates	  FANCD2/FANCI	  that	  is	  located	  centrally	  in	  the	  FA	  pathway.	  	  As	  a	  result,	  FANCD2	  dissociates	  from	  FANCI	  and	  localizes	  to	  the	  site	  of	  damage	  where	  it	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recruits	   downstream	   FA	   components110,111:	   FAN1	   (Fanconi	   Anemia	   nuclease	   1),	  FANCP	   (Slx4),	   FANCD1	   (BRCA2),	   FANCO,	   FANCJ	   (BACH1/BRIP)	   and	   FANCN	  (PALB2).	  	  The	  downstream	  components	  make	  incisions	  on	  one	  strand	  to	  unhook	  the	  ICL,	  which	  separates	  the	  DNA	  strands	  such	  that	  a	  DSB	  is	  created	  on	  one	  chromatid,	  and	  a	  gap	  with	  the	  ICL	  lesion	  on	  the	  other	  chromatid.	  	  Ironically,	  the	  cell	  is	  now	  left	  with	  an	  ICL	  lesion	  and	  a	  DSB	  to	  repair.	   	   In	  order	  to	  repair	  the	  resulting	  ICL	  lesion,	  translesion	  polymerases	  are	   recruited	   to	  bypass	   the	   lesion	  and	   fill	   in	   the	  gap;	  and	  the	  DSB	  is	  subsequently	  repaired	  by	  the	  HR	  pathway,	  which	  uses	  the	  newly	  repaired	  sister	  chromatid	  as	  the	  homologous	  template107,112.	  The	   HR	   pathway	   is	   intimately	   connected	   to	   the	   FA	   pathway.	   	   In	   the	   HR	  pathway,	   BRCA1	   is	   required	   to	   interact	  with	  BRCA2,	   through	  PALB2,	   in	   order	   for	  Rad51	  to	  be	  recruited	  onto	  DNA.	  	  The	  identification	  of	  FANCD1	  (BRCA2)	  and	  FANCN	  (PALB2)	  in	  the	  FA	  pathway113,	  and	  a	  study	  reporting	  that	  Rad51	  is	  involved	  in	  ICL	  repair114	  clearly	  show	  the	  interaction	  between	  the	  HR	  and	  FA	  pathways.	  	  However,	  it	   is	   not	   clear	   how	   these	   pathways	   are	   regulated	   and	   further	   investigation	   is	  warranted.	  	  
The	  NHEJ	  Pathways	  
	   NHEJ	  is	  another	  DSB	  repair	  pathway	  that	  is	  mechanistically	  distinct	  from	  the	  HR	  pathway12.	   	   In	  contrast	   to	  HR,	  NHEJ	  generally	  simply	  religates	   the	   two	  ends	  of	  broken	  DNA	  together	  and	  does	  not	  require	  a	  homologous	  template	  for	  repair.	  	  NHEJ	  repair	  has	   the	  advantage	  of	   speed	  over	  HR;	  however,	   it	   is	   error	  prone.	   	   In	  human	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cells	  NHEJ	  is	  the	  primary	  DSB	  repair	  pathway	  and	  evolutionarily,	  it	  has	  been	  argued	  that	  this	  is	  so	  because	  the	  large	  human	  genome	  contains	  many	  non-­‐coding	  regions	  that	  can	  buffer	  the	  errors	  derived	  from	  NHEJ	  repair	  in	  exchange	  for	  faster	  repair.	  	  In	  contrast,	   in	   yeast,	   HR	   is	   the	   predominant	   DSB	   repair	   pathway	   because	   with	   a	  concise	   and	   intron-­‐less	   yeast	   genome,	   they	   cannot	   “afford”	   the	   errors	   that	   NHEJ	  would	  generate.	  	  	  NHEJ	  exists	  as	  two,	  biochemically	  and	  mechanistically	  distinct	  sub	  pathways:	  a	  main	  “classic”	  end-­‐joining	  pathway	  (C-­‐NHEJ)	  and	  one	  interchangeably	  referred	  to	  as	  microhomology-­‐mediated	   end	   joining	   (MMEJ)115-­‐117,	   alternative	  NHEJ	   (A-­‐NHEJ),	  or	  backup	  NHEJ	  (B-­‐NHEJ)118,119	  (hereafter	  referred	  to	  as	  A-­‐NHEJ).	   	  Neither	  of	  these	  NHEJ	   sub	   pathways	   are	   precise;	   the	   C-­‐NHEJ	   repair	   mechanism	   involves	   minimal	  DNA	  end	  processing,	  whereas	  A-­‐NHEJ	  mechanistically	  results	  in	  deletions	  per	  force	  that	  are	  often	  accompanied	  by	  microhomology	  at	  the	  repair	  junction.	  The	   C-­‐NHEJ	   pathway	   consists	   of	   at	   least	   7	   components;	   Ku70,	   Ku86,	   DNA-­‐PKcs,	   Artemis,	   XRCC4,	   XLF	   and	   LIGIV.	   	   This	   is	   an	   important	   pathway	   because	   it	   is	  essential	   for	   the	   development	   of	   the	   immune	   system	   where	   it	   repairs	   DSB	  intermediates	   during	   V(D)J	   recombination	   and	   class	   switch	   recombination	   for	  antibody	  diversification,	  telomere	  maintenance,	  and	  genome	  maintenance12.	  	  In	  the	  event	  of	  a	  DSB,	  Ku	  is	  thought	  to	  be	  the	  first	  protein	  to	  bind	  to	  both	  ends	  of	  the	  DNA.	  	  Ku70	   and	   Ku86	   are	   highly	   expressed	   in	   mammalian	   cells	   and	   they	   form	   a	  heterodimer	   (Ku).	   	   Ku	   possesses	   a	   torroidal	   shape	   that	   fits	   snuggly	   on	   to	   ends	   of	  DNA	  duplexes	  with	  a	  high	  dissociation	  constant	   in	  the	  range	  of	  ~10	  nM12,29.	   	  Once	  bound	  to	  DNA,	  Ku	  protects	   the	  vulnerable	  DNA	  ends	   from	  nucleolytic	  degradation	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and	   recruits	   DNA-­‐PKcs,	   a	   phosphoinositol-­‐3-­‐like	   family	   serine/threonine	   protein	  kinase120.	   	  Ku	  and	  DNA-­‐PKcs	  assembled	  on	  the	  DNA	  end	  constitute	  DNA-­‐dependent	  protein	  kinase	  complex	  (DNA-­‐PK).	   	  The	  assembly	  of	  DNA-­‐bound	  DNA-­‐PK,	  activates	  the	   kinase	   activity	   of	   the	   DNA-­‐PKcs	   catalytic	   subunit,	   which	   in	   turn	   recruits	   the	  nuclease	  Artemis	  to	  trim	  the	  ends	  of	  the	  broken	  DNA12.	   	  In	  particular,	  the	  nuclease	  activity	  of	  Artemis	  opens	  the	  hairpins	  of	  V(D)J	  recombination	  intermediates	  in	  order	  to	   generate	   DNA	   ends	   that	   are	   compatible	   for	   ligation.	   	   In	   the	   final	   step,	   another	  trimeric	  complex	  that	  consists	  of	  LIGIV,	  XLF	  and	  XRCC4	  ligates	  the	  ends	  of	  the	  break	  together121.	  The	   C-­‐NHEJ	   pathway	   is	   a	   metaphorical	   double-­‐edged	   sword.	   	   Although	   C-­‐NHEJ	   plays	   a	   role	   in	  maintaining	   genomic	   stability,	   there	   are	   several	   studies	   that	  report	   that	   C-­‐NHEJ	   also	   contributes	   to	   genomic	   instability.	   	   For	   example,	   the	  inhibition	   of	   DNA-­‐PK	   reduces	   genomic	   instability	   of	   BRCA2-­‐	   and	   BRCA1-­‐deficient	  cells122,123.	  	  Moreover,	  the	  inactivation	  of	  C-­‐NHEJ	  (Ku	  or	  LIGIV)	  in	  BRCA1-­‐	  or	  FANC-­‐deficient	  cells	  reduces	  the	  frequency	  of	  abnormal	  chromosomes124,125.	  In	   contrast	   to	   C-­‐NHEJ	   and	  HR,	   the	  mechanism	   and	   regulation	   of	   A-­‐NHEJ	   is	  unclear.	   	   However,	   it	   is	   known	   that	   the	   signature	   motif	   of	   A-­‐NHEJ	   repair	   is	  microhomology	  at	  the	  repair	  junctions	  and	  that	  the	  reaction	  is	  “Ku	  independent”126.	  	  The	  microhomology	  that	  is	  observed	  in	  A-­‐NHEJ	  repair	  junctions	  is	  thought	  to	  result	  from	   DNA	   resection	   of	   the	   DSB	   ends	   to	   generate	   3’	   ssDNA	   with	   regions	   of	  microhomology	   (generally	   a	   few	   nucleotides),	   which	   are	   subsequently	   used	   for	  ligation	   127.	   	   Therefore,	   if	   a	   break	   occurs	   in	   a	   stretch	   of	   nucleotides	   between	   two	  regions	  of	  microhomology,	  A-­‐NHEJ	  will	  delete	  the	  stretch	  of	  nucleotides	  and	  one	  of	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the	   regions	   of	   microhomology	   and	   leave	   behind	   just	   one	   of	   the	   original	  microhomology	  regions	  at	  the	  repair	  junction.	  A-­‐NHEJ	   is	   thought	   to	   be	   a	   minor	   pathway	   of	   NHEJ	   because	   it	   is	   usually	  detected	  only	  in	  the	  absence	  of	  C-­‐NHEJ128.	  	  Early	  efforts	  to	  characterize	  end	  joining	  properties	   in	  mammalian	   cells	   identified	   two	  classes	  of	   repair	   junctions:	  one	  with	  simple	   ligations,	   and	   another	  with	  microhomology129,130.	   	   Studies	   in	   yeast	   showed	  that	  in	  the	  absence	  of	  Ku,	  cells	  employ	  an	  alternative	  repair	  mechanism	  that	  can	  still	  mediate	  joining	  with	  microhomology	  in	  the	  repair	  junctions117,128.	  	  Subsequently,	  in	  
vitro	   data	   demonstrated	   that	   a	   Ku-­‐independent,	   alternative	   end	   joining	   pathway	  was	   indeed	   present	   and	   responsible	   for	   the	   microhomology	   at	   the	   repair	  junctions131,132.	  	  In	  recent	  years,	  the	  A-­‐NHEJ	  pathway	  has	  been	  gaining	  interest	  as	  a	  key	  player	  in	   genomic	   stability.	   	   Transgenic	   mice	   with	   targeted	   knockouts	   for	   Ku70,	   Ku80,	  XRCC4,	  or	  LIGI,	   in	  a	  p53-­‐deficient	  background	  have	  increased	  incidence	  of	  tumors;	  furthermore,	  the	  translocations	  found	  in	  these	  tumors	  bear	  the	  signature	  motif	  of	  A-­‐NHEJ	  (microhomology)133,134.	  	  Another	  study	  involving	  mouse	  embryonic	  stem	  cells	  with	   a	   translocation	   reporter	   system	   also	   reported	   that	   the	   majority	   of	  translocations	   had	   microhomology	   sequences	   at	   the	   repair	   junctions135.	   	   Most	  compellingly,	   microhomology	   signatures	   have	   been	   found	   at	   the	   breakpoints	   of	  chromosomal	   rearrangements	   in	   primary	   human	   cancer	   cells127,136;	   though	   it	   is	  important	  to	  note	  that	  A-­‐NHEJ	  is	  likely	  not	  solely	  responsible	  for	  such	  events.	  	  These	  findings	   have	   spurred	   an	   interest	   in	   identifying	   the	   components	   of	   the	   A-­‐NHEJ	  pathway.	   	  Currently,	  it	  is	  known	  that	  poly	  (ADP-­‐ribose)	  polymerase-­‐1	  (PARP-­‐1),	  X-­‐
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ray	  cross	   complementing	  1	   (XRCC1),	  DNA	   ligase	   III	   (LIGIII),	  polynucleotide	  kinase	  (PNK)	  as	  well	  as	  Flap	  endonuclease	  1	  (Fen-­‐1)115,116,119,132,137,138	  are	   likely	   involved;	  however,	  further	  investigation	  to	  identify	  other	  factors	  is	  warranted.	  	  
The	  Choice	  Between	  HR	  or	  NHEJ	  
	   In	  mammalian	   cells,	   NHEJ	   is	   the	   predominant	   pathway	   and	   is	   active	   in	   all	  phases	   of	   the	   cell	   cycle,	   whereas	   HR	   is	   predominantly	   active	   in	   the	   S-­‐	   and	   G2-­‐	  phases.	  	  Currently,	  it	  is	  thought	  that	  the	  choice	  between	  HR	  and	  NHEJ	  is	  regulated	  at	  the	   level	   of	   end	   resection139.	   	   Thus,	   C-­‐NHEJ	   is	   preferred	  when	   there	   is	   little	   to	   no	  resection,	  A-­‐NHEJ	  when	   there	   is	  modest	   resection,	  whereas	  HR	   requires	   the	  most	  extensive	  resection16,33,118,128,140,141.	  In	   S-­‐	   and	   G2-­‐phases	   when	   HR	   is	   active,	   CDKs	   modulates	   the	   activity	   of	  resection	   factors	  by	  phosphorylation	   in	  order	   to	  bias	   the	  pathway	   choice	   towards	  HR	  repair	  of	  DSBs49,50,56,142,143.	   	  In	  contrast,	  the	  p53	  binding	  protein	  1	  (53BP1)	  also	  plays	  a	  significant	  role	  in	  pathway	  choice	  when	  NHEJ	  is	  used	  for	  the	  repair	  of	  DSBs.	  	  At	   DSBs	   in	   G1,	   53BP1	   recruits	   PTIP	   and	   RIF1,	   which,	   in	   turn	   represses	   the	  recruitment	   of	   BRCA1-­‐CtIP.	   	   The	   repression	   of	   BRCA1-­‐CtIP	   essentially	   blocks	   the	  DNA	  resection	  that	  is	  necessary	  for	  HR,	  and	  perforce	  promotes	  NHEJ.	  	  Conversely,	  in	  the	   S-­‐	   and	   G2-­‐phases,	   the	   activation	   of	   BRCA1-­‐CtIP	   by	   CDKs	   prevents	   the	  accumulation	   of	   53BP1	   at	   DSBs122,123,144-­‐147.	   	   These	   studies	   provide	   evidence	   that	  repair	  pathway	  choice	  is	  a	  complex	  process,	  but	  one	  that	  generally	  revolves	  around	  the	  access	  of	  DNA	  resection	  factors	  to	  the	  DNA	  ends.	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Recombinant	  Adeno-­‐Associated	  Virus	  (rAAV)	  and	  Gene	  Targeting	  	   Adeno-­‐associated	   virus	   (AAV)	   is	   a	   small	   (20	   to	   25	   nm	   in	   diameter),	  nonenveloped,	   4.7	   kb	   single-­‐stranded	   DNA	   (ssDNA)	   virus	   belonging	   to	   the	  
Parvoviridae	  family148.	   	   It	   is	   estimated	   that	  50	   to	  90%	  of	   the	  human	  population	   is	  seropositive	   for	   AAV149;	   however,	   there	   is	   no	   conclusive	   evidence	   for	   any	  association	  of	  AAV	  with	  disease	  or	  pathology.	  	  To	  date,	  six	  AAV	  serotypes	  have	  been	  identified	  in	  primates	  (AAV-­‐1	  to	  AAV-­‐6)	  and	  only	  AAV	  type	  2	  (AAV-­‐2)	  isolated	  from	  humans150.	  	   	   	   	   	   	  AAV	  is	  a	  defective	  virus	  dependent	  on	  the	  presence	  of	  a	  helper	  virus,	  usually	  adenovirus	   or	  herpesvirus,	   for	   replication.	   	   The	  AAV	  genome	   is	   encapsidated	   as	   a	  ssDNA	  molecule	  of	  4680	  bases	  with	  inverted	  terminal	  repeat	  (ITR)	  sequences	  of	  145	  bases	  at	  each	  end.	  	  The	  viral	  genome	  contains	  two	  open	  reading	  frames	  (ORFs)	  that	  encode	  for	  the	  proteins	  Rep	  (replication)	  and	  Cap	  (capsid).	   	  Three	  promoters	  have	  been	   found:	  p5,	  p19,	  and	  p40	  151.	   	  Along	  with	  alternative	  splicing	  and	   through	   the	  use	  of	  different	  initiation	  codons,	  AAV	  can	  generate	  4	  Rep	  and	  3	  Cap	  proteins,	  each	  with	   specialized	   functions.	   	   The	   ITRs	   are	   cis-­‐acting	   elements	   required	   for	  replication,	   packaging	   and	   integration	   of	   the	  AAV	   genome	   into	   the	   genome	   of	   the	  host150.	  	  	  Since	  AAV	  does	  not	  inflict	  human	  diseases,	  it	  was	  touted	  as	  the	  next	  vehicle	  for	  gene	  therapy.	  	  As	  a	  result,	  a	  recombinant	  form	  of	  AAV	  (rAAV)	  was	  developed	  that	  is	  not	  capable	  of	  carrying	  out	  a	  lytic	  infection.	  	  The	  rAAV	  genome	  was	  constructed	  by	  “gutting”	  the	  AAV	  genome	  (i.e.	  rep	  and	  cap)	  and	  replacing	  them	  with	  sequences	   in	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place	  for	  the	  gene	  of	  interest	  between	  the	  two	  ITRs149,152,153,	  such	  that	  the	  resultant	  chimeric	  virus	  will	  have	  a	  packaging	  capacity	  around	   the	  size	  of	   the	  AAV	  genome,	  between	  4.1	  to	  4.9	  kb.	  	  	  A	  unique	  feature	  of	  modifying	  the	  genome	  of	  rAAV	  is	  that	  it	  is	  quite	  efficient	  at	  knocking	  out	  genes	  in	  human	  cells	  by	  utilizing	  the	  host’s	  HR	  pathway.	  	  The	  overall	  gene	   targeting	   frequency	   is	   3%,	   or	   3	   correct	   targeting	   events	   in	   every	   100	  productive	   transductions	   or	   genomic	   integrations154,155.	   	   rAAV	   mediated	   gene	  targeting	  is	  100-­‐fold	  more	  efficient	  compared	  to	  traditional	  transfection	  methods154.	  	  rAAV	  methodology	  is	  both	  simple	  and	  expeditious;	  the	  entire	  experiment	  to	  knock	  out	   a	   gene	   can	   take	   as	   little	   as	   2	   months.	   	   A	   simple	   protocol	   driven	   almost	  exclusively	  by	  PCR	  to	  construct	  the	  targeting	  vectors	  and	  viral	  stocks	  enhanced	  the	  ease	   of	  working	  with	   rAAV	   vectors.	   	   Additionally,	   the	   rAAV	   targeting	   (homology)	  arms	  are	   short	  enough	   (<	  1.0	  kb)	   to	  enable	   screening	   the	   resulting	  clones	  by	  PCR	  instead	   of	   Southern	   blots,	   once	   again	   expediting	   the	   targeting	   process,	   and	   the	  homology	  arms	  can	  be	  modified	  to	  “flox”	  exons	  of	  interest.	  	  In	  recent	  years	  rAAV	  has	  gained	  popularity	  to	  generate	  knockout	  human	  cell	  lines	  in	  many	  fields	  of	  study155.	  The	   first	   generation	   of	   rAAV	   knockout	   vectors	   were	   constructed	   with	   a	  promoter-­‐driven,	  NEO	  selection	  cassette154,156.	  	  In	  a	  correct	  gene	  targeting	  event,	  the	  rAAV	  vector	  utilizes	  the	  HR	  pathway	  to	  locate	  the	  correct	  locus	  and	  replace	  the	  exon	  of	   interest	  with	   the	  PGK:NEO	  selection	  cassette	   to	  yield	  a	  correctly	   targeted,	  G418	  resistant	   clone.	   	   The	   downside	   of	   this	   generation	   of	   vectors	   was	   that	   promoter-­‐driven	   NEO	   selection	   cassette	   conferred	   G418-­‐resistance	   to	   rAAV	   vectors	   that	  integrate	  randomly	  in	  the	  genome.	  	  Since	  the	  majority	  of	  the	  integration	  events	  are	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random,	  this	  vector	  creates	  a	  large	  pool	  of	  non-­‐targeted,	  G418	  resistant	  clones.	  	  As	  a	  result,	   the	  population	  of	  correctly	   targeted	  clones	   is	  highly	  diluted	   in	  the	  selection	  process,	  and	  lowers	  the	  efficiency	  of	  screening.	  To	   enrich	   for	   correctly-­‐targeted,	   G418-­‐resistant	   clones	   in	   the	   screening	  process,	   the	   synthetic	   exon	   promoter	   trap	   (SEPT)	   knockout	   vector	   was	  developed157.	  	  The	  SEPT	  vector	  does	  not	  have	  a	  promoter;	  instead,	  it	  is	  constructed	  with	  a	  splice	  acceptor	  upstream	  of	  an	  internal	  ribosomal	  entry	  site	  (IRES)	  sequence	  to	  express	  NEO.	  	  Therefore,	  the	  SEPT	  vector	  only	  confers	  G418	  resistance	  to	  clones	  that	  are	  correctly	   targeted	  or	  when	  the	  vector	   fortuitously	   integrates	   into	  random	  ORFs.	   	   The	   SEPT	   vector	   effectively	   enriches	   for	   correctly	   targeted	   clones	   by	  eliminating	   the	   numerous	   random	   integration	   events	   that	   do	   not	   occur	   in	   ORFs.	  	  With	   the	   SEPT	   vector,	   the	   average	   targeting	   frequency	   is	   increased	   by	   6-­‐fold	  compared	  to	  the	  promoter-­‐driven	  knockout	  vectors157.	  	  
The	  Human	  HCT116	  Cell	  Line	  
	  	   The	  cell	   line	  of	  our	  choice	  is	  the	  human	  colorectal	  adenocarcinoma	  HCT116	  cell	   line.	   	  This	  cell	   line	  has	  46	  chromosomes	  with	   intact	  p53158.	   	  HCT116	  is	  MLH1-­‐deficient	   which	   renders	   it	   mismatch	   repair	   defective159.	   	   Since	   MMR	   generally	  impedes	   gene	   targeting,	   the	   HCT116	   cell	   line	   is	   particularly	   amenable	   to	   this	  technology.	   	   There	   are	   over	   40	   reports	   of	   successful	   gene	   targeting	   having	   been	  carried	  out	  HCT116	  cells,	  allowing	  for	  an	  assessment	  of	  the	  null	  phenotype155.	  	  The	  ease	   of	   knocking	   out	   genes	   in	   this	   cell	   line	   has	   provided	   our	   laboratory	   with	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countless	  isogenic	  mutant	  cell	  lines	  that	  are	  essentially	  as	  powerful	  as	  yeast	  genetic	  models.	  	  
Summary	  
	  	   In	  summary,	  human	  cells	  have	  evolved	  multiple	  DNA	  DSB	  repair	  pathways:	  HR,	   C-­‐NHEJ,	   and	   A-­‐NHEJ.	   	   HR	   repair	   requires	   extensive	   DNA	   resection	   and	   a	  homologous	  template	  in	  the	  form	  of	  an	  undamaged	  sister	  chromatid	  that	  can	  result	  in	  error-­‐free	  repair.	  	  In	  contrast,	  the	  C-­‐	  and	  A-­‐NHEJ	  pathways	  simply	  rejoin	  the	  two	  ends	  of	  broken	  DNA	  together	  and	  do	  not	  require	  a	  homologous	  template	  for	  repair.	  	  	  Recent	   studies	   report	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	   the	   nucleases	   that	  resect	  DNA	  DSBs.	   	   These	   studies	   depend	  on	   siRNA	  knockdowns	   and	  only	   address	  response	  to	  exogenous	  DNA	  damaging	  agents,	  and	  they	  fail	  to	  address	  gene	  function	  in	   an	   otherwise	   unperturbed	   cell	   nor	   do	   they	   test	   their	   essential	   functions51-­‐
53,57,63,94,160,161.	  	  To	  fill	  this	  void,	  I	  have	  constructed	  genetic	  models	  in	  human	  somatic	  cells	   that	   are	   conditionally	   null	   for	   CtIP,	   EXO1	   and	  DNA2.	   	  With	   these	   cell	   lines,	   I	  made	  novel	  observations:	  1)	  CtIP,	  EXO1	  and	  DNA2	  are	  all	  essential	   in	  human	  cells,	  2)	   CtIP	   and	   EXO1	   are	   intimately	   involved	   in	   DNA	   replication,	   3)	   CtIP,	   EXO1,	   and	  DNA2	  are	  coregulated,	  and	  4)	  CtIP,	  EXO1,	  and	  DNA2	  coordinately	  regulate	  BRCA2,	  Rad51,	  FANCD2,	  and	  CHK1.	  In	  a	  second	  project,	   I	  characterized	  differences	   in	  C-­‐NHEJ	  and	  A-­‐NHEJ.	   	  The	  Ku-­‐dependent	  C-­‐NHEJ	  repair	  is	  by	  no	  means	  precise	  due	  to	  minimal	  end	  processing	  of	   DSBs,	   whereas	   the	   A-­‐NHEJ	   repair	   mechanism	   involves	   greater	   end	   processing	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that	  is	  often	  accompanied	  by	  microhomology	  at	  the	  repair	  junction118,128,140.	  	  In	  this	  study,	  we	  have	  found	  that	  Ku	  is	  a	  unique	  C-­‐NHEJ	  factor	  that	  actively	  represses	  the	  A-­‐NHEJ	  pathway.	  The	   HR	   and	   NHEJ	   pathways	   must	   be	   carefully	   regulated.	   	   DSBs	   or	   DNA	  damage	  that	  arise	  during	  DNA	  replication	  are	  preferably	  repaired	  by	  HR	  because	  it	  is	  error-­‐free;	  however,	  cells	  compromised	  for	  HR	  or	  FA	  are	  susceptible	   to	  NHEJ	  to	  repair	  these	  DSBs1,122-­‐125.	  	  Alas,	  the	  resulting	  NHEJ	  repair,	  while	  fixing	  the	  immediate	  problem	  often	  leads	  to	  chromosomal	  aberrations	  that	  are	  ultimately	  detrimental	  to	  the	  cell113,125,139,162.	  	  In	  this	  study,	  we	  show	  by	  genetically	  inactivating	  CtIP	  and	  EXO1	  that	   the	   absence	   of	   DNA	   resection	   results	   in	   53BP1	   being	   heavily	   recruited	   to	  chromatin,	   which	   allows	   NHEJ	   to	   dictate	   DSB	   repair.	   	   As	   a	   result	   we	   observe	  extremely	  high	  rates	  of	  chromosomal	  aberrations.	  	  Together,	  these	  studies	  indicate	  that	  HR	  and	  NHEJ	  are	  regulated	  by	  DNA	  resection.	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Homologous	  recombination	  begins	  with	  an	  essential	  step	  where	  the	  ends	  of	  a	  double-­‐stranded	   break	   are	   resected	   to	   generate	   long	   tracts	   of	   ssDNA.	   	   In	   human	  cells,	   several	   studies	   have	   identified	   that	   CtIP	   and	   EXO1	   are	   required	   for	   the	  resection	   of	   DSBs.	   	   CtIP	   also	   plays	   a	   major	   role	   in	   the	   DNA	   damage	   response	  pathway	  and	  together	  with	  the	  EXO1	  exonuclease,	   it	   facilitates	  extensive	  resection	  to	   expose	   long	   tracks	  of	   ssDNA,	  which	  drives	   the	  HR	   repair	  process.	   	  To	  date,	   the	  majority	   of	   studies	   on	   CtIP	   and	   EXO1	   function	   rely	   on	   siRNA	   knockdown	   and	  subsequent	  exposure	  to	  DNA	  damaging	  agents.	  	  Inasmuch	  as	  we	  have	  learned	  from	  these	  studies,	  they	  are	  nonetheless	  predicated	  on	  a	  cell’s	  response	  to	  DNA	  damaging	  agents	   and	   they	   fail	   to	   address	   the	   essential	   functions	   of	   CtIP	   and	   EXO1	   in	   an	  unperturbed	  cell.	  	  The	  construction	  of	  human	  cells	  conditionally-­‐null	  for	  CtIP,	  EXO1,	  and	  DNA2	  have	  helped	  us	   further	  understand	  the	   functions	  of	   these	  genes.	   	   In	   the	  absence	  of	  CtIP	  or	  EXO1,	  replication	  forks	  stall	  and	  collapse	  into	  DSBs	  even	  without	  the	  presence	  of	  DNA	  damaging	  agents.	  	  We	  also	  find	  that	  CtIP,	  EXO1,	  and	  DNA2	  are	  co-­‐regulated	   and	   that	   they	   coordinately	   regulate	   the	   protein	   levels	   of	   FANCD2,	  BRCA2,	  Rad51,	  and	  CHK1.	  	  	  	  	  
	  	   	  42	  
Introduction	  DNA	  double-­‐stranded	  breaks	  (DSBs)	  are	  the	  most	  lethal	  form	  of	  DNA	  lesions	  for	  a	  cell	  and	  they	  must	  be	  repaired	  if	  the	  cell	  is	  to	  survive.	  	  In	  human	  cells,	  DSBs	  are	  repaired	   by	   the	   non-­‐homologous	   end	   joining	   (NHEJ)1,2	   or	   homologous	  recombination	   (HR)	   pathways3.	   	   These	   two	   DSB	   repair	   pathways	   are	  mechanistically	  distinct.	  NHEJ	  directly	  re-­‐ligates	  two	  broken	  ends	  of	  DNA1,3	  and	  can	  be	   error	   prone4	   resulting	   in	   the	   loss	   of	   genetic	   information,	   whereas	   the	   HR	  pathway	  requires	  homologous	  templates	  for	  repair	  and	  is	  generally	  error-­‐free3.	  	  The	   genomic	   landscape	   of	   a	   human	   cell	   is	   wrought	   with	   obstacles	   for	   an	  active	   replication	   fork.	   	  Highly	   repetitive	   regions	   in	   the	  human	  genome,	   including	  trinucleotide	   repeats	   (TNRs),	   telomeres,	   LINE,	   SINE,	   DNA	   transposons,	   and	   ALU	  repeat	   elements	   transiently	   form	   complex	   DNA	   structures	   at	   periods	   when	   they	  become	  single-­‐stranded5-­‐7.	  	  During	  DNA	  replication,	  these	  complex	  DNA	  structures,	  such	  as	  hairpins,	   triplex	  and	  quadruplex	  DNA	  become	  barriers	   to	  DNA	  replication	  and	  they	  can	  trigger	  replication	  fork	  stalling4,8-­‐10.	  	  For	  example,	  common	  fragile	  sites	  (CFS)	   are	   late	   replicating,	   AT-­‐rich	   repetitive	   regions	   that	   are	   prone	   to	   breakage	  when	  cells	  are	  under	  replication	  stress	  or	  when	  ATR	  function	  is	  compromised11-­‐13.	  	  Recently,	  a	  second	  class	  of	  CFS	  described	  as	  Early	  replicating	  common	  fragile	  sites	  (ERCFs)	  was	  discovered.	  	  As	  their	  name	  implies,	  ERCFs	  are	  early	  replicating	  regions.	  	  Most	   are	   GC	   enriched	   (LINE,	   SINE,	   ALU	   and	   tRNA)	   sequences	   that	   are	   prone	   to	  breakage	  during	  DNA	  replication14.	  	  Similar	  to	  CFs,	  ERCFs	  are	  more	  prone	  to	  break	  if	  ATR	  is	  inhibited11-­‐13.	   	  The	  presence	  of	  these	  fragile	  sites	  suggests	  that	  the	  volatility	  of	  DNA	  replication	  is	  currently	  underestimated.	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In	  HR,	  DNA	  resection	  is	  an	  essential	  step	  that	  occurs	  at	  DSB	  ends	  to	  unveil	  3’-­‐overhang	   stretches	   of	   single-­‐stranded	   DNA	   that	   are	   required	   to	   complete	   the	  repair3,15,16.	  	  This	  resection	  pathway	  was	  initially	  delineated	  in	  yeast	  (Saccharomyces	  
cerevisiae)	   as	   a	   2-­‐tiered	   process.	   	   SAE2	   (CtIP	   in	   humans)	   and	   the	   MRX	   complex	  (MRN	  complex	  in	  humans)	  comprised	  of	  Mre11,	  Rad50	  and	  Xrs2	  (Nbs1	  in	  humans),	  begins	   the	   resection	   process	   at	   the	   DSBs	  with	   a	  minimal	   resection17,18	   of	   100	   bp,	  followed	  by	  long-­‐range	  resection	  facilitated	  by	  EXO1	  and	  DNA2	  to	  extend	  over	  kb	  in	  length19-­‐21.	   	   DNA219-­‐21	   is	   essential	   in	   yeast	   because	   it	   also	   carries	   out	   an	   essential	  function	   in	   Okazaki	   fragment	   processing22-­‐24	   whereas	   SAE2	   and	   EXO1	   are	   not	  required	  for	  survival.	  In	  humans,	   it	  also	  well	  understood	  that	  CtIP	  (CtBP	  interacting	  protein)25	   	   is	  an	  important	  HR	  factor26.	  	  CtIP	  interacts	  with	  the	  MRN	  complex27,28	  and	  localizes	  to	  sites	  of	  DSBs27-­‐30	   to	  mediate	  further	  resection	  by	  EXO131	  and	  DNA231,32.	   	  However,	  CtIP	  appears	   to	  have	  additional	   functions	   from	  apart	   from	  DSB	  resection.	   	  Human	  CtIP	  is	  the	  most	  divergent	  protein	  of	  all	  the	  resection	  factors	  described	  above	  and	  it	  has	   been	   shown	   to	   interact	   with	   BRCA133-­‐35,	   Rb36,	   PCNA37,	   CDK238,	   and	   ATM28,34	  emphasizing	   roles	   of	   CtIP	   in	   the	   DNA	   damage	   response	   (DDR)	   signaling	   pathway	  and	  checkpoint	  regulation.	  	  	  CtIP	   is	   an	   essential	   gene	   in	   mice,	   where	   it	   was	   suggested	   to	   carry	   out	   an	  essential	   function	   in	  cell	  cycle	  regulation	  with	  Rb39.	   	   In	  a	  recent	  study,	   two	  human	  CtIP	  mutations	   that	   result	   in	  CtIP	  C-­‐terminal	   truncations	  were	   identified	   in	  Seckel	  (SCKL2)	   and	   Jawad	   (J)	   syndrome	   patients40	   (characterized	   by	   microcephaly	   and	  developmental	  defects).	  	  The	  SCKL2	  and	  J	  mutations	  are	  thought	  to	  be	  hypomorphic	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in	  mediating	  DNA	  resection.	  	  However,	  they	  still	  possess	  the	  Rb-­‐interacting	  domain	  at	  their	  N-­‐terminus	  strongly	  suggesting	  that	  CtIP	  maybe	  essential	  in	  humans,	  similar	  to	  mice30,36.	  EXO1	   is	   a	   multitasking	   nuclease41.	   	   EXO1	   plays	   a	   role	   in	   telomere	  maintenance	  by	  tailoring	  G-­‐overhangs	  for	  t-­‐loop	  structure	  formation42	  in	  mice,	  and	  it	   is	   also	   a	   well-­‐established	   factor	   in	   the	   mismatch	   repair	   (MMR)	   pathway43-­‐47.	  	  Moreover,	  EXO1	  is	  reported	  to	  be	  involved	  in	  DNA	  replication	  from	  studies	  showing	  tight	  regulation	  of	  EXO1	  during	  replication	  stress1,48-­‐50	  3,51,52,	  and	  in	  a	  recent	  study,	  EXO1	  was	  reported	   to	   travel	   intimately	  with	   the	  replication	   fork	   in	  an	   isolation	  of	  proteins	  on	  nascent	  DNA	  –	  mass	  spectrometry	  (iPOND-­‐MS)	  study1,3,53.	   	  EXO1	  is	  not	  essential	  in	  mice4,54,55	  but	  it	  is	  unknown	  if	  this	  is	  also	  the	  case	  for	  humans.	  	  Typically,	  the	   lethality	   of	   a	   mouse	   gene	   directly	   translates	   to	   their	   human	   counterparts;	  however,	  exceptions	  do	  occur.	  	  For	  instance,	  Ku86	  null	  mice	  are	  viable3,56,	  whereas	  Ku86	  null	  human	  cells	  do	  not	  survive5-­‐7,57,58.	  	  	  	  In	  vitro	  studies	  suggest	  that	  DNA2	  and	  EXO1	  can	  operate	  as	  3	  distinct	  forms	  of	   resection	  machines.	   	   Initially,	   two	   studies	   reported	   that	   both	   DNA2	   and	   EXO1	  individually	   interact	   with	   BLM,	   MRN,	   and	   RPA	   to	   resect	   dsDNA4,8-­‐10,59,60,	   thereby	  suggesting	   that	   there	   are	   two	   redundant	   DSB	   resection	   complexes.	   	   However,	  another	   study	   described	   a	   third	   resection	  machine	   in	  which	   human	   single	   strand	  binding	   protein	   (hSSB1)	   and	  MRN	  were	   demonstrated	   to	   specifically	   activate	   the	  nuclease	   activity	   of	   EXO1,	   but	   not	   DNA23,61-­‐64.	   	   The	   regulation	   of	   these	   resection	  complexes	   and	   their	   potential	   preferences	   for	   different	   types	   of	   DNA	   damage	  requires	  further	  investigation.	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Human	  DNA2	  has	  not	  been	  very	  well	  characterized;	  however,	  much	  has	  been	  learned	  from	  yeast.	  	  Yeast	  DNA2	  was	  initially	  described	  as	  a	  flap	  endonuclease	  that	  excises	   5’-­‐flap	   ssDNA	   structures	   resulting	   from	   the	   displacement	   of	   Okazaki	  fragments	  during	  Polymerase	  δ	  extension.	  	  The	  excision	  by	  DNA2	  leaves	  behind	  ~6	  nt	   long	   flaps	  which	  are	   further	  processed	  by	  FEN-­‐1	   to	   create	   ligatable	  nicks	   to	  be	  sealed	  by	  DNA	  ligase	  I	  or	  LIGI65.	  	  More	  recently,	  studies	  have	  shown	  that	  yeast	  DNA2	  is	  a	  nuclease,	  downstream	  of	  SAE2	  (CtIP	  in	  human),	  which	  functions	  synergistically	  with	  EXO1	  in	  the	  resection	  of	  DSBs21.	  	  EXO1	  can	  provide	  partial	  compensation	  in	  the	  absence	  of	  DNA2;	  however,	  the	  contrary	  is	  not	  true,	  indicating	  that	  DNA2	  may	  play	  an	  accessory	  role	  in	  DSB	  resection21	  	   Human	  DNA2	  possesses	  canonical	  helicase	  and	  endonuclease	  domains	  in	  its	  N-­‐	  and	  C-­‐termini,	  respectively.	  	  However,	  human	  DNA2	  in	  vitro	  is	  devoid	  of	  helicase	  activity	   and	   only	   has	   active	   endonucleolytic	   activity66.	   	   In	   human	   cells,	   DNA2	   is	  found	  in	  mitochondria,	  where	  it	  is	  required	  for	  mitochondrial	  DNA	  stability,	  and	  the	  nucleus,	  where	  it	  is	  required	  for	  genomic	  stability67.	  	  	  The	   vast	   majority	   of	   studies	   on	   CtIP27-­‐30,68,69,	   EXO131,48,50,51,63,64,70,	   and	  DNA23,15,16,31,32	   have	   been	   based	   on	   transiently	   knocking	   down	   CtIP,	   EXO1,	   and	  DNA2,	   followed	   by	   examining	   the	   cell’s	   responses	   to	   DNA	   damaging	   agents.	  	  Inasmuch	   information	   as	   these	   studies	   provide,	   it	   is	   unknown	   whether	   CtIP	   and	  EXO1	   are	   essential	   genes	   in	   human	   cells	   and	   what	   their	   precise	   roles	   in	   DNA	  replication	  and	  repair	  may	  be.	  To	   further	   investigate	   the	   functions	   of	   CtIP	   and	   EXO1	   in	   otherwise	  unperturbed	  cells,	  we	  constructed	  HCT116	  cell	   lines	  that	  are	  conditionally-­‐null	   for	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CtIP	   and	  EXO1.	   	   This	   powerful	   genetic	  model	   allowed	  us	   to	  make	   observations	   of	  cellular	  behavior	  in	  the	  absence	  of	  these	  essential	  genes.	  	  After	  inactivating	  CtIP	  and	  EXO1	  by	  Cre-­‐mediated	  recombination	  of	  the	  “Floxed”	  allele,	  the	  CtIP	  and	  EXO1-­‐null	  cells	  have	  a	  time	  window	  of	  5-­‐7	  days	  before	  completely	  dying	  off.	  	  This	  provides	  us	  with	  a	  generous	  window	  of	   time	   to	  observe	   the	   temporal	  dynamics	  of	  DNA	  repair	  factors	   and	   cellular	   behavior.	   	   In	   the	   absence	   of	   DNA	   damaging	   agents	   or	   DNA	  replication	   inhibitors,	   the	   inactivation	   of	   CtIP	   or	   EXO1	   cannot	   rescue	   replication	  forks	   that	   stall	   in	   repetitive	   regions	  where	  breakage-­‐prone	  CFs	   and	  ERCFs	   reside.	  	  Ultimately,	  the	  stalled	  forks	  collapse	  into	  DSBs.	  	  For	  the	  first	  time,	  we	  also	  show	  that	  CtIP	  and	  EXO1	  are	  co-­‐regulated,	  and	  that	  they	  also	  regulate	  the	  stability	  of	  FANCD2	  and	   several	   important	  HR	   factors	   including	  BRCA2,	  Rad51,	   CHK1,	   and	  DNA2.	   	  We	  argue	  that	  CtIP	  and	  EXO1	  are	  essential	   for	  replication	   forks	   to	  overcome	  naturally	  occurring	  barriers.	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Results	  
	  
Construction	   of	   human	   conditional	   CtIP-­‐,	   EXO1-­‐,	   and	  DNA2-­‐null	  
somatic	  cell	  lines	  The	   majority	   of	   studies	   on	   CtIP,	   EXO1,	   and	   DNA2	   rely	   solely	   on	   their	  transient	  inactivation	  by	  siRNA	  knockdown	  and	  then	  measure	  the	  cells’	  response	  to	  DNA	  damaging	  agents.	  	  Although	  siRNA	  methods	  swiftly	  lead	  to	  important	  findings,	  they	  fail	  to	  address	  the	  essential	  functions	  of	  CtIP	  and	  EXO1	  in	  an	  unperturbed	  cell.	  	  Therefore,	  we	  derived	  HCT116	  cells	   that	  are	  conditionally-­‐null	   for	  CtIP,	  EXO1	  and	  DNA2.	  The	   conditional	   CtIPFlox/-­‐	  and	  EXO1Flox/-­‐	  HCT116	   cell	   lines	  were	   constructed	  with	  the	  aid	  of	  recombinant	  adeno-­‐associated	  virus	  (rAAV)-­‐mediated	  gene	  targeting	  technology17,18,71.	   	   In	   order	   to	   inactivate	  CtIP	   and	  EXO1,	  we	  used	   a	   synthetic	   exon	  promoter	  trap	  (SEPT):Neo	  selection	  cassette19-­‐21,72	  strategy	  to	  target	  exons	  2	  and	  3	  of	   the	   CtIP	   and	   EXO1	   genomic	   loci,	   respectively.	   	   These	   exons	   were	   specifically	  chosen	   because	   their	   loss	   creates	   frameshift	  mutation,	   in	   the	   open	   reading	   frame	  after	  Cre-­‐mediated	  excision.	  To	   target	   the	   first	   CtIP	   and	   EXO1	   alleles,	   rAAV	   targeting	   vectors	   were	  designed	   with	   3	   loxP	   sites	   sequentially	   flanking	   the	   exon(s)	   and	   the	   SEPT:Neo	  selection	  cassette	  (Fig.	  1A).	   	  The	  correctly	  targeted	  G418	  resistant	  clones	  (CtIPNeo/+	  and	   EXO1Neo/+)	   were	   transiently	   transfected	   with	   a	   PGK	   driven,	   Cre-­‐expressing	  plasmid	  (pPGK	  Cre)	  to	  remove	  the	  SEPT:Neo	  cassette	  and	  restore	  expression	  of	  the	  “Floxed”	   allele,	  CtIPF/+	   and	  EXO1F/+	   (Fig.	  1B).	   	   For	   the	   second	   round	  knockout,	  we	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utilized	   non-­‐conditional	   knockout	   vectors	   designed	  with	   2	   loxP	   sites	   to	   flank	   the	  SEPT:Neo	  cassette.	   	  The	  correctly	  targeted	  clones	  (CtIPF/Neo	  and	  EXO1F/Neo,	  Fig.	  1C)	  were	   transiently	   transfected	  with	   pPGK	  Cre	   to	   derive	   the	   CtIPF/-­‐	   and	   EXO1F/-­‐	   null	  HCT116	  cell	  lines	  (Fig.	  1D).	  DNA2	   is	   triploid	   in	   the	  HCT116	  cell	   line	  and	  all	   three	  alleles	  were	   targeted	  with	   a	   rAAV	   targeting	   vector	   designed	  with	   3	   loxP	   sites	   sequentially	   flanking	   the	  exon	   and	   the	   SEPT:Neo	   selection	   cassette	   (Fig.	   1G).	   	   After	   the	   first	   round	   of	  targeting,	   correctly	   targeted	   G418	   resistant	   clones	   (DNA2Neo/+/+,	   Fig.	   1H)	   were	  transiently	   transfected	   with	   a	   pPGKCre	   to	   remove	   the	   SEPT:Neo	   cassette	   and	  restore	  expression	  of	  the	  “Floxed”	  allele,	  DNA2F/+/+	  (Fig.	  1I).	  	  The	  desired	  DNA2F/+/+	  clone	   was	   identified	   and	   subsequently	   targeted	   at	   a	   second	   allele	   to	   generate	   a	  DNA2F/Neo/+	  cell	   line.	   	   DNA2F/Neo/+	  cells	  were	   transiently	   transfected	  with	   pPGKCre	  (Fig.	  1J)	  and	  clones	  were	  identified	  that	  had	  undergone	  a	  single	  Cre	  recombination	  event	  that	  had	  completely	  excised	  the	  “Floxed”	  exon	  and	  SEPT:Neo	  cassette	  on	  the	  second	   targeted	   allele	   (DNA2F/-­‐/+,	   Fig.	   1K).	   	   The	   third	   and	   final	   allele	   in	  DNA2F/-­‐/+	  cells	   was	   targeted	   in	   a	   similar	   fashion	   as	   the	   second	   round.	   	   Correctly	   targeted	  DNA2F/-­‐/Neo	   clones	   (Fig.	   1L)	   were	   identified	   and	   Cre’d	   for	   a	   “true”	   conditional	  DNA2F/-­‐/-­‐	  null	  cell	  line	  (Fig.	  1M).	  	  Finally,	  we	  established	  a	  Cre-­‐Estrogen	  Receptor	  (CreERt2)	  inducible	  system	  by	   stably	   integrating	   a	   CreERt2-­‐expressing	   plasmid	   into	   the	   CtIPF/-­‐,	   EXO1F/-­‐,	   and	  DNA2F/-­‐/-­‐	  (Figs.	  1E	  &	  1N)	  cell	  lines	  via	  PiggyBac	  transposition.	  	  The	  characterization	  of	   CtIP-­‐/-­‐,	   EXO1-­‐/-­‐,	   and	   DNA2-­‐/-­‐/-­‐	   null	   cells	   is	   conveniently	   achieved	   by	   adding	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tamoxifen	   to	   CtIPF/-­‐:CreERt2,	   EXO1F/-­‐:CreERt2,	   and	   DNA2F/-­‐/-­‐:CreERt2	   cells	   in	  culture	  to	  synchronously	  induce	  the	  excision	  of	  the	  nuclear	  “Floxed”	  exons.	  	  
CtIP	  and	  EXO1	  are	  required	  for	  survival	  in	  human	  somatic	  cells	  CtIP	   is	   an	   essential	   gene	   in	  mice19-­‐21,39.	   	   CtIP-­‐/-­‐	   embryos	   die	   at	  D4.0,	  where	  they	  arrest	  in	  G0-­‐phase,	  thus	  making	  it	  impossible	  to	  characterize	  any	  CtIP-­‐/-­‐	  mouse	  embryonic	  fibroblasts	  (MEFs).	  	  In	  contrast,	  EXO1-­‐/-­‐	  mice	  are	  viable	  with	  phenotypes	  of	  sterility	  and	  cancer	  predisposition22-­‐24,39.	  	  In	  most	  cases	  the	  lethality	  of	  a	  gene	  in	  mice	   implies	   a	   similar	   phenotype	   for	   its	   human	   ortholog,	   hence	   leading	   us	   to	  postulate	   that	   CtIP,	   but	   not	   EXO1,	   might	   be	   essential	   in	   human	   somatic	   cells.	  	  However,	  exceptions	  do	  exist	  such	  as	  Ku86,	  where	  Ku86-­‐null	  mice	  are	  alive25,56	  but	  Ku86-­‐null	  human	  cells	  do	  not	  survive26,57,58.	  	   To	   induce	   the	   excision	  of	   “floxed”	   exons	   in	   the	  CtIPF/-­‐:CreERt2	   and	  EXO1F/-­‐:CreERt2	   cell	   lines,	   a	   final	   concentration	   of	   10	   nM	   tamoxifen	   was	   added	   to	   the	  cultures.	  	  Whole	  cell	  extracts	  were	  then	  prepared	  from	  the	  indicated	  time	  points	  to	  monitor	   CtIP	   and	   EXO1	   expression	   levels	   by	   western	   analysis.	   	   After	   3	   days	   of	  tamoxifen	   exposure,	   CtIP	   (Fig.	   2A)	   and	   EXO1	   (Fig.	   2B)	   protein	   levels	   were	  undetectable	   in	   the	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   respectively.	   In	  contrast,	   cells	   treated	   with	   just	   EtOH	   (carrier)	   as	   controls,	   maintained	   their	  respective	  expression	  of	  CtIP	  and	  EXO1	  (Fig.	  2A	  &	  2B)	   throughout	   the	  duration	  of	  the	  experiment.	  	  Thus,	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  are	  efficiently	  converted	  into	   CtIP-­‐	   and	   EXO1-­‐null	   cells	   after	   the	   CreERt2	   fusion	   protein	   is	   induced	   by	  tamoxifen.	   	   The	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   display	   a	   proliferation	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pattern	   similar	   to	  WT:CreERt2	   in	   the	   absence	   of	   tamoxifen	   (Fig.	   2C).	   	   In	   contrast,	  CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   failed	   to	   proliferate	   like	  WT:CreERt2	   cells	   in	  the	  presence	  of	  tamoxifen	  (Fig.	  2D).	  	  Therefore,	  human	  somatic	  cells	  cannot	  survive	  without	  CtIP	  or	  EXO1.	  	  	   	  When	  the	  cells	  stopped	  growing	  after	   tamoxifen	  treatment	  we	  noticed	  that	  the	  nuclei	  of	  CtIP-­‐	  and	  EXO1-­‐	  null	  cells	  shared	  morphological	  phenotype	  similar	  to	  X-­‐ray	   irradiated	   cells,	   in	   which	   their	   nuclei	   dramatically	   increased	   in	   size	   due	   to	  severe	  DNA	  damage	   (data	  not	   shown).	   	  Consistent	  with	   this	  observation:	   the	  DNA	  damage	  marker	  p53	  was	  highly	   elevated	   in	   tamoxifen-­‐treated	  CtIPF/-­‐:CreERt2	   and	  EXO1F/-­‐:CreERt2	  cells	  (Fig.	  2A	  and	  2B).	  	  This	  is	  a	  strong	  indicator	  that	  DNA	  damage	  is	  accumulating	  in	  the	  absence	  of	  CtIP	  and	  EXO1.	  	   Since	  the	  HCT116	  cell	  line	  are	  MLH1-­‐deficient73,	  we	  were	  concerned	  that	  the	  lethality	  of	  CtIP	  and	  EXO1	  may	  be	  synthetic	  with	  MLH1.	  	  Therefore,	  we	  established	  MLH1	   expressing	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   (Fig.	   1SC).	   	   After	  treating	  CtIPF/-­‐:CreERt2	  +	  MLH1	  and	  EXO1F/-­‐:CreERt2	  +	  MLH1	  cells	  with	  tamoxifen,	  we	   observed	   an	   identical	   lack	   of	   proliferation	   in	   the	  MTS	   colormetric	   assay	   (Fig.	  S1B),	   alongside	   with	   the	   diminishing	   protein	   levels	   of	   CtIP	   and	   EXO1	   (Fig.	   S1C).	  	  Thus,	  CtIP	  and	  EXO1	  are	   still	   essential	   in	  MLH1-­‐expressing	  cells,	   and	   they	  are	  not	  synthetically	  lethal	  with	  the	  absence	  of	  MLH1.	  	  	  In	  summary,	  we	  have	  shown	  that	  the	  CreERt2	  inducible	  system	  is	  functional	  such	   that	   CtIP	   and	   EXO1	   are	   inactivated	   in	   response	   to	   tamoxifen.	   	   We	   also	  established	  that	  human	  somatic	  cells	  do	  not	  survive	  the	  absence	  of	  CtIP	  or	  EXO1	  and	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accumulate	   DNA	   damage	   as	   measured	   by	   the	   up-­‐regulation	   of	   p53	   levels.	  	  Importantly,	  all	  of	  this	  occurred	  without	  any	  external	  sources	  of	  genotoxins.	  	  
Loss	  of	  CtIP	  or	  EXO1	  induces	  chromosomal	  aberrations	  	   Since	  damaged	  DNA	  presumably	  accumulates	  (Figs.	  2A	  &	  2B)	  in	  the	  absence	  of	   CtIP	   and	   EXO1,	   we	   sought	   to	   assess	   the	   effects	   of	   this	   absence	   on	   genomic	  stability	   by	   karyotype	   analysis.	   	   For	   this	   experiment,	  we	  used	  CtIPF/-­‐:CreERt2	   and	  EXO1F/-­‐:CreERt2	   cells	   that	   were	   immediately	   exposed	   to	   tamoxifen	   (day	   0)	   as	  controls	   and	   compared	   them	   to	   cells	   exposed	   to	   tamoxifen	   for	   1	   day	   and	   the	   last	  possible	  time	  points	  when	  the	  samples	  can	  yield	  metaphase	  spreads	  for	  analysis	  (7	  days	  for	  CtIP	  and	  5	  days	  for	  EXO1).	  	  	  At	   day	   0,	   the	   karyotypes	   of	   CtIPF/-­‐:CreERt2	   appear	   normal	   with	   diploid	  chromosomes,	  minimal	  breaks	  and	  no	  evidence	  of	  chromosomal	  fragmentation	  (Fig.	  3A	  &	  Table	  1).	  	  However,	  after	  one	  day	  of	  tamoxifen	  treatment,	  chromosomal	  breaks	  in	   the	   CtIP-­‐null	   cells	   become	   more	   frequent,	   and	   metaphases	   with	   >15	   breaks	  appeared	  in	  13%	  of	  the	  analyzed	  metaphases	  (Fig.	  3A	  &	  Table	  1).	   	  Congruent	  with	  increased	  breaks,	  we	  found	  quantifiable	  chromosome	  fragments	  (1	  to	  15)	  in	  70%	  of	  the	   metaphases	   and	   13%	   additional	   metaphases	   that	   were	   too	   fragmented	   to	  quantify.	   	  We	   also	   observed	   increased	   aneuploidy,	  where	   60%	  of	   the	  metaphases	  had	   47	   to	   60	   chromosomes	   and	   13%	  of	   the	  metaphases	  were	   tetraploid.	   	   After	   7	  days	  of	   tamoxifen	   treatment,	   the	  chromosomal	  abnormalities	  of	  CtIP-­‐null	   cells	  are	  more	  severe	  as	  metaphases	  with	  >15	  breaks	  and	  severely	  fragmented	  chromosomes	  doubled	   from	   13%	   to	   27%.	   	   Additionally,	   aneuploidy	   was	   more	   severe	   with	   an	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increase	   to	   17%	   tetraploid	  metaphases	   and	   7%	   octaploid	  metaphases	   (Fig.	   3A	   &	  Table	  1).	  	  	  	   Similarly	   at	   day	   0,	   EXO1F/-­‐:CreERt2	   cells	   appeared	   normal	   with	   diploid	  chromosomes,	  minimal	  breaks	  and	  no	  evidence	  of	  chromosomal	  fragmentation	  (Fig.	  3B	   &	   Table	   2).	   	   After	   one	   day	   of	   tamoxifen	   treatment,	   the	   chromosomal	  abnormalities	  in	  EXO1-­‐null	  cells	  were	  more	  severe	  than	  CtIP-­‐null	  cells	  with	  75%	  of	  the	   metaphases	   containing	   >15	   breaks	   and	   fragments	   were	   detected	   in	   all	  metaphases.	   	  Furthermore,	  60%	  of	  the	  daylong	  tamoxifen-­‐treated	  EXO1F/-­‐:CreERt2	  cells	  were	  extremely	  fragmented	  while	  the	  remaining	  40%	  had	  <15	  fragments,	  and	  all	  metaphases	  were	   in	   the	  diploid	  range.	   	  After	  5	  days	  of	   tamoxifen	  treatment,	  all	  EXO1-­‐null	  metaphases	  had	  >15	  breaks	  and	  extremely	  fragmented	  chromosomes.	  	  In	  addition,	  70%	  of	  the	  metaphases	  were	  tetraploid	  (Fig.	  3	  &	  Table	  2).	  	  	   Radial	  structures	  are	  rare	  forms	  of	  chromosomal	  fusions	  commonly	  seen	  in	  Fanconi	   Anemia	   patient	   cells	   treated	  with	   replication	   inhibitors74.	   	   Control	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   did	   not	   exhibit	   any	   radial	   chromosomes.	  	  However,	  16%	  of	  tamoxifen-­‐treated	  CtIPF/-­‐:CreERt2	  cells	  acquired	  1	  to	  3	  radials,	  and	  3%	  had	  more	  than	  3	  radials	  after	  1	  or	  7	  days	  respectively	  of	  tamoxifen	  treatment.	  	  In	  the	  EXO1F/-­‐:CreERt2	  cells,	  we	  found	  that	  radial	  structures	  occurred	  at	  even	  higher	  frequency	  than	  CtIPF/-­‐:CreERt2	  cells.	   	  After	  one	  day	  of	  tamoxifen	  exposure,	  45%	  of	  the	  EXO1F/-­‐:CreERt2	  cells	  acquired	  1	  to	  3	  radials	  and	  after	  5	  days,	  50%	  of	  the	  cells	  had	  acquired	  1	  to	  3	  radials	  and	  20%	  had	  more	  than	  3	  radials.	  	  Thus,	  the	  loss	  of	  CtIP	  or	   EXO1	   results	   not	   only	   in	   chromosomal	   fragmentations,	   but	   also	   in	   fusions	   and	  radial	  structures.	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CtIP	  and	  EXO1	  regulate	  global	  DNA	  replication	  	  
	   CtIP	   and	   EXO1	   have	   mainly	   been	   described	   as	   resection	   factors	   in	   DNA	  damage	   repair.	   	   However,	   CtIP	   has	   been	   implicated	   in	   regulation	   of	   the	   cell	   cycle	  because:	  i)	  CtIP	  is	  cell	  cycle	  regulated	  gene,	  which	  peaks	  during	  S	  and	  G2	  phases27-­‐
30,75,	   ii)	  CtIP	   interacts	  with	  Rb31,36,76,	   a	  major	   cell	   cycle	   regulator,	   and	   iii)	  CtIP-­‐null	  MEFs	  arrest	  in	  G031,32,39.	  	  And	  recently,	  EXO1	  was	  found	  to	  be	  intimately	  associated	  with	  replication	  forks	  in	  an	  iPOND-­‐MS	  study33-­‐35,53.	  	  	   Using	  asynchronous	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells,	  we	  analyzed	  cell	  cycle	  profiles	  of	  cells	  via	  an	  EdU	  incorporation	  assay	  that	  lacked	  CtIP	  or	  EXO1	  to	  determine	   whether	   CtIP	   and	   EXO1	   play	   direct	   roles	   in	   DNA	   replication.	   EtOH-­‐treated	   WT:CreERt2,	   CtIPF/-­‐:CreERt2,	   and	   EXO1F/-­‐:CreERt2	   cells	   appeared	   to	  maintain	  normal	  cell	   cycle	  profiles	  with	  distinct	  G1-­‐,	  S-­‐	  and	  G2-­‐phases	   throughout	  the	  duration	  of	  the	  experiment	  (Fig.	  4A,	  4B,	  &	  4C).	  	  	  In	  stark	  contrast,	   the	  cell	  cycle	  profiles	  of	  tamoxifen-­‐treated	  CtIPF/-­‐:CreERt2	  and	   EXO1F/-­‐:CreERt2	   cells	   were	   severely	   altered	   compared	   to	   tamoxifen-­‐treated	  WT:CreERt2	  cells	  and	   their	  EtOH-­‐treated	  counterparts	   (Fig.	  4).	   	  A	  day	  after	  CtIPF/-­‐:CreERt2	   (Fig.	   4D	   &	   Fig.	   S3F)	   and	   EXO1F/-­‐:CreERt2	   cells	   were	   treated	   with	  tamoxifen,	  (Fig	  4E	  &	  Fig	  S3F)	  virtually	  all	  of	  the	  cells	  occupied	  G2-­‐phase.	  	  Eventually,	  the	  entire	  populations	  of	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  become	  aneuploid	  such	  that	  they	  exceed	  4N	  DNA	  content	  (Figs.	  4D	  &	  4F).	   	  During	   the	  acquisition	  process,	  we	  could	  not	  resolve	  cells	  with	  a	  DNA	  content	  that	  surpassed	  the	  linear	  detection	  threshold,	  indicating	   that	   there	  were	   cells	  with	  potentially	  8N+	  DNA	  content.	   	   Therefore,	  we	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acquired	  data	  in	  logarithmic	  scale	  to	  identify	  missing	  populations	  of	  aneuploid	  cells.	  	  Indeed,	   after	   7	   days	   of	   tamoxifen	   treatment,	   the	  majority	   of	   CtIP-­‐	   and	   EXO1-­‐null	  cells	  were	  detected	  with	  8N	  DNA	  content	  (Figs.	  S2D	  &	  S2F).	   	   Interestingly,	  we	  also	  observed	  16N	  DNA	  content	  in	  cells	  lacking	  CtIP	  but	  not	  EXO1.	  From	  these	  experiments	  we	  conclude	  that	  CtIP	  and	  EXO1	  are	  required	  for	  the	  regulation	  of	  normal	  DNA	  replication	  and	  cell	  cycle	  progression.	   	  In	  the	  absence	  of	  CtIP	  or	  EXO1,	  continuous	  DNA	  replication	  without	  concomitant	  mitosis	  occurs	  until	  cells	  accumulate	  abnormally	  large	  amounts	  of	  DNA	  ranging	  from	  8N	  to	  16N.	  	  	  	  
CtIP	  and	  EXO1	  are	  required	  for	  normal	  replication	  tract	  length	  It	  was	  clear	  that	  DSBs	  are	  occurring	  endogenously	  in	  CtIP-­‐	  or	  EXO1-­‐null	  cells	  as	  evidenced	  by	  the	  accumulation	  of	  chromosomal	  aberrations	  (Fig.	  3)	  and	  elevated	  p53	   levels	   (Fig.	   2).	   	   Moreover,	   the	   DSBs	   in	   these	   cells	   must	   originate	   from	  endogenous	  sources	  since	  the	  cells	  were	  not	  exposed	  to	  any	  DNA	  damaging	  agents.	  	  Importantly,	  DNA	  damage	  such	  as	  DSBs,	   lesions,	  and	  crosslinks	  can	  spontaneously	  occur	  during	  DNA	   replication	   in	   S-­‐phase.	   	   Stalled	   replication	   forks	   that	  do	  not	   get	  reinitiated	  will	  collapse	   into	  DSBs	  that	  can	  result	   in	  chromosomal	  aberrations	  36,64	  
13,37	   38,62,63.	   	   Furthermore,	   rodent	   cells	   defective	   for	   HR	   (BRCA2-­‐deficient	   and	  dominant	   negative	   Rad51	   expression	   in	   V79	   hamster	   cells)	   suffer	   from	   slower	  replication	  fork	  velocities77,	  and	  CHK1-­‐deficient	  cells	  suffer	  from	  shorter	  replication	  tract	  lengths78.	  	  In	  conjunction	  with	  our	  data	  showing	  and	  continued	  DNA	  synthesis	  (Fig.	  4),	  these	  studies	  in	  aggregate	  strongly	  hinted	  at	  DNA	  replication	  as	  the	  source	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of	  DNA	  damage	  in	  the	  absence	  of	  CtIP	  and	  EXO1.	  	  In	  other	  words,	  we	  hypothesized	  that	  CtIP	  or	  EXO1	  are	  required	  for	  normal	  DNA	  replication	  progression.	  We	   assessed	   the	   direct	   impact	   of	   the	   loss	   of	   CtIP	   and	   EXO1	   on	   DNA	  replication	   through	   a	   dual-­‐labeled	   DNA	   fiber	   analysis.	   	   In	   this	   experiment,	   we	  compared	  DNA	  replication	  tract	  lengths	  in	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  treated	  with	   tamoxifen	   for	   2	   and	   3	   days	   to	   DNA	   replication	   tract	   lengths	   of	   their	  EtOH-­‐treated	   counterparts	   and	   WT:CreERt2	   cells.	   	   Replication	   tracts	   were	   first	  labeled	  with	  digoxigenin-­‐dUTP	  (red)	  for	  15	  min	  followed	  by	  EdU	  (green)	  for	  30	  min.	  	  Tract	   lengths	   of	   the	   second	   label	   (green)	   that	   followed	   the	   first	   label	   (red)	   were	  used	  as	  a	  relative	  measure	  of	  replication	  velocity	  (Fig.	  5D).	  	  	  WT:CreERt2	   cells	   produced	  median	   tract	   lengths	   of	   15.9	   μm	  whereas	   tract	  lengths	  of	  EtOH-­‐treated	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  were	  significantly	  shorter,	  with	  median	  tract	  lengths	  of	  14.4	  μm	  (p	  <	  0.001)	  and	  11.8	  μm	  (p	  <	  0.0001),	  respectively	   (Fig.	   5D).	   	   Therefore,	   cells	   that	   lack	   one	   allele	   of	   CtIP	   and	   EXO1	   are	  haploinsufficient	   for	   DNA	   replication	   with	   slower	   replication	   fork	   velocities.	  	  Strikingly,	   after	  2	  days	  of	   tamoxifen	   treatment,	   the	  median	   tract	   lengths	  of	   CtIPF/-­‐:CreERt2	  measured	   7.9	   μm	   (Fig.	   5B)	   and	   EXO1F/-­‐:CreERt2	  measured	   7.2	   μm	   (Fig.	  5C),	   which	  were	   2-­‐fold	   shorter	   (Fig.	   5D)	   than	  WT:CreERt2	   tract	   lengths.	   	   After	   3	  days	  of	  tamoxifen	  treatment,	  replication	  tracts	  were	  severely	  shortened	  to	  median	  lengths	  of	  3.0	  μm	   in	  CtIPF/-­‐:CreERt2	   (Fig.	  5B)	  and	  2.8	  μm	   in	  EXO1F/-­‐:CreERt2	   (Fig.	  5C).	  	  	  	   The	   fiber	   analysis	   demonstrated	   that	   replication	   forks	   have	   drastically	  reduced	   velocities	   in	   the	   absence	   of	   CtIP	   and	   EXO1.	   	   To	   extend	   these	   studies,	  we	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analyzed	  chromatin	  fractions	  for	  PCNA	  by	  western	  analysis.	  	  In	  the	  WT:CreERt2	  and	  EtOH-­‐treated	  cells;	  we	  observed	  that	  the	  unmodified	  PCNA	  was	  the	  majority	  species	  in	  the	  chromatin	  (Fig.	  5E).	  	  Strikingly,	  when	  the	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  were	  exposed	  to	  tamoxifen,	  their	  unmodified	  PCNA	  drastically	  shifted	  toward	  the	   larger,	   modified	   PCNA	   species	   over	   the	   course	   of	   the	   experiment.	   	   Previous	  experiments	  show	  that	  PCNA	  ubiquitylation	  functions	  as	  a	  ‘code’	  for	  DNA	  damage	  to	  alert	   the	   cell	   of	   the	   different	   types	   of	   defects	   that	   arise	   during	  DNA	   replication79,	  which	  is	  correlated	  with	  our	  findings.	  
In	  toto,	  these	  data	  suggest	  that	  CtIP	  and	  EXO1	  are	  normally	  closely	  associated	  with	   the	   replication	   fork	   and	  PCNA	   for	   normal	  DNA	   replication	   progression.	   	   The	  notion	   that	   CtIP	   and	   EXO1	  maybe	   closely	   associated	  with	   replication	   forks	   is	   not	  unfounded	   because	   CtIP	   associates	  with	   PCNA	  during	   replication37,40	   and	   EXO1	   is	  associate	  with	  nascent	  DNA	  strands30,36,53.	   	  We	  extend	   these	  observations	   to	  show	  that	   the	   absence	   of	   CtIP	   or	   EXO1	   directly	   impacts	   on	   DNA	   replication	   fork	  progression.	  
	  
The	   loss	  of	  CtIP	  and	  EXO1	   leads	   to	  stalled	  replication	   forks	  and	  
DSBs	  	   	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  experience	  severe	  DNA	  replication	  defects	  (Fig.	  5).	  	  Here,	  we	  sought	  for	  other	  markers	  at	  the	  whole	  cell	  level	  to	  confirm	  the	  presence	  of	  DNA	  damage	  and	  replication	  fork	  stalling.	  	  Additionally,	  we	  also	  took	  advantage	  of	  a	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relatively	  large	  time	  window	  before	  the	  cell	  dies	  to	  acquire	  a	  temporal	  view	  of	  the	  dynamics	  of	  these	  markers	  in	  cells	  lacking	  CtIP	  and	  EXO1.	  	  	   The	  phosphorylated	  form	  of	  H2AX	  (γH2AX)	   is	  a	  marker	  of	  DNA	  DSBs41,80,81.	  	  WT:CreERt2	  cells	  on	  average	  possessed	  only	  2	  γH2AX	  foci	  per	  cell	  whereas	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  treated	  with	  EtOH	  had	  an	  average	  of	  5	  and	  6	  foci	  per	   cell,	   respectively.	   	   This	   observation	   confirmed	   the	   happloinsufficiency	   we	  observed	   earlier	  with	   fork	   progression	   (Fig.	   5).	   	   In	   stark	   contrast,	   CtIPF/-­‐:CreERt2	  cells	   possessed	   a	   range	   from	  16	   to	   27	   γH2AX	   foci	   per	   cell	   over	   a	   5	   day	   course	   of	  tamoxifen	   treatment	   and	   EXO1F/-­‐:CreERt2	   cells	   scored	   even	   higher	   with	   a	   range	  from	  23	  to	  25	  gH2AX	  foci	  per	  cell.	  	  These	  numbers	  are	  significantly	  higher	  compared	  to	  WT:CreERt2	  or	  even	  camptothecin	  (CPT)	  treated	  cells.	  	  The	  γH2AX	  foci	  persisted	  throughout	   the	   course	   of	   the	   experiment	   indicating	   that	   many	   DSBs	   remain	  unrepaired	   consistent	   with	   the	   breaks	   and	   fragments	   observed	   in	   the	   karyotype	  analysis	  we	  described	  above	  (Fig.	  3	  and	  Table	  1).	  	  	   53BP1	   is	   a	   major	   NHEJ	   mediator42,82,83	   and	   it	   is	   an	   antagonist	   of	   the	   CtIP	  activity	   required	   for	   HR43-­‐47,84,85.	   	   53BP1	   is	   responsible	   for	   the	   genotoxic	   NHEJ-­‐mediated	  repair	  that	  results	   in	  chromosomal	  abnormalities86	  and	  it	   is	  proposed	  to	  inhibit	  HR	  by	  opposing	  CtIP-­‐mediated	  end-­‐resection83-­‐85.	   	   Since	   the	   lack	  of	  CtIP	  or	  EXO1	  apparently	  renders	  HR	  defective,	  we	  hypothesized	  that	  53BP1	  may	  now	  have	  free	  reign	  to	  mediate	  DSB	  repair	  in	  CtIP-­‐	  and	  EXO1-­‐null	  cells.	  WT:CreERt2	   and	   EtOH-­‐treated	   CtIPF/-­‐:CreERt2	   cells	   averaged	   less	   than	   1	  53BP1	   focus	   per	   cell.	   	   The	   EtOH-­‐treated	   EXO1F/-­‐:CreERt2	   cells	   in	   contrast,	   which	  also	  have	  the	  most	  γH2AX	  foci	  amongst	  the	  controls,	  scored	  significantly	  higher	  with	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3.5	  53BP1	   foci	  per	   cell	   (Figs.	   6A	  and	  6B)	   	  After	   a	  day	  of	   tamoxifen	   treatment,	   the	  CtIPF/-­‐:CreERt2	   cells	   scored	   6	   foci	   per	   cell	   whereas	   EXO1F/-­‐:CreERt2	   increased	  dramatically	   reaching	   a	   peak	   of	   24	   foci	   per	   cell.	   	   With	   increasing	   lengths	   of	  tamoxifen	  treatment,	   the	  average	  53BP1	  foci	   in	  CtIPF/-­‐:CreERt2	  cells	  climbed	  to	  11	  per	   cell	   after	   3	   days	   and	   peaked	   at	   14	   per	   cell	   after	   5	   days.	   	   Conversely,	   EXO1F/-­‐:CreERt2	  cells	  displayed	  a	  different	  trend,	  where	  the	  average	  53BP1	  foci	  gradually	  decreased	   to	   13	   and	   11	   per	   cell	   after	   3	   and	   5	   days,	   respectively	   of	   tamoxifen	  treatment	  (Figs	  6A	  and	  6B).	  	  	  To	   support	   this	   immunofluorescence	   (IF)	   data,	   we	   prepared	   whole	   cell	  extracts	   (WCE)	   and	   chromatin	   fractions	   in	   order	   to	   assess	   chromatin	   recruitment	  patterns.	   	  Over	  the	  course	  of	  this	  experiment,	  53BP1	  recruitment	  to	  the	  chromatin	  increased	   after	   tamoxifen	   treatment	   in	   the	   CtIPF/-­‐:CreERt2	   cells,	   whereas	   the	  opposite	   occurs	   in	   EXO1F/-­‐:CreERt2	   cells.	   	   This	   trend	   in	   chromatin	   recruitment	  strongly	  mirrors	  the	  IF	  data	  (Figs.	  6A	  &	  6B).	  	  So	   far,	  we	  have	   shown	   that	   CtIP-­‐	   and	  EXO1-­‐null	   cells	   suffer	   extensive	  DNA	  DSBs	  in	  addition	  to	  very	  short	  replication	  tract	   lengths.	   	  Moreover,	   the	  majority	  of	  the	  chromatin-­‐bound	  PCNA	  in	  these	  cells	  is	  modified,	  consistent	  with	  the	  presence	  of	  high	  levels	  of	  lesions	  at	  the	  replication	  forks.	  	  Thus,	  we	  next	  wanted	  to	  determine	  whether	  DNA	  replication	  is	  the	  source	  of	  the	  DSBs.	  	  FANCD2	  is	  a	  component	  of	  the	  Fanconi	   Anemia	   (FA)	   pathway	   that	   forms	   nuclear	   foci	   at	   stalled	   forks,	   which	   is	  required	   for	   restarting	   stalled	   replication	   forks68,87.	   	   In	  addition,	  RPA,	  another	  key	  HR	   factor,	   also	   forms	   foci	   in	   stalled	   replication	   forks88,89.	   	   Therefore,	  we	   analyzed	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FANCD2	  and	  RPA	   foci	   to	   evaluate	   if	   persistent	   stalled	   forks	   occurred	   in	  CtIP-­‐	   and	  EXO1-­‐null	  cells.	  	   WT:CreERt2	   cells	   averaged	   1	   FANCD2	   focus	   per	   cell	   whereas	   both	   CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  treated	  with	  EtOH	  had	  an	  average	  of	  2	  FANCD2	  foci	  per	  cell	  (Figs.	  6A	  &	  6C).	   	  This	  increase	  in	  FANCD2	  foci	  is	  again	  consistent	  with	  earlier	   observations	   of	   haploinsufficiency	   in	   these	   cell	   lines.	   	   In	   comparison,	  WT:CreERt2	   exposed	   to	   hydroxyurea	   had	   an	   average	   of	   7	   FANCD2	   foci	   per	   cell.	  	  After	   a	   day	   of	   tamoxifen	   treatment,	   we	   observed	   that	   FACND2	   foci	   reached	   their	  peaks	   in	   CtIPF/-­‐:CreERt2	   and	  EXO1F/-­‐:CreERt2	   cells	  with	   5	   and	   7	   FANCD2	   foci	   per	  cell.	  	  After	  3	  and	  5	  days	  of	  tamoxifen	  treatment,	  a	  steep	  reduction	  of	  FANCD2	  foci	  to	  less	  than	  1	  focus	  per	  cell	  was	  observed	  in	  both	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells.	  	   We	   observed	   the	   same	   dynamics	   for	   RPA	   foci.	   	   Control	   WT:CreERt2	   cells	  averaged	   less	  than	  1	  RPA	  focus	  per	  cell,	  whereas	  both	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	   cells	   treated	   with	   EtOH	   had	   an	   average	   of	   1.6	   and	   2.8	   FANCD2	   foci,	  respectively,	  per	  cell.	   	  WT:CreERt2	  exposed	  to	  hydroxyurea	  exhibited	  6.8	  RPA	  foci	  per	   cell,	   consistent	   with	   HU’s	   well-­‐documented	   ability	   to	   stall	   replication	   forks90.	  	  After	   a	   day	   of	   tamoxifen	   treatment,	   RPA	   foci	   also	   reached	   their	   peaks	   in	   CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  with	  6.5	  and	  7.3	  RPA	  foci	  per	  cell.	  	  After	  3	  and	  5	  days	  of	  tamoxifen	  treatment,	  RPA	  foci	  in	  CtIPF/-­‐:CreERt2	  cells	  declined	  to	  4	  and	  2.7	  foci,	  respectively.	  	  EXO1F/-­‐:CreERt2	  cells	  experienced	  an	  even	  steeper	  decline	  after	  3	  and	  5	  days	  of	   tamoxifen	   treatment	  with	  averages	  of	  1.2	   and	   less	   than	  1	   focus	  per	  cell,	  respectively.	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   The	   chromatin	   recruitment	   patterns	   of	   FANCD2,	   RPA,	   and	   53BP1	   were	  identical	   to	   the	   foci	   dynamics	   of	   the	   respective	   proteins	   (Fig.	   6G).	   	   Interestingly,	  FANCD2	   protein	   levels	   in	   the	   WCE	   and	   chromatin	   fractions	   dropped	   below	  detection	  levels	  in	  CtIP-­‐	  and	  EXO-­‐null	  cells	  (Figs.	  6F	  &	  6G),	  suggesting	  that	  CtIP	  and	  EXO1	  may	   regulate	   FANCD2	   expression	   or	   stability	   (see	   also	   below).	   	   In	   contrast,	  RPA	  and	  53BP1	  levels	  in	  WCE	  were	  abundant	  and	  their	  expression/stability	  did	  not	  seem	  to	  be	  diminished	  (Figs.	  6F	  &	  6G).	  	   Collectively,	   these	   observations	   suggested	   that	   the	   inactivation	   of	   CtIP	   or	  EXO1	  triggers	  DNA	  replication	  fork	  stalling.	  	  And	  since	  the	  forks	  cannot	  be	  restarted,	  the	   stalled	   forks	  may	   persist	   for	   a	   few	   days	   and	   then	   collapse	   into	  DSBs	   that	   are	  improperly	  repaired	  by	  NHEJ.	  	  	  
CtIP	   and	   EXO1	   are	   co-­‐regulated	   and	   they	   coordinately	   regulate	  
HR	  factors	  	   Using	  western	  analysis	  of	  WCE	  and	  chromatin	   fractions,	  we	  were	  surprised	  to	  observe	  coordinate	  regulation	  of	  CtIP	  and	  EXO1	  (Figs.	  6F	  &	  6G).	  	  Thus,	  in	  CtIPF/-­‐:CreERt2	  cells	  treated	  with	  tamoxifen	  not	  only	  is	  CtIP	  depleted,	  but	  also	  EXO1	  (Fig.	  6F).	  	  An	  identical,	  loss	  of	  CtIP	  expression	  was	  also	  observed	  in	  EXO1-­‐null	  cells	  (Fig.	  6F).	   	   Additionally,	   we	   also	   observed	   that	   FANCD2	   levels	   were	   dependent	   on	   the	  levels	  of	  CtIP	  and	  EXO1	  (Fig.	  6F).	  	  These	  observations	  suggested	  that	  DNA	  resection	  may	  directly	  regulate	  HR	  via	  the	  coordinate	  co-­‐regulation	  of	  key	  HR	  factors.	   	  Thus,	  we	   next	   determined	   whether	   this	   stability	   effect	   could	   be	   extended	   to	   other	   HR	  factors	  that	  act	  downstream	  of	  FANCD2.	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   CtIPF/-­‐:CreERt2	   and	  EXO1F/-­‐:CreERt2	   cells	  were	   treated	  with	   tamoxifen	   and	  then	  harvested	  after	  1,	  3,	  5,	   and	  7	  days	   to	  prepare	  WCE	   (Fig.	  7A).	   	  These	  extracts	  were	   first	  probed	   for	  CtIP	  and	  EXO1	  expression.	   	  As	  expected,	  both	  proteins	  were	  responsive	  to	  tamoxifen	  and	  their	  expression	  levels	  dropped	  below	  detection	  levels	  over	  the	  course	  of	  the	  experiment	  (Fig.	  7A).	  	  Surprisingly,	   after	   3	   days	   of	   tamoxifen	   treatment,	   FANCD2,	   BRCA2,	   and	  Rad51	  were	  also	  barely	  detectable	  in	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  (Fig.	  7A).	   	   We	   then	   asked	   if	   this	   coordinate	   regulation	   could	   be	   extended	   to	   DNA2	  because	  like	  CtIP	  and	  EXO1,	   it	   is	  required	  for	  DSB	  resection.	   	   In	  the	  CtIP-­‐null	  cells,	  DNA2	  was	  rapidly	  degraded	  to	  levels	  below	  detection,	  similar	  to	  Rad51,	  BRCA2,	  and	  FANCD2.	  	  Conversely,	  in	  EXO1-­‐null	  cells,	  we	  observed	  DNA2	  was	  shifted	  to	  a	  larger	  species	   that	   persisted	   at	   day	   3	   and	   5	   after	   EXO1	   inactivation	   and	   was	   then	  undetectable	  (together	  with	  CtIP)	  at	  the	  latest	  time	  point	  (Day	  7).	  	  This	  suggests	  that	  the	  stability	  of	  DNA2	  is	  also	  dependent	  on	  CtIP	  and	  EXO1.	  	  	  	  The	   loss	   of	   CtIP	   or	   EXO1	   triggers	   replication	   fork	   stalling	   and,	   in	   theory,	  should	   activate	   the	   ATR-­‐CHK1	   checkpoint.	   	   Very	   unexpectedly,	   however,	   CHK1	  protein	  levels	  were	  downregulated	  in	  a	  dramatic	  fashion	  similar	  to	  FANCD2,	  BRCA2,	  and	   RAD51	   in	   both	   CtIP-­‐	   and	   EXO1-­‐null	   cells	   (Fig.	   7A).	   	   ATR	   levels	   were	  downregulated	  to	  below	  WT:CreERt2	  levels	  in	  CtIP-­‐null	  cells	  while	  ATR	  levels	  were	  not	   affected	   in	   the	   EXO1-­‐null	   cells	   until	   CtIP	   expression	   dropped	   below	  detection	  levels	  (Fig.	  7A).	  	  Furthermore,	  the	  mediator	  of	  ATR-­‐CHK1	  signaling,	  Claspin91,92,	  was	  also	  degraded,	  which	  is	  consistent	  with	  studies	  showing	  that	  CHK1	  regulates	  Claspin	  levels93.	   	  The	   loss	  of	  CHK194	  and	  Claspin95,96	  expression,	  and	   the	  reduction	   in	  ATR	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(Fig.	  7A)	   levels	   indicated	   that	   the	  cells	  are	  under	  prolonged	  genotoxic	   stress	   from	  stalled	  replication	  forks	  and	  cannot	  recover	  from	  checkpoint	  activation.	  	  Stalled	   forks	   that	   collapse	   into	  DSBs	   signal	   that	   damage	   through	   the	   ATM-­‐CHK2	   pathway.	   	   Importantly,	   CtIP-­‐	   and	   EXO1-­‐null	   cells	   had	   elevated	   total	   CHK2	  levels	   and	   phosphorylated	   CHK2	   (Threonine68)97	   (Fig.	   7B),	   and	   ATM	   was	   also	  upregulated	   and	   activated	   shown	   by	   the	   phosphorylation	   of	   ATM	   at	   Serine198198	  (Fig.	  7B).	   	  Supporting	  our	  earlier	  conclusion	  that	  HR	  is	  disabled	  and	  that	  the	  DSBs	  are	  being	  repaired	  by	  NHEJ,	  the	  expression	  of	  the	  key	  NHEJ	  factor,	  Ku86,	  remained	  steady	  (Fig.	  7A).	  We	   next	   investigated	   whether	   a	   proteasomal	   degradation	   pathway	   was	  responsible	   for	   the	  rapid	  downregulation	  of	  HR	   factors	   in	   the	  absence	  of	  CtIP	  and	  EXO1.	  	  Cells	  treated	  with	  EtOH	  or	  tamoxifen	  for	  24	  hr	  followed	  by	  1	  uM	  of	  MG132,	  a	  well-­‐documented	  proteasome	  inhibitor99	  or	  DMSO	  (control).	  	  WCE	  were	  prepared	  in	  the	  following	  12-­‐	  and	  24-­‐hr	  time	  points.	  	  In	  the	  controls,	  cells	  that	  were	  treated	  with	  EtOH	   and	   MG132	   showed	   that	   the	   proteins	   of	   interest	   accumulated	   over	   time	  whereas	   DMSO-­‐treated	   cells	   maintained	   normal	   protein	   levels.	   	   In	   both	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   treated	   with	   tamoxifen,	   we	   observed	   that	  FANCD2,	   BRCA2,	   Rad51,	   and	   CHK1	   are	   likely	   regulated	   through	   the	   proteasomal	  degradation	  pathway	  because	  their	  protein	  levels	  were	  rescued	  -­‐at	  least	  partially-­‐	  in	  the	  presence	  of	  MG132	  but	  not	  in	  DMSO	  (Fig.	  7C).	   	  These	  results	  demonstrate	  that	  FANCD2,	  BRCA2,	  Rad51,	  and	  CHK1	  are	  rapidly	  degraded	  by	   the	  proteasome	  when	  persistently	   stalled	   replication	   forks	   induced	   by	   the	   absence	   of	   DNA	   resection	  cannot	  be	  restarted.	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The	   co-­‐regulation	   and	   coordinate	   regulation	   of	   CtIP,	   EXO1,	   and	  
DNA2	  DNA2	  is	  an	  additional	  important	  DNA	  resection	  factor.	  	  We	  also	  constructed	  a	  DNA2F/-­‐/-­‐:CreERt2	  conditionally-­‐null	  HCT116	  cell	  line	  and	  showed	  that	  DNA2	  is	  also	  an	  essential	  gene	  in	  human	  somatic	  cells	  (data	  not	  shown).	  	  We	  used	  this	  cell	  line	  to	  investigate	  whether	  loss	  of	  DNA2	  would	  also	  impact	  the	  stability	  of	  CtIP,	  EXO1,	  and	  HR	  factors.	  	  We	  prepared	  WCE	  from	  DNA2F/-­‐/-­‐:CreERt2,	  CtIPF/-­‐:CreERt2,	  and	  EXO1F/-­‐:CreERt2	  cells	  that	  were	  treated	  with	  tamoxifen	  after	  1,	  3,	  and	  5	  days.	  	  Consistently,	  the	  protein	   levels	  of	  CtIP,	  EXO1,	  and	  DNA2	  in	  the	  corresponding	  conditionally-­‐null	  cell	  lines	  diminished	  to	  levels	  below	  detection	  after	  tamoxifen	  treatment;	  indicating	  that	  the	  inducible	  CreERt2	  system	  was	  functional	  (Fig.	  8A).	  As	   previously	   observed	   (Fig.	   7A),	  we	   saw	   an	   immediate	   downregulation	   of	  CtIP	  protein	  levels	  after	   inactivating	  EXO1.	   	   In	  striking	  contrast,	   the	  inactivation	  of	  DNA2	  led	  to	  an	  increase	  in	  CtIP	  protein	  levels	  at	  day	  1,	  which	  then	  followed	  by	  the	  los	  of	  CtIP	  expression	  at	  days	  3	  and	  5.	  	  Upon	  the	  inactivation	  of	  DNA2	  and	  CtIP	  with	  tamoxifen,	   EXO1	   protein	   levels	   were	   immediately	   downregulated	   to	   undetectable	  levels	   by	   day	   3.	   	   Additionally,	   the	   inactivation	   of	   DNA2	   also	   resulted	   in	   the	   rapid	  degradation	  of	  BRCA2,	  FANCD2,	  Rad51	  and	  CHK1	  protein	  levels.	  	  To	   extended	   analysis	   of	   the	   novel	   phenotypes	   of	   coordinate	   regulation,	  we	  also	   characterized	   GM637	   cells,	   which	   is	   an	   immortalized	   but	   otherwise	   normal,	  human	   fibroblast	   cell	   line100.	   	   In	   this	   cell	   line,	  we	   individually	  knocked	  down	  CtIP,	  EXO1,	   and	   DNA2	   by	   siRNA	   and	   found	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	   indeed	   co-­‐
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regulated.	   	  Additionally,	   the	  protein	   levels	   of	   FANCD2	  were	   also	   rapidly	  degraded	  after	  knocking	  down	  CtIP,	  EXO1,	  or	  DNA2	  (Fig.	  8C).	  	  This	  experiment	  shows	  that	  the	  regulatory	  functions	  of	  CtIP,	  EXO,	  and	  DNA2	  are	  not	  specific	  to	  the	  HCT116	  cell	  line.	  In	   aggregate,	   our	   findings	   suggest	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	   co-­‐regulated.	   	   The	   regulation	   pattern	   observed	   between	   them	   are	   slightly	   different	  such	   that:	   1)	   CtIP	   inactivation	   leads	   to	   rapid	   degradation	   of	   EXO1	   and	   DNA2,	   2)	  EXO1	   inactivation	   leads	   to	   a	   slower	   degradation	   of	   CtIP	   and	  DNA2	  protein	   levels,	  and	  3)	  DNA2	  inactivation	  leads	  to	  an	  increase	  uniquely	  in	  CtIP	  expression	  followed	  by	   the	  rapid	  degradation	  of	  both	  CtIP	  and	  EXO1.	   	  Furthermore,	  we	  also	  show	  that	  CtIP,	  EXO1,	  and	  DNA2	  are	  epistatic	  in	  human	  cells	  in	  the	  sense	  that	  their	  inactivation	  results	  in	  the	  similar	  and	  synchronous	  degradation	  of	  BRCA2,	  FANCD2,	  Rad51,	  and	  CHK1.	  	  Finally,	  the	  chromatin	  recruitment	  patterns	  of	  HR	  factors	  in	  CtIP-­‐,	  EXO1-­‐	  and	  DNA2-­‐null	  cells	  were	  inspected	  because	  the	  global	  protein	  levels	  from	  the	  WCE	  do	  not	  always	  reflect	  chromatin	  recruitment.	  	  As	  expected,	  the	  diminishing	  presence	  of	  CtIP,	  EXO1	  and	  DNA2	  in	  the	  chromatin	  of	  the	  corresponding	  conditionally-­‐null	  cell	  lines	   indicated	   that	   the	   inducible	   CreERt2	   system	  was	   functional	   upon	   tamoxifen	  treatment	  (Fig.	  8D).	  The	  chromatin	  recruitment	  of	  CtIP	  was	  much	  stronger	  in	  DNA2	  heterozygous	  cells	   compared	   to	   EXO1	   heterozygous	   cells.	   	   The	   complete	   inactivation	   of	   DNA2,	  however,	  resulted	   in	  decreased	  recruitment	  of	  CtIP	  at	  day	  1,	  which	  became	  barely	  detectable	   at	   the	   remaining	   time	   points.	   	   In	   contrast,	   we	   observed	   moderate	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chromatin	  recruitment	  of	  CtIP	  1	  day	  after	  EXO1	  inactivation,	  although	  recruitment	  at	  later	  time	  points	  was	  undetectable.	  The	  chromatin	  recruitment	  of	  EXO1	  was	  significantly	  different	  between	  CtIP-­‐and	   DNA2-­‐null	   cells	   (Fig.	   8D).	   	   Upon	   inactivation	   of	   CtIP,	   moderate	   EXO1	  recruitment	   was	   observed	   only	   at	   day	   1	   but	   not	   at	   the	   later	   time	   points.	  	  Interestingly,	  the	  inactivation	  of	  DNA2	  triggered	  a	  heavy	  recruitment	  of	  EXO1	  to	  the	  chromatin	   at	   day	   1,	   which	   was	   followed	   by	   a	   gradual	   decrease	   at	   days	   3	   and	   5.	  	  Despite	  the	  decrease,	  the	  chromatin	  levels	  of	  EXO1	  were	  still	  well	  above	  the	  level	  of	  detection.	   	  In	  contrast	  to	  what	  had	  been	  observed	  with	  WCEs,	  DNA2	  was	  recruited	  and	  persisted	  in	  the	  chromatin	  fractions	  of	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  throughout	  the	  duration	  of	  the	  experiment.	  	  The	  fates	  of	  FANCD2,	  BRCA2,	  and	  Rad51	  were	  similar	  to	  their	  corresponding	  WCE	  protein	  levels	  such	  that	  they	  were	  not	  present	  (or	  degraded)	  in	  the	  chromatin	  fractions	  of	  CtIP-­‐,	  EXO1-­‐,	  and	  DNA2-­‐null	  cells	  by	  day	  3	  and	  thereafter	  (Fig.	  8E).	  	  This	  observation	   further	   corroborates	   the	  dogma	   that	  BRCA2,	   FANCD2,	   and	  Rad51	   are	  HR	  factors	  that	  reside	  downstream	  of	  resection.	  In	  summary,	  the	  inactivation	  of	  DNA2	  initially	  triggers	  heavy	  recruitment	  of	  EXO1	  to	  the	  chromatin,	  which	  then	  gradually	  decreases	  over	  time.	   	  In	  contrast,	  the	  inactivation	  of	  EXO1	  triggers	  recruitment	  of	  DNA2	  to	  the	  chromatin	  at	  steady	  levels	  over	  time.	   	  This	  suggests	  that	  the	  two	  nucleases	  downstream	  of	  CtIP	  may	  mutually	  compensate	   for	   the	   loss	   of	   each	   other.	   	   The	   invariability	   of	   each	   single	   mutant,	  however,	   indicates	   that	   whatever	   compensation	   is	   occurring	   is	   insufficient	   to	  support	  viability.	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Discussion	  We	  have	  constructed	  three	  novel	  and	  powerful	  genetic	  models	  using	  human	  somatic	   cells	   that	   are	   conditionally-­‐null	   (with	   inducible	   CreERt2	   system)	   for	   CtIP,	  EXO1,	  or	  DNA2.	  	  With	  these	  cell	  lines,	  we	  discovered	  that	  CtIP,	  EXO1,	  and	  DNA2	  are	  essential	   genes	   in	   the	   HCT116	   cell	   line.	   	   The	   HCT116	   cell	   line	   is	   also	   MLH1	  deficient73	   and	   we	   were	   concerned	   that	   the	   lethality	   of	   CtIP	   and	   EXO	   may	   be	  synthetic	  with	  MLH1.	   	  To	  address	   this	   concern,	  we	   showed	   that	  MLH1-­‐expressing	  HCT116	   cells	   still	   do	   not	   survive	   without	   CtIP	   and	   EXO1,	   thereby	   excluding	   the	  possibility	   that	  CtIP	  and	  EXO1	  are	  synthetically	   lethal	  with	  MLH1.	   	  Given	  that	  CtIP	  and	   EXO1	   are	   essential	   for	   survival,	   we	   deduced	   that	   they	   carry	   out	   essential	  function(s)	   even	   in	   the	   absence	   of	   exogenous	   DNA	   damage.	   	   These	   studies	   have	  revealed	  essential	  function(s)	  for	  these	  genes	  and	  also	  uncovered	  a	  novel	  regulation	  of	  the	  HR	  pathway	  by	  CtIP	  and	  EXO1	  in	  human	  somatic	  cells.	  	  
CtIP	  and	  EXO1	  are	  required	  to	  maintain	  genomic	  stability	  	  	  CtIP	  and	  EXO1	  maintain	  genomic	  stability31.	  	  Thus,	  when	  CtIP	  and	  EXO1	  were	  knocked-­‐down	   the	   cells	   were	   more	   susceptible	   to	   radial	   chromosome	   formation	  when	  exposed	  to	  DNA	  damaging	  agents31,83.	  We	  showed	  here	  that	  cells	  completely	  lacking	   CtIP	   or	   EXO1	   suffer	   from	   elevated	   levels	   of	   chromosomal	   breaks,	  fragmentations,	   and	   aneuploidy	   as	   well	   as	   radials.	   	   One	   of	   the	   more	   compelling	  aspects	   of	   our	   study	   is	   that	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	  were	   never	  exposed	   to	   DNA	   damaging	   agents,	   showing	   that	   all	   these	   chromosomal	  abnormalities	  were	  manifested	  endogenously.	  	  It	  is	  also	  perhaps	  important	  to	  point	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out	  that	  during	  the	  analysis	  we	  noticed	  many	  fusion	  events	  that	  were	  too	  complex	  to	  analyze	  and	  omitted	  from	  the	  dataset.	  	  Therefore,	  our	  results	  strongly	  supported	  the	  argument	  that	  CtIP	  and	  EXO1	  maintain	  genome	  stability	  and	  led	  us	  to	  postulate	  that	  CtIP	  and	  EXO1	  have	  essential	  roles	  in	  DNA	  replication.	  
	  
CtIP,	  EXO1,	  and	  CHK1	  are	  epistatic	  in	  regulating	  DNA	  replication	  The	   inactivation	   of	   CtIP	   or	   EXO1	   triggered	   continued	   DNA	   synthesis	   that	  resulted	   in	   cells	   containing	   an	   extremely	   high	   DNA	   content.	   	   The	  maximum	  DNA	  content	   peaked	   at	   approximately	   16N	   in	   CtIP-­‐null	   cells	   and	   8N	   EXO1-­‐null	   cells,	  which	   was	   in	   agreement	   with	   the	   karyotype	   analyses	   showing	   octaploid	  chromosomes	  only	  in	  CtIP-­‐null	  cells.	  	  Extending	  our	  studies	  on	  DNA	  replication,	  we	  showed	  that	  replication	  fork	  tract	  lengths	  drastically	  decreased	  in	  a	  time-­‐dependent	  manner	   in	   CtIP-­‐	   and	   EXO1-­‐null	   cells.	   	   Interestingly,	   we	   also	   observed	   that	   the	  inactivation	  of	  CtIP	  or	  EXO1	  causes	  rapid	  CHK1	  degradation	  (Fig.	  7A).	  	  	  We	  argue	  that	  the	  replication	  phenotypes	  and	  the	  CHK1	  loss	  in	  the	  absence	  of	   CtIP	   and	   EXO1	   are	   correlated	   events.	   	   Supporting	   our	   argument,	   similar	   DNA	  replication	  phenotypes	  have	  been	  reported	  as	  a	  result	  of	  CHK1	  deficiency.	  	  Previous	  studies	   showed	   that	   the	   inhibition	   of	   CHK1	   in	   human	   cells	   causes	   increased	  DNA	  replication	   initiation101	   and	   checkpoint	   mutants	   in	   yeast	   lead	   to	   continued	   DNA	  synthesis	   and	   increased	   breaks102.	   	  Moreover,	  DT40	  CHK1-­‐/-­‐	   cells,	   replication	   fork	  progression	   is	   severely	   impaired	   with	   severely	   short	   replication	   tract	   lengths78.	  	  Collectively,	   these	   data	   support	   our	   argument	   that	   CtIP,	   EXO1,	   and	   CHK1	   are	  
	  	   	  68	  
epistatic	  in	  a	  pathway	  that	  regulates	  DNA	  replication	  initiation,	  fork	  progression	  and	  that	  they	  contribute	  to	  genome	  stability.	  
	  
CtIP	  and	  EXO1	  are	  closely	  associated	  with	  the	  replication	  fork	  to	  
prevent	  replication	  fork	  collapse	  and	  mutagenic	  NHEJ	  repair	  Highly	   repetitive	   regions	   in	   the	   human	   genome,	   including	   trinucleotide	  repeats	  (TNRs),	  telomeres,	  LINE,	  SINE,	  DNA	  transposons,	  and	  ALU	  repeat	  elements	  transiently	   form	   complex	   DNA	   structures	   at	   periods	   when	   they	   become	   single-­‐stranded5-­‐7	  such	  that	  they	  can	  become	  barriers	  to	  DNA	  replication	  and	  thus	  trigger	  replication	  fork	  stalling4,8-­‐10.	   	  CFs	  and	  ERCFs	  reside	   in	  these	  repetitive	  regions	  and	  are	  prone	  to	  breakage	  during	  DNA	  replication14	  and	  they	  break	  more	  so	  when	  ATR	  is	  inhibited11-­‐13.	  	  Furthermore,	  previous	  studies	  reported	  that:	  i)	  CtIP	  is	  tethered	  to	  PCNA	   at	   the	   replication	   fork	   to	   survey	   for	   replication	   associated	   damages	   and	  activate	   checkpoints,	   ii)	  PCNA	  promotes	  processive	   resection	  by	  EXO1	   in	  vitro,	   iii)	  EXO1	  is	  associated	  with	  nascent	  DNA	  strands	  during	  replication.	  	  Together,	   our	   experiments	   and	   previous	   studies,	   suggest	   that	   in	   CtIP-­‐	   and	  EXO1-­‐null	  cells	  replication	  forks	  stall	  at	  highly	  repetitive	  regions	  and	  then	  collapse	  into	   DSBs.	   	   Therefore,	   CtIP	   and	   EXO1	   are	   likely	   working	   in	   concert	   with	   the	  replication	   forks	   to	   prevent	   fork	   stalling	   when	   they	   encounter	   complex	   DNA	  structures	  at	  repetitive	  regions.	  In	   both	   CtIP	   and	   EXO1-­‐null	   cells,	   FANCD2	   and	   RPA	   foci	   formation	   and	  chromatin	  recruitment	  dynamics	  were	  similar,	  where	  they	  initially	  peaked	  and	  then	  diminished	   in	   a	   time	   dependent	   manner.	   	   Additionally,	   PCNA	   was	   modified	   and	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subsequently	  accumulated	  over	  time	  in	  the	  chromatin	  fractions	  of	  CtIP-­‐	  and	  EXO1-­‐null	   cells.	   	   Together,	   these	   events	   indicate	   that	   the	   absence	   of	   CtIP	   and	   EXO1	  strongly	  triggers	  the	  stalling	  of	  replication	  forks	  that	  then	  persist	  over	  days	  because	  they	  cannot	   restart.	   	   Since	   this	  event	  coincides	  with	  high	   levels	  of	  γH2AX	   foci	  and	  increasing	  CHK2	  and	  ATM	  activation,	  we	  also	  argue	  that	  the	  stalled	  forks	  eventually	  collapse	  to	  form	  DSBs.	  	  	  CtIP	  and	  53BP1	  compete	  for	  DSBs83	  and	  53BP1	  is	  modulated	  by	  ATM	  to	  and	  performs	  toxic	  NHEJ	  repairs86	  that	  result	  in	  chromosomal	  radials	  and	  fusions.	  	  With	  the	  HR	  pathway	  disabled	  in	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  and	  the	  concomitant	  activation	  of	  ATM-­‐CHK2,	   53BP1103,104	  may	  now	  be	   free	   to	  monopolize	   all	   the	  DSBs	   for	  NHEJ	  repair	   which	   result	   in	   the	   chromosomal	   aberrations86	   that	   we	   observed	   in	   the	  karyotype	  analysis	  of	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  (Fig.	  3).	  	  
Regulatory	  functions	  of	  CtIP,	  EXO1,	  and	  DNA2	  We	  show	  here	  that	  CtIP,	  EXO1,	  and	  DNA2	  are	  co-­‐regulated.	  	  The	  loss	  of	  CtIP,	  EXO1,	  or	  DNA2	  ultimately	  results	  in	  the	  downregulation	  of	  the	  other	  two	  proteins.	  	  As	   surprising,	   CtIP,	   EXO1,	   and	   DNA2	   also	   coordinately	   regulate	   FANCD2,	   BRCA2,	  Rad51,	  and	  CHK1	  expression.	  	  Thus,	  the	  inactivation	  of	  CtIP,	  EXO1,	  or	  DNA2	  triggers	  the	   simultaneous	   degradation	   of	   FANCD2,	   BRCA2,	   Rad51,	   and	   CHK1	   that	   was	  mediated	   by	   the	   proteasome.	   	   The	   loss	   of	   these	   proteins	   essentially	   renders	   the	  HR3,16,105	   and	   FA	  pathways	   inactive.	   	   These	   observations	   demonstrate	   that	   the	   FA	  and	  HR	  pathways	  are	  closely	  connected	  by	  DNA	  resection.	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The	  influence	  of	  CHK1	  on	  DNA	  replication	  CHK1	   plays	   a	   significant	   role	   in	   DNA	   replication.	   	   In	   human	   cells,	   CHK1	  inhibition	  causes	  increased	  replication	  initiation	  101.	   	  Another	  study	  in	  human	  cells	  also	   showed	   that	   prolonged	   genotoxic	   stress	   leads	   to	   CHK1	   degradation94.	  	  Furthermore,	  DT40	  CHK1-­‐/-­‐	  cells	  have	  very	  short	  DNA	  replication	  tracts	  and	  present	  with	  cell	   cycle	  defects78.	   	  Lastly,	  Rad53	  (i.e.,	  CHK1)	  mutants	   in	  yeast	  suffered	  with	  continued	  DNA	  synthesis	  and	   increased	  breaks102.	   	  Claspin	   is	   the	  mediator	   for	   the	  ATR-­‐CHK1	   signaling	   and	   it	   is	   regulated	   by	   CHK1	   protein	   levels91-­‐93.	   	   Like	   CHK1,	  Claspin	  also	  influences	  replication	  fork	  progression	  106.	  	  	  CHK1	  degradation	  is	  a	  normal	  response	  to	  replication	  stress.	  	  When	  CHK1	  is	  activated	  it	  must	  be	  degraded	  in	  order	  for	  the	  cell	  to	  terminate	  the	  checkpoint	  and	  recover.	   	   The	   degradation	   process	   was	   teased	   apart	   when	   cells	   were	   exposed	   to	  prolonged	  genotoxic	  stress	  where	  it	  was	  then	  observed	  that	  CHK1	  was	  degraded	  by	  the	   proteasome94.	   	   Claspin	   shares	   a	   similar	   fate	   with	   CHK1	   after	   checkpoint	  activation96	  and	  Claspin	  protein	  levels	  are	  regulated	  by	  CHK1.	  	  Unlike	  CHK1,	  Claspin	  is	  expressed	   in	  S-­‐	  and	  G2-­‐	  phases	  and	  degraded	  upon	  entry	   into	  mitosis96.	   	   In	  our	  CtIP-­‐	  and	  EXO1-­‐null	  human	  cells	  CHK1	  as	  well	  as	  Claspin	  is	  degraded	  in	  concert	  with	  severely	  shortened	  DNA	  replication	  tract	  lengths.	  	  We	  argue	  that	  the	  inactivation	  of	  CtIP	   or	   EXO1	   triggers	   replication	   fork	   stalling	   that	   results	   in	   a	   Claspin-­‐mediated	  CHK1	   activation.	   	   Since	   the	   stalled	   replication	   forks	   cannot	   restart,	   CHK1	   and	  Claspin	  are	  constantly	  activated	  and	  degraded.	  	  As	  a	  result,	  checkpoint	  termination	  and	  cell	  cycle	  progression	  cannot	  take	  place.	  	  Finally,	  without	  ATR-­‐CHK1,	  the	  stalled	  replication	  forks	  are	  destabilized63,70	  64	  and	  collapse	  into	  DSBs107.	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Claspin	  degradation	  can	  also	  be	  caused	  as	  a	  byproduct	  of	  mitotic	  entry.	  	  This	  seems	   unlikely,	   to	   be	   relevant	   to	   our	   data,	   however	   because	   CtIP-­‐	   and	   EXO1-­‐null	  cells	   no	   longer	  proliferate	   and	   the	   robust	  CHK2	  activation	   (Fig.	   7A)	   indicates	   that	  the	  cells	  are	  arrested.	  
	  
	  
Summary	  In	  an	  unperturbed	  S-­‐phase,	  a	  replication	  forks	  eventually	  run	  into	  repetitive	  regions	  that	   causes	   them	   to	   stall.	   	   Through	   Claspin,	   the	   ATR-­‐CHK1	   pathway	   is	   activated	  which	  in	  turn,	  stabilizes	  the	  stalled	  forks	  and	  recruits	  replication	  fork	  restart	  factors	  including	  FANCD2,	  BRCA2,	   and	  Rad51.	   	   CtIP	   and	  EXO1	  are	   also	   closely	   associated	  with	   the	   replication	   forks,	   presumably	   through	   docking	   on	   to	   PCNA.	   	   The	   close	  proximity	   of	   CtIP	   and	   EXO1	   permits	   swifter	   action	   on	   the	   stalled	   forks	   for	   end	  resection	   that	  creates	  access	   for	  FANCD2,	  BRCA2,	  and	  Rad51	  to	  restart	   the	  stalled	  forks	   in	   timely	   manner.	   	   However,	   in	   the	   absence	   of	   CtIP	   and	   EXO1,	   stalled	  replication	   forks	   are	   unable	   to	   restart	   because	   the	   FANCD2,	   BRCA2	   and	   Rad51	  cannot	   correctly	   access	   the	   stalled	   forks.	   	   As	   the	   stalled	   forks	   persist	   over	   time,	  CHK1	   and	   Claspin	   is	   under	   constant	   activation	   and	   degradation	   with	   no	   time	   to	  recover	   their	   protein	   levels.	   	   As	   a	   result,	   ATR	   cannot	   stabilize	   the	   stalled	   forks	  without	  CHK1	  and	  the	  forks	  are	  now	  susceptible	  to	  fork	  collapse.	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  Materials	  and	  Methods	  	  
Cell	  culture	  The	  wild-­‐type	  HCT116	  cell	  line	  and	  mutant	  derivatives	  were	  cultured	  in	  McCoy’s	  5A	  medium	  containing	  10%	  fetal	  bovine	  serum,	  100	  U/ml	  penicillin/streptomycin	  in	  a	  humidified	  incubator	  with	  5%	  CO2	  at	  37	  oC.	  	  Applicable	  cell	  lines	  were	  selected	  in	  0.5	  to	   1	   mg/ml	   G418	   concentrations	   during	   gene	   targeting	   selection	   and	   1ug/mL	   of	  puromycin	   for	   the	   selection	   of	   stable	   CreERt2	   expressing	   cells.	   	   To	   induce	   stalled	  replication	  forks	  and	  DSBs,	  cells	  were	  exposed	  to	  1	  mM	  hydroxyurea	  for	  24	  hr,	  and	  10	   uM	   camptothecin	   for	   4	   hr,	   respectively.	   	   CreERt2	   was	   induced	   by	   5	   nM	   of	  tamoxifen	  to	  excise	  floxed	  alleles	  in	  the	  nucleus.	  	  	  	  	  
CreERt2	  and	  MLH1	  expression	  vector	  construction	  PB/SB-­‐CG-­‐DEST	   (Puro)	   has	   been	   described108.	   	   Cre-­‐ER	  t2	   was	   PCR	   amplified	   from	  pCAG-­‐CreERt2	  (Addgene,	  Plasmid	  14797)	  with	  HincII	  and	  AvrII	  sites	  engineered	  into	  the	   forward	   and	   reverse	  primers,	   respectively.	   	   The	  purified	  CreERt2	  PCR	  product	  was	   digested	   with	   HincII	   and	   AvrII	   (New	   England	   BioLabs)	   and	   ligated	   into	  pENTR221	  with	   compatible	   SnaBI	   and	   XbaI	   restriction	   sites.	   	   LR	   clonase	   reaction	  (Invitrogen)	  was	  then	  performed	  using	  PB/SB-­‐CG-­‐DEST	  (Puro)	  and	  pENTR221-­‐	  Cre-­‐ER,	   following	   the	  manufacturer’s	   instructions.	   	   A	  MLH1	   cDNA	  was	   PCR	   amplified	  from	   pCEP9	   MLH1	   (Addgene,	   Plasmid16458)	   with	   primers	   containing	   attB1	   and	  attB2	   sites.	   	   The	   MLH1	   PCR	   product	   was	   first	   cloned	   into	   pDONR221	   via	   a	   BP	  clonase	   reaction,	   and	   subsequently	   cloned	   into	   PB/SB-­‐CG-­‐DEST	   (Neo)	   via	   a	   LR	  clonase	  reaction	  according	  to	  the	  manufacturer’s	  instructions.	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  rAAV	  knockout	  vector	  construction	  and	  rAAV	  production	  rAAV	   knockout	   vector	   construction	   as	   well	   as	   rAAV	   production	   was	   carried	   out	  according	   to	   methodologies	   and	   procedures	   as	   described109.	   	   PCR	   products	   were	  amplified	   from	   wild-­‐type	   HCT116	   genomic	   DNA	   with	   the	   Phusion	   Polymerase	  Enzyme	  (Thermo	  Scientific).	  	  Primer	  sequences	  are	  shown	  in	  table	  S1.	  	  	  
Genomic	  DNA	  isolation	  and	  PCR	  screening	  To	   screen	   for	   correctly	   targeted	   clones,	   genomic	   DNA	   was	   isolated	   in	   a	   96-­‐well	  format	   with	   DirectLysis–PCR	   Reagent	   (ViagenBiotech).	   	   A	   homemade	   Taq	  polymerase	   was	   used	   in	   the	   screening	   PCR,	   and	   screening	   primers	   are	   available	  upon	  request.	  	  	  	  
Immunostaining	  Cells	  were	  grown	  in	  chamber	  slides.	  	  After	  two	  rinses	  with	  1X	  PBS,	  cells	  were	  fixed	  in	  4%	  paraformaldehyde	  for	  10	  min.	   	  Cells	  were	  permeabilized	  with	   ice-­‐cold	  0.1%	  Triton	   X-­‐100,	   CSK	   buffer	   (10	  mM	  HEPES-­‐KOH,	   pH	   7.4,	   300	  mM	   sucrose,	   100	  mM	  NaCl,	   3	   mM	  MgCl2)	   10	  min,	   washed	   twice	   with	   0.1%	   Tween	   20,	   1X	   PBS	   (PBST).	  	  Permeabilized	  cells	  were	  blocked	  with	  5%	  fish	  skin	  gelatin	  or	  5%	  BSA,	  1X	  PBS,	  0.1%	  Tween	  20	  for	  1	  hr,	  and	  incubated	  with	  primary	  antibody	  and	  incubated	  for	  30	  min	  at	  RT,	  or	  overnight	  at	  4°C.	  	  Cells	  were	  washed	  3	  x	  5	  min	  with	  0.1%	  Tween	  20,	  1X	  PBS	  and	   incubated	  with	   secondary	   antibodies	   for	  30	  min	   at	   room	   temperature.	   	   	   Cells	  were	  washed	  3	  x	  5	  min	  with	  PBST	  again,	  incubated	  in	  2	  ug/mL	  DAPI	  for	  3	  min,	  dried	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  and	   mounted	   on	   to	   cover	   slips	   (No.	   1	   thickness)	   with	   ProLong®	   Gold	   Antifade	  Reagent	  (P36934)	  from	  Life	  Technologies.	  	  All	  washes	  were	  carried	  out	  with	  gentle	  shaking.	   Slides	   were	   viewed	   with	   Zeiss	   Axioplan	   2	   confocal	   microscope	   at	   60X.	  	  Images	  and	  foci	  were	  analyzed	  with	  FIJI.	  	  
Cell	  viability	  assay	  Cells	  were	  seeded	  at	  400	  cells/well	  in	  96-­‐well	  plates	  the	  day	  before	  exposing	  cells	  to	  5	  nM	  Tamoxifen	  or	  an	  equivalent	  volume	  of	  EtOH.	  	  Cell	  viability	  was	  measured	  at	  the	  indicated	  time	  points	  with	  the	  CellTiter	  96®	  AQueous	  One	  Solution	  Cell	  Proliferation	  Assay	   from	  Promega	  according	   to	  manufacturer’s	   instructions.	   	  Wavelengths	  were	  measure	  at	  492	  nm	  on	  a	  Wallac	  plate	  reader.	  	  
DNA	  fiber	  assays	  Prior	   to	   labeling	   replicating	   forks	   with	   digoxigenin-­‐dUTP	   (Dig-­‐dUTP),	   cells	   were	  treated	   with	   a	   hypotonic	   buffer	   solution	   (10	   mM	   HEPES,	   30	   mM	   KCl,	   pH	   7.4)	   to	  allow	   efficient	   transport	   of	   dig-­‐dUTP	   into	   the	   nucleus.	   	   Cells	  were	   incubated	  with	  100	  mM	  Dig-­‐dUTP	   for	   15	  min,	   followed	  by	  50	  uM	  EdU.	   	  After	   labeling,	   cells	  were	  harvested	  with	   a	   10-­‐fold	   excess	   of	   unlabeled	   cells,	   fixed	   (3:1	  methanol:acetic	   acid	  fixative	  solution)	  and	  dropped	  onto	  slides.	  	  Slides	  were	  dipped	  in	  cell	  lysis	  solution	  and	  DNA	  fibers	  were	  stretched	  by	  gravity.	  	  For	  visualization,	  Dig-­‐dUTP	  was	  stained	  with	   a	   primary	   sheep	   anti-­‐digoxigenin	   antibody	   from	   Roche,	   followed	   by	   a	  secondary	   Alexa	   Fluor®	   594	   Donkey	   anti-­‐sheep	   IgG	   (H+L)	   antibody	   from	   Life	  Technologies.	   	   Incorporated	  EdU	  was	   first	   labeled	  with	   a	   biotin	   via	   click	   reaction,	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  followed	   by	   streptavidin,	   Alexa	   Fluor®	   488	   conjugate.	   	   Slides	   were	   viewed	   on	   a	  Zeiss	   Axioplan	   2	   confocal	  microscope	   and	   replication	   tract	   lengths	  were	  measure	  with	  FIJI.	  	  Tract	  length	  results	  are	  takes	  from	  two	  experiments	  (N=100/experiment).	  	  Error	   bars	   represent	   the	   standard	   error	   of	   the	   mean	   and	   significance	   was	  determined	  by	  the	  Mann-­‐Whitney	  test,	  where	  P	  <	  0.001,	  and	  P	  <	  0.0001	  are	  ***,	  and	  ****,	  respectively.	  	  
Whole	   cell	   extract	   (WCE)	   preparation	   and	   chromatin	  
fractionation	  of	  human	  cells	  For	  WCE	   preparation,	   cells	   were	   trypsinized	   and	   washed	   with	   1X	   PBS.	   	   The	   cell	  pellets	  were	  suspended	  in	  cell	  lysis	  buffer	  (in	  10	  mM	  Tris	  pH	  7.4,	  150	  mM	  NaCl,	  1%	  NP-­‐40,	   0.5%	   sodium	   deoxycholate,	   1	   mM	   EDTA,	   1	   mM	   DTT,	   complete	   protease	  inhibitor	   cocktail	   tablets	   by	   Roche).	   	   For	   chromatin	   fractions,	   cell	   pellets	   were	  resuspended	  in	  CSK	  buffer	  (10	  mM	  HEPES-­‐KOH,	  pH	  7.4,	  300	  mM	  sucrose,	  100	  mM	  NaCl,	   3	   mM	   MgCl2,	   complete	   protease	   inhibitor	   cocktail	   tablets	   by	   Roche)	   and	  prepared	  as	  described110.	  	  
Karyotype	  analysis	  Karyotype	   analysis	   was	   sourced	   to	   the	   Cytogenomics	   Shared	   Resource	   at	   the	  University	  of	  Minnesota.	  	  	  	  
EdU	  incorporation	  assay	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  Cells	  were	   incubated	  with	   10uM	  EdU	   for	   40	  min	   for	   EdU	   incorporation.	   	   400,000	  cells	  were	   harvested	   and	   labeled	  with	   the	   Click-­‐iT®	  EdU	  Alexa	   Fluor®	   647	   Flow	  Cytometry	   Assay	   Kit	   (Life	   Technologies),	   according	   to	   a	   described	   modified	  procedure	  111.	  	  	  	  
Immunoblotting	  and	  antibodies	  20-­‐27	   ug	   of	  WCE	   and	   chromatin	   samples	  were	   separated	   on	   4-­‐15%	  gradient	   gels	  (Bio-­‐Rad)	   and	   transferred	   on	   to	   PVDF	   membranes	   (GE	   Healthcare).	   	   Membranes	  were	  blocked	  with	  5%	  nonfat	  powdered	  milk	  (Amresco)	  for	  1	  hr,	  and	  probed	  with	  primary	  antibodies	  over	  night	  at	  4°C	  with	  gentle	  rocking.	  	  Horseradish	  peroxidase-­‐conjugated	  secondary	  antibodies	  and	  ECL	  Prime	  detection	  solution	  (GE	  Healthcare)	  were	   used	   to	   detect	   protein	   bands.	   	   Membranes	   were	   stripped	   with	   Restore	  Western	  Blot	  Stripping	  Buffer	  (Thermo	  Scientific).	  	  A	  List	  of	  antibodies	  is	  shown	  in	  Table	  S3.	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  Figure	  Legends	  Figure	  1.	  	  Construction	  of	  conditional	  CtIP	  and	  EXO1-­‐null	  cell	  lines	  Scheme	  for	  inactivating	  CtIP	  and	  EXO1.	  (A)	  Partial	  diagrams	  of	  the	  human	  CtIP	  and	  EXO1	   loci.	   Numbered	   rectangles	   represent	   exons	   and	   solid	   triangles	   depict	   loxP	  sites.	  Conditional	  rAAV	  knockout	  vectors	  were	  designed	  to	  target	  exons	  2	  and	  3	  of	  CtIP	  and	  EXO1,	  respectively.	  Correctly	  targeted	  clones,	  (B)	  CtIPNeo/+	  and	  EXO1Neo/+	  clones	   were	   transiently	   transfected	   with	   a	   Cre-­‐expressing	   plasmid	   (+PGK	   Cre)	   to	  excise	   the	   SEPT:Neo	   cassette.	   (C)	   G418	   sensitive	   CtIPF/+	   and	   EXO1F/+	   clones	  retaining	  the	  “floxed”	  exon	  were	  identified	  and	  subjected	  to	  a	  second	  round	  of	  gene	  targeting	   with	   a	   non-­‐conditional	   knockout	   vector	   (SEPT:Neo).	   	   The	   SEPT:Neo	  cassette	  in	  the	  (D)	  CtIPF/Neo	  and	  EXO1F/Neo	  	  null	  cell	  lines	  was	  again	  excised	  by	  pPGK-­‐Cre	   transient	   transfection	   to	  yield	   “floxed”	  conditional	   (E)	  CtIPF/-­‐	   and	  EXO1F/-­‐	  null	  cell	  lines.	  (F)	  The	  inducible	  CreERt2	  recombinase	  system	  was	  established	  by	  stably	  introducing	  a	  CreERt2-­‐expressing	  plasmid	  via	  PiggyBac	   transposition.	   	  Scheme	   for	  inactivating	   DNA2.	   (G)	   Partial	   diagram	   of	   the	   human	   DNA2	   locus.	   Numbered	  rectangles	  represent	  exons	  and	  solid	   triangles	  depict	   loxP	  sites.	   	  Conditional	   rAAV	  knockout	   vectors	   were	   designed	   to	   target	   exon	   2	   of	   DNA2.	   	   Correctly	   targeted	  clones,	   (H)	  DNA2Neo/+/+	   clones	  were	   transiently	   transfected	  with	   a	   Cre-­‐expressing	  plasmid	  (+PGK	  Cre)	  to	  excise	  the	  SEPT:Neo	  cassette.	   	   (I)	  G418	  sensitive	  DNA2F/+/+	  clones	  retaining	  the	  “floxed”	  exon	  were	  identified	  and	  subjected	  to	  a	  second	  round	  of	   gene	   targeting	   with	   the	   same	   conditional	   knockout	   vector.	   	   (J)	   The	   SEPT:Neo	  cassette	   in	   DNA2F/Neo/+	   cell	   lines	   was	   excised	   again	   by	   pPGK-­‐Cre	   transient	  transfection	  to	  yield	  (K)	  DNA2F/-­‐/+	  null	  cell	   lines.	   	  (L)	  The	  third	  allele	  was	  knocked	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  out	  in	  a	  similar	  fashion	  with	  the	  same	  conditional	  knockout	  vector	  and	  (M)	  excision	  of	  the	  SEPT:Neo	  cassette	  in	  DNA2F/-­‐/Neo	  yielded	  a	  conditional	  DNA2F/-­‐/-­‐	  null	  cell	  line.	  	  (N)	   The	   inducible	   CreERt2	   recombinase	   system	   was	   established	   by	   stably	  introducing	  a	  CreERt2-­‐expressing	  plasmid	  via	  PiggyBac	  transposition.	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  Figure	  2.	  CtIP	  and	  EXO1	  are	  essential	  in	  human	  somatic	  cells	  Tamoxifen	  induces	  the	  loss	  of	  CtIP	  and	  EXO1	  expression.	  A-­‐B)	  Cells	  were	  plated	  the	  day	  before	  adding	  EtOH	  or	   tamoxifen.	   	  Cells	  were	  harvested	   for	  whole	  cell	  extract	  (WCE)	  preparation	   after	   1,	   3,	   5	   and	  7	   days	   post-­‐tamoxifen	   or	  EtOH	  exposure	   and	  separated	  on	  a	  4	   to	  15%	  polyacrylamide	  gel.	   	  The	  membrane	  was	   immunoblotted	  with	   antibodies	   against	   CtIP,	   EXO1	   and	   p53.	   Cells	   do	   not	   grow	  without	   CtIP	   and	  EXO1.	  Cells	  were	  plated	  on	  96-­‐well	  plates	  at	  500	  cells	  per	  well	  in	  triplicate	  the	  day	  before	  adding	  EtOH	  (C)	  or	  tamoxifen	  (D)	  and	  cell	  growth	  was	  measured	  via	  a	  MTS	  colormetric	  assay.	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  Figure	  3.	  CtIP	  and	  EXO1	  are	  required	  for	  genomic	  stability	  The	   loss	   of	   CtIP	   and	   EXO1	   induces	   severe	   chromosomal	   aberrations.	   A)	  Representative	  karyotypes	  of	  CtIPF/-­‐:CreERt2	  cells	  and	  B)	  EXO1F/-­‐:CreERt2	  cells	  in	  a	  time	  course	  exposure	  to	  tamoxifen.	   	  Red	  arrows	  indicate	  chromosomal	  breaks	  and	  blue	  arrows	  represent	  radials.	  Chromosome	  fragments	  are	  labeled	  with	  a	  red	  f.	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  Figure	  4.	  CtIP	  and	  EXO1	  regulate	  DNA	  replication	  Increased	  DNA	   replication	   initiation	   in	   the	   absence	   of	   CtIP	   and	  EXO1.	   	   Cells	  were	  plated	  the	  day	  before	  adding	  EtOH	  or	  tamoxifen.	  	  On	  the	  indicated	  time	  points,	  cells	  were	  incubated	  with	  EdU	  for	  40	  mins	  and	  harvested	  for	  staining	  accordingly	  to	  the	  manufacturer’s	   instructions.	   	   EdU	   was	   labeled	   with	   Alexa-­‐Fluor	   647	   to	   measure	  nucleotide	   incorporation	   and	   propidium	   idodide	   (PI)	   was	   used	   to	   measure	   DNA	  content.	   	   On	   the	   X-­‐axis:	   PI	   and	   Y-­‐axis:	   EdU	   Alexa	   Fluor	   647.	   A)	   WT:CreERt2,	   B)	  CtIPF/-­‐:CreERt2	  and	  C)	  EXO1F/-­‐:CreERt2	  cells	  in	  EtOH	  for	  7	  days.	   	  Cell	  cycle	  profiles	  of	   A)	   WT:CreERt2,	   B)	   CtIPF/-­‐:CreERt2	   and	   C)	   EXO1F/-­‐:CreERt2	   cells	   treated	   with	  EtOH	   for	   7	   days.	   	   Cell	   cycle	   profiles	   of	   C)	  WT:CreERt2,	   D)	   CtIPF/-­‐:CreERt2	   and	   E)	  EXO1F/-­‐:CreERt2	  cells	  treated	  with	  tamoxifen.	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  Figure	  5.	  CtIP	  and	  EXO1	  are	  required	  for	  normal	  DNA	  replication	  tract	  lengths	  Loss	   of	   CtIP	   and	   EXO1	   severely	   reduces	   DNA	   replication	   fork	   velocities.	   	   Dual	  labeling	   of	   DNA	   fibers.	   	   A)	   Cells	   were	   plated	   in	   48-­‐well	   plates	   the	   day	   before	  tamoxifen	  or	  EtoH	   treatment.	   	  After	  2	  and	  3	  days	   the	  cells	  were	   first	   labeled	  with	  Digoxigenin-­‐dUTP	  for	  15	  min	  and	  then	  with	  EdU	  for	  30	  min.	  	  Digoxigenin-­‐dUTP	  was	  stained	   with	   Alexa-­‐Fluor	   594	   (red)	   and	   EdU	   was	   stained	   with	   Alexa-­‐Fluor	   488	  (Green).	  	  Representative	  images	  of	  dual-­‐labeled	  fibers	  and	  their	  median	  replication	  tract	   lengths	  (Med)	   in	  microns	   from	  (B)	  WT:CreERt2	  cells,	   (C)	  CtIPF/-­‐:CreERt2	  and	  (D)	   EXO1F/-­‐:CreERt2	   cells	   treated	   with	   EtOH	   or	   tamoxifen.	   	   (E)	   Box	   plots	   of	  replication	   tract	   lengths	   from	   a	   total	   200	   fibers	   (from	   two	   independent	  experiments).	  	  The	  Mann-­‐Whitney	  test	  show	  that	  replication	  tract	  lengths	  in	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  treated	  with	  EtOH	  or	  tamoxifen	  are	  significantly	  shorter	  than	  those	  of	  WT:CreERt2	  cells.	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  Figure	  6.	  Inactivation	  of	  CtIP	  and	  EXO1	  triggers	  severe	  replication	  fork	  stalling	  Inactivation	  of	  CtIP	  and	  EXO1	   induces	  DSBs	  and	  DNA	  damage	   foci	  associated	  with	  replication	  fork	  stalling.	   	  A)	  Cells	  were	  grown	  in	  4-­‐well	  chamber	  slides	  and	  treated	  with	  EtOH	  or	  tamoxifen	  the	  next	  day.	  	  At	  the	  indicated	  time	  points,	  cells	  were	  fixed	  with	   paraformaldehyde	   and	   stained	  with	   the	   appropriate	   antibodies.	   	   γH2AX	   and	  53BP1	   foci	   were	   induced	   by	   incubating	   WT:	   Cre	   ERt2	   cells	   with	   10	   uM	  Camptothecin	  (CPT)	  for	  4	  hr;	  FANCD2	  and	  RPA	  foci	  were	  induced	  by	  incubating	  WT:	  Cre	  ERt2	  cells	  with	  1	  mM	  hydroxyurea	  for	  24	  hr.	   	  Foci	  were	  scored	  from	  a	  total	  of	  400	  nuclei	  from	  two	  independent	  experiments	  and	  bars	  represent	  average	  foci	  per	  cell.	  	  B)	  Representative	  images	  of	  γH2AX	  in	  red,	  C)	  53BP1	  foci	  in	  red,	  D)	  FANCD2	  in	  green	  and	  E)	  RPA	  in	  red.	  	  Images	  in	  blue	  represent	  DAPI	  staining	  of	  nuclear	  DNA.	  	  F)	  Western	  analysis	  of	  whole	  cell	  extracts	  (WCE)	  and	  G)	  chromatin	  fractions	  prepared	  from	  cells	  at	  the	  indicated	  time	  points	  and	  conditions.	  	   	  
	  	   	  84	  
	  Figure	  7.	  CtIP	  and	  EXO1	  levels	  are	  mutually	  dependent	  and	  they	  regulate	  HR	  factors	  A)	  Cells	  were	  plated	  on	  10	  cm	  dishes	  and	  treated	  with	  EtOH	  or	  10	  uM	  tamoxifen	  the	  next	  day.	  	  Cells	  were	  harvested	  after	  1,	  3,	  5,	  and	  7	  days	  after	  tamoxifen	  treatment	  or	  7	   days	   after	   EtOH	   treatment	   for	  whole	   cell	   extract	   preparation	   (WCE).	   	  WCE	  was	  electrophoresed	  on	  a	  4-­‐15%	  polyacrylamide	  gel	  and	  immunoblotted	  with	  antibodies	  against	  CtIP	  and	  EXO1.	  	  The	  membrane	  was	  stripped	  and	  reprobed	  with	  antibodies	  against	  the	  indicated	  HR	  and	  DNA	  replication	  factors.	  	  CtIP	  and	  EXO1	  regulate	  CHK1	  and	   other	   cell	   cycle	   related	   factors.	   	   B)	   The	   same	   membrane	   from	   above	   was	  stripped	   and	   reprobed	   for	   CHK1	   and	   other	   cell-­‐cycle	   checkpoint	   related	   proteins.	  	  The	  26S	  proteasome	  complex	  degrades	  the	  proteins	  regulated	  by	  CtIP	  and	  EXO1.	  	  C)	  Cells	  were	  plated	  on	  10	  cm	  dishes	  and	  allowed	  to	  grow	  overnight	  before	  adding	  10	  uM	  of	  tamoxifen	  or	  EtOH.	  	  24	  hr	  later	  1	  mM	  MG132	  or	  DMSO	  was	  added	  to	  the	  plates	  that	   still	   contain	   10uM	   Tamoxifen	   or	   DMSO.	   	   After	   12	   and	   24	   hr	   post	   MG132	  exposure,	  cells	  were	  harvested	  for	  WCE	  preparation.	  	  WCE	  were	  separated	  on	  a	  4	  to	  15%	  polyacrylamide	  gel	  and	  probed	  for	  the	  indicated	  proteins	  of	  interest.	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  Figure	  8.	  Coordinate	  regulation	  of	  CtIP,	  EXO1	  and	  DNA2	  CtIP,	  EXO1	  and	  DNA2	  are	  co	  regulated.	  	  A)	  WCE	  from	  WT	  HCT116	  and	  the	  indicated	  derivatives	   were	   separated	   on	   a	   4	   to	   15%	   polyacrylamide	   gradient	   gel	   and	  immunoblotted	   with	   antibodies	   against	   CtIP,	   and	   subsequently	   stripped	   and	  reprobed	   for	   EXO1	   and	   DNA2.	   	   B)	   CtIP,	   EXO1,	   and	   DNA2	   coordinately	   regulate	  BRCA2,	  FANCD2,	  Rad51	  and	  CHK1.	   	  The	   co-­‐regulation	  of	  CtIP,	  EXO1,	   and	  DNA2	   is	  not	   specific	   to	   the	  HCT116	   cell	   line.	   	   C)	   CtIP,	   EXO1	   and	  DNA2	   are	   co-­‐regulated	   in	  normal	  cells	  (GM637	  fibroblasts),	  and	  coordinately	  regulate	  FANCD2	  protein	  levels.	  	  The	   loss	   of	   CtIP,	   EXO1	   and	   DNA2	   triggers	   chromatin	   recruitment	   of	   DNA	   repair	  factors.	   	  D)	  Chromatin	  fractions	  from	  wild-­‐type	  HCT116	  cells	  and	  derivatives	  were	  separated	   on	   a	   4	   to	   15%	   polyacrylamide	   gradient	   gel	   and	   probed	   with	   the	  appropriate	   antibodies.	   	   F)	   CtIP,	   EXO1,	   and	   DNA2	   coordinately	   regulate	   BRCA2,	  FANCD2,	  Rad51	  and	  CHK1.	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  Table	   1.	   Quantitation	   of	   chromosomal	   aberrations	   in	   tamoxifen-­‐treated	   CtIPF/-­‐:CreERt2	  cells	  Final	   time	   points	   of	   the	   indicated	   cell	   lines	   were	   chosen	   based	   on	   availability	   of	  metaphases	   for	   analysis.	   	   Metaphases	   were	   scored	   for	   breaks,	   chromosome	  fragments,	   aneuploidy,	   and	   radial	   structures.	   	   All	   values	   are	   represented	   as	  percentage	  of	  metaphases	  analyzed.	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  Table	   2.	   Quantitation	   of	   chromosomal	   aberrations	   in	   tamoxifen-­‐treated	   EXO1F/-­‐:CreERt2	  cells	  Final	   time	   points	   of	   the	   indicated	   cell	   lines	   were	   chosen	   based	   on	   availability	   of	  metaphases	   for	   analysis.	   	   Metaphases	   were	   scored	   for	   breaks,	   chromosome	  fragments,	   aneuploidy,	   and	   radial	   structures.	   	   All	   values	   are	   represented	   as	  percentage	  of	  metaphases	  analyzed.	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  Supplementary	  Figure	  Legends	  	  Supplementary	  Figure	  1.	  	  CtIP	  and	  EXO1	  are	  not	  synthetically	  lethal	  with	  MLH1.	  	   MLH1-­‐expressing	   cells	   cannot	   survive	   without	   CtIP	   or	   EXO1.	   A)	   CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cells	  stably	  expressing	  MLH1	  were	  plated	  on	  96-­‐well	  plates	   at	   500	   cells	   per	   well	   in	   triplicates	   the	   day	   before	   adding	   EtOH	   (A)	   or	  tamoxifen	  (B).	  Cell	  growth	  was	  measured	  via	  MTS	  colormetric	  assay	  at	  the	  indicated	  time	  points.	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  Supplementary	  Figure	  2.	  	  Loss	  of	  CtIP	  and	  EXO1	  disrupts	  the	  cell	  cycle.	  	   Loss	  of	  CtIP	   and	  EXO1	   severely	  disrupts	   a	  normal	   cell	   cycle.	  Data	   from	   the	  EdU	  incorporation	  assay	  are	  plotted	  in	  the	  form	  of	  histograms	  for	  a	  different	  view	  of	  DNA	   content.	   	   After	   7	   days	   of	   EtOH	   treatment,	   WT:	   CreERt2	   (Fig.	   S2A),	   CtIPF/-­‐:CreERt2	  (Fig.	  S2B)	  and	  EXO1F/-­‐:CreERt2	  (Fig.	  S2C)	  have	  normal	  G1	  and	  G2	  peaks.	  	  However,	   in	   the	   presence	   of	   tamoxifen	   CtIPF/-­‐:CreERt2	   (Fig.	   S2B)	   and	   EXO1F/-­‐:CreERt2	   (Fig.	   S2C)	   cells	   gradually	   lose	   their	   G1	   and	  G2	   peaks	   and	   indiscriminate	  peaks	   representing	   DNA	   content	   >4N	   begin	   to	   arise	   at	   day	   3,	   and	   by	   day	   7	   the	  histograms	   appear	   disordered	   with	   DNA	   content	   exceeding	   the	   linear	   range	   of	  detection.	   	  As	  we	  expected,	  WT:CreERt2	   (Fig.	   S2B)	  have	  normal	   cell	   cycle	  profiles	  throughout	  the	  duration	  of	  the	  experiment.	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  Supplementary	  Figure	  3.	   	  Loss	  of	  CtIP	  and	  EXO1	  leads	  to	  continued	  DNA	  synthesis	  and	  aneuploidy.	  	   Data	  from	  the	  EdU	  incorporation	  assay	  were	  acquired	  in	  logarithmic	  scale	  to	  include	   missing	   events.	   	   After	   7	   days	   of	   EtOH	   treatment,	   WT:CreERt2	   (Fig.	   S2A),	  CtIPF/-­‐:CreERt2	   (Fig.	   S2B)	   and	  EXO1F/-­‐:CreERt2	   (Fig.	   S2C)	   have	   normal	  G1	   and	  G2	  peaks.	  	  However,	  in	  the	  presence	  of	  tamoxifen	  CtIPF/-­‐:CreERt2	  (Fig.	  S2B)	  and	  EXO1F/-­‐:CreERt2	   (Fig.	   S2C)	   cells	   gradually	   lose	   their	   G1	   and	  G2	   peaks	   and	   indiscriminate	  peaks	   representing	   DNA	   content	   >4N	   begin	   to	   arise	   at	   day	   3,	   and	   by	   day	   7	   the	  histograms	   appear	   disordered	   with	   DNA	   content	   exceeding	   the	   linear	   range	  detection.	   	  As	  we	  expected,	  WT:CreERt2	   (Fig.	   S2B)	  have	  normal	   cell	   cycle	  profiles	  throughout	  the	  duration	  of	  the	  experiment.	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  Supplementary	  Table	  1.	  rAAV	  knockout	  vector	  construction	  	  Primer	   sequences	   used	   to	   construct	   knockout	   vectors	   for	   CtIP,	   EXO1,	   and	   DNA2.	  	  PCR	  products	  of	  the	  indicated	  Fragment	  1	  and	  Fragment	  2	  primer	  pairs	  are	  fused	  to	  generate	   the	   left	   homology	   arms	   that	   contain	   a	   “Floxed”	   allele	   of	   all	   conditional	  knockout	  vectors.	  PCR	  products	  were	  cloned	  into	  TOPO	  cloning	  vectors,	  digested	  to	  reveal	  compatible	  sticky	  ends	  and	  finally	  ligated	  appropriately	  as	  described109.	  	  Supplementary	   Table	   2.	   List	   of	   antibodies	   for	   western	   analyses	   and	  immunofluorescence	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  Figure	  1	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   Vector	  Construction	  Primers	   	  	  CtIP	  Conditional	  Knockout	  Vector	   	  	  CtIP	  CKO	  LHA	  Frag1	  Not1	  Fwd	   5'	  atacatacgcggccgccctttattctaagagaggcatgaa	  3'	  CtIP	  CKO	  LHA	  Frag1	  LoxP	  Rev	  	   5’cgtataatgtatgctatacgaagttatcatttttagaatttggga	  	  	  	  -­‐ggggaagg	  3’	  	  	  CtIP	  CKO	  LHA	  Frag2	  LoxP	  Fwd	   5’	  cgtatagcatacattatacgaagttatctgggcttgtgtt	  	  	  	  	  	  -­‐tcatcctg	  3'	  CtIP	  CKO	  LHA	  Frag2	  XbaI	  Rev	  	   5’ggtattgcttctagacaaagccactacagtctcaacaa	  3’	  CtIP	  CKO	  RHA	  ECoRI	  Fwd	  	   5'agcaataccgaattcttgttgagactgtagtggctttg	  3'	  CtIP	  CKO	  RHA	  NotI	  Rev	  	   5’	  atacatacgcggccgcgatcagctgggcacagca	  3’	  
CtIP	  Straight	  Knockout	  Vector	   	  	  CtIP	  SKO	  LHA	  Not1	  Fwd	   5’	  atacatacgcggccgcccagctcatatttagtttctgga	  3’	  CtIP	  SKO	  LHA	  XbaI	  Rev	  	   5’	  ggtattgcttctagacacaagcccagatatcctca	  3’	  CtIP	  SKO	  RHA	  EcoRI	  Fwd	  	   5’	  agcaataccgaattctagtggctttgtatacctttgtatgac	  3’	  CtIP	  SKO	  RHA	  NotI	  Rev	  	   5’	  atacatacgcggccgcgatcagctgggcacagcagc	  3'	  
EXO1	  Conditional	  Knockout	  Vector	   	  	  EXO1	  CKO	  LHA	  Frag1	  Not1	  Fwd	   5'atacatacgcggccgcctctgtatagaaagggcttagg	  3'	  EXO1	  CKO	  LHA	  Frag1	  LoxP	  Rev	  	   5'cgtataatgtatgctatacgaagttatgactgcagtggcc	  	  	  	  -­‐tatatc	  3'	  EXO1	  CKO	  LHA	  Frag2	  LoxP	  Fwd	   5'	  cgtatagcatacattatacgaagttatggactccaagct	  	  	  	  -­‐ttctctt	  3'	  EXO1	  CKO	  LHA	  Frag2	  XbaI	  Rev	  	   5'	  atacatactctagaaaaaaggcactgtaggtctc	  3'	  EXO1	  CKO	  RHA	  ECoRI	  Fwd	  	   5'	  agcaataccgaattcgagtatcaagacactgatggac	  3'	  EXO1	  CKO	  RHA	  NotI	  Rev	  	   5'	  atacatacgcggccgcgaactacttgaccctccaag	  3'	  
EXO1	  Straight	  Knockout	  Vector	   	  	  EXO1	  SKO	  LHA	  Not1	  Fwd	   5'	  atacatacgcggccgcgacagagggataaagtgaagat	  3'	  EXO1	  SKO	  LHA	  XbaI	  Rev	  	   5'	  atacatactctagaatactacctctaatgccacttg	  3'	  EXO1	  SKO	  RHA	  EcoRI	  Fwd	  	   5'	  agcaataccgaattcgggtacagaaaacatactgcta	  3'	  EXO1	  SKO	  RHA	  NotI	  Rev	  	   5'	  atacatacgcggccgccttgatcccatgagatagtaac	  3'	  
DNA2	  Conditional	  Knockout	  
Vector	   	  	  DNA2	  CKO	  LHA	  Frag1	  Not1	  Fwd	   5'	  ataagaatgcggccgcctctacccaaagtgtggtatgtg	  3'	  DNA2	  CKO	  LHA	  Frag1	  LoxP	  Rev	  	   5'	  cgtataatgtatgctatacgaagttatgtaaacgtattaggga	  	  	  	  -­‐ggcttc	  3'	  DNA2	  CKO	  LHA	  Frag2	  LoxP	  Fwd	   5'	  cgtatagcatacattatacgaagttatcgtttacatgtagga	  	  	  	  	  -­‐acctaagc	  3'	  DNA2	  CKO	  LHA	  Frag2	  XbaI	  Rev	  	   5'	  gctctagagctagcactgccacctcatag	  3'	  DNA2	  CKO	  RHA	  ECoRI	  Fwd	  	   5'	  ccggaattccttcgaatcttgttcagggctta	  3'	  DNA2	  CKO	  RHA	  NotI	  Rev	  	   5'	  atagtttagcggccgcaatattcaggccaagcacagtag	  3'	  CKO:	  Conditional	  Knockout,	  SKO:	  Straight	  Knockout,	  Frag:	  Fragment,	  LHA:	  Left	  	  Homology	  arm,	  RHA:	  Right	  Homology	  Arm	  
Table	  S2	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  WB:	  Western	  Blot,	  IF:	  Immunofluorescence	  	  
Antibody	   Cat.	  No./Clone	   Manufacturer	   Application	  RPA	  	   9H8	  
AbCam	  
WB/IF	  53BP1	  	   ab36823	   WB/IF	  EXO1	   ab95012	   WB	  CtIP	   ab70163	   WB	  GAPDH	   ab9484	   WB	  DNA2	   ab96488	   WB	  γH2AX	   A300-­‐081A	  
Bethyl	  Scientific	  
IF	  H2AX	   A300-­‐082A	   WB	  BRCA2	   Ab-­‐1	   Calbiochem	   WB	  ATM	   Phospho	  CHK1/2	  Sampler	  Kit	  #9931	   Cell	  Signaling	  Technolgies	  
WB	  pATM	  S1981	   WB	  CHK2	   WB	  pCHK2	  T68	   WB	  ATR	   27095	   WB	  FANCD2	   100-­‐182	   Novus	  Biologicals	   IF	  PCNA	   FL261	  
Santa	  Cruz	  
Biotechnologies	  
WB	  14-­‐3-­‐3σ	  	   C18	   WB	  Cdc25C	  	   H-­‐6	   WB	  CHK1	  	   G-­‐4	   WB	  Claspin	  	   Q20	   WB	  FANCD2	  	   Fl17	   WB	  Ku86	   B11	   WB	  MRE11	  	   C16	   WB	  Rad51	  	   H92	   WB	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CHAPTER	  III:	  
Ku	  Regulates	  The	  Pathway	  Choice	  Of	  
DNA	  Double-­‐Strand	  Break	  Repair	  In	  
Human	  Somatic	  Cells	  
	  	  	  








	  	  	  	  	  	  	  
This	  chapter	  is	  a	  replicate	  of	  a	  pubcication	  in	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  e1000855	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  Ku	  regulates	  the	  non-­‐homologous	  end	  joining	  pathway	  choice	  of	  DNA	  double-­‐strand	  break	  repair	  in	  human	  somatic	  cells.	  
	  
	  
	   	  
	   	   Fattah	  et	  al.	  
	   122	  
	   The	   repair	   of	   DNA	   double-­‐strand	   breaks	   (DSBs)	   is	   critical	   for	   the	  maintenance	   of	   genomic	   integrity	   and	   viability	   for	   all	   organisms.	   	  Mammals	   have	  evolved	   at	   least	   two	   genetically	   discrete	   ways	   to	   mediate	   DNA	   DSB	   repair:	  homologous	   recombination	   (HR)	   and	   non-­‐homologous	   end	   joining	   (NHEJ).	   	   In	  mammalian	  cells,	  most	  DNA	  DSBs	  are	  preferentially	  repaired	  by	  NHEJ.	  	  Recent	  work	  has	   demonstrated	   that	  NHEJ	   consists	   of	   at	   least	   two	   sub-­‐pathways	   -­‐	   the	  main	  Ku	  heterodimer-­‐dependent	   or	   “classic”	   NHEJ	   (C-­‐NHEJ)	   pathway	   and	   an	   “alternative”	  NHEJ	   (A-­‐NHEJ)	   pathway,	   which	   usually	   generates	   microhomology-­‐mediated	  signatures	  at	  the	  repair	  junctions.	  	  In	  our	  study,	  recombinant	  adeno-­‐associated	  virus	  knockout	  vectors	  were	  utilized	  to	  construct	  a	  series	  of	  isogenic	  human	  somatic	  cell	  lines	   deficient	   in	   the	   core	   C-­‐NHEJ	   factors	   (Ku,	   DNA-­‐PKcs,	   XLF,	   and	   LIGIV)	   and	   the	  resulting	  cell	  lines	  were	  characterized	  for	  their	  ability	  to	  carry	  out	  DNA	  DSB	  repair.	  	  The	  absence	  of	  DNA-­‐PKcs,	  XLF	  or	  LIGIV	  resulted	   in	  cell	   lines	   that	  were	  profoundly	  impaired	   in	   DNA	  DSB	   repair	   activity.	   	   Very	   unexpectedly,	   Ku86-­‐null	   cells	   showed	  wild-­‐type	  levels	  of	  DNA	  DSB	  repair	  activity	  that	  was	  dominated	  by	  microhomology	  joining	   events	   indicative	   of	   A-­‐NHEJ.	   	   Correspondingly,	   A-­‐NHEJ	   DNA	   DSB	   repair	  activity	  could	  also	  be	  efficiently	  de-­‐repressed	   in	  LIGIV-­‐	  and	  DNA-­‐PKcs-­‐null	   cells	  by	  subsequently	  reducing	  the	  level	  of	  Ku70.	  	  These	  studies	  demonstrate	  that	  in	  human	  cells	   C-­‐NHEJ	   is	   the	   major	   DNA	   DSB	   repair	   pathway	   and,	   more	   importantly,	   they	  show	   that	  Ku	   is	   the	  critical	  C-­‐NHEJ	   factor	   that	   regulates	  DNA	  DSB	  repair	  pathway	  choice.	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Author	  Summary	  	   Humans	   utilize	   at	   least	   two	   major	   pathways	   to	   repair	   DNA	   double-­‐strand	  breaks	   (DSBs):	   homologous	   recombination	   (HR)	   and	   non-­‐homologous	   end	   joining	  (NHEJ)	  and	  there	  are	  at	  least	  two	  genetically	  discrete	  sub-­‐pathways	  of	  NHEJ:	  classic-­‐NHEJ	   (C-­‐NHEJ)	   and	   alternative-­‐NHEJ	   (A-­‐NHEJ).	   	   Since	   the	   products	   generated	   by	  each	  of	  these	  three	  repair	  (sub)pathways	  differ	  substantially	  from	  one	  another,	  it	  is	  biologically	  critical	  that	  certain	  DNA	  DSBs	  are	  repaired	  by	  certain	  DNA	  DSB	  repair	  pathways.	   	  How	  this	  pathway	  choice	   is	  made	  was	  unclear.	   	   In	  this	  study,	  knockout	  human	   cell	   lines	   that	   are	  defective	   in	   core	  C-­‐NHEJ	   factors	  were	   generated.	   	  These	  cell	   lines	   are	   by-­‐and-­‐large	   extremely	   deficient	   in	  DNA	  DSB	   repair,	   proving	   that	   C-­‐NHEJ	  is	  the	  major	  DNA	  DSB	  repair	  pathway	  in	  human	  cells.	  	  Unexpectedly,	  cell	  lines	  reduced	  for	  the	  C-­‐NHEJ	  factors	  Ku70	  or	  Ku86,	  carried	  out	  proficient	  DNA	  DSB	  repair	  because	  of	  hyperactive	  A-­‐NHEJ.	  	  In	  published	  work	  [1]	  and	  work	  that	  is	  in	  press	  [2],	  we	  have	  also	  demonstrated	   that	  Ku	  suppresses	  HR	  throughout	   the	  genome	  and	  at	  telomeres,	  respectively.	   	  Collectively,	  these	  data	  imply	  that	  Ku	  ensures	  that	  C-­‐NHEJ	  is	  the	  major	  DNA	  DSB	  repair	  pathway	  by	  two	  mechanisms;	   i)	  enabling	  C-­‐NHEJ	  and	  
ii)	  by	  actively	  suppressing	  HR	  and	  A-­‐NHEJ.	  	  Thus,	  Ku	  is	  the	  critical	  regulator	  of	  DNA	  DSB	  repair	  pathway	  choice	  in	  human	  somatic	  cells.	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Introduction	  	   One	  of	  the	  most	  harmful	  lesions	  a	  cell	  can	  encounter	  is	  a	  DNA	  double-­‐strand	  break	  (DSB).	   	  In	  all	  organisms,	  efficient	  repair	  of	  these	  DNA	  DSBs	  is	  critical	  for	  the	  maintenance	   of	   genomic	   integrity	   and	   viability	   [3].	   	   Unfortunately,	   DNA	  DSBs	   are	  frequently	  generated	  endogenously	  during	  normal	   cellular	  processes	   such	  as	  DNA	  replication,	   lymphoid	   V(D)J	   or	   class-­‐switch	   recombination	   and	   are	   induced	  exogenously	   by	   the	   exposure	   to	   a	   variety	   of	   genotoxic	   agents	   such	   as	   ionizing	  radiation	  or	  chemotherapeutics	   [4].	   	  Cells	  have	  conspired	   to	  meet	   this	  demand	  on	  their	  genetic	  material	  with	  the	  evolution	  of	  two	  mechanistically	  distinct	  pathways	  to	  repair	  DNA	  DSBs:	  homologous	  recombination	  (HR),	  which	  takes	  advantage	  of	  either	  a	  homologous	  chromosome	  or	  a	  sister	  chromatid	   to	   join	   the	  broken	  DNA	  ends	   [5]	  and	  non-­‐homologous	  end	  joining	  (NHEJ),	  a	  process	  that	  directly	  joins	  the	  DNA	  DSB	  with	  little	  or	  no	  sequence	  homology	  between	  the	  broken	  ends	  [4].	   	  In	  bacteria	  and	  lower	   eukaryotes,	   HR	   dominates	   the	   DNA	   DSB	   repair	   events	   whereas	   in	   higher	  eukaryotes,	  and	  especially	  in	  mammals,	  NHEJ	  is	  the	  preferred	  pathway	  for	  DNA	  DSB	  repair.	   	   NHEJ	   consists	   of	   at	   least	   two	   genetically	   and	   biochemically	   distinct	   sub-­‐pathways:	   a	   main	   —	   “classic”	   —	   end-­‐joining	   pathway	   (C-­‐NHEJ)	   and	   one	  interchangeably	   referred	   to	   as	   microhomology-­‐mediated	   end	   joining	   (MMEJ)	   [6],	  alternative	  NHEJ	  (A-­‐NHEJ),	  or	  backup	  NHEJ	  (B-­‐NHEJ)	  [7,8]	  (hereafter	  referred	  to	  as	  A-­‐NHEJ).	   	   C-­‐NHEJ,	   while	   by	   no	   means	   precise,	   results	   in	   minimal	   DNA	   end	  processing,	  whereas	  A-­‐NHEJ	  mechanistically	  results	   in	  deletions	  per	   force	   that	  are	  often	   accompanied	   by	  microhomology	   at	   the	   repair	   junction	   {[9,10];	   reviewed	   by	  [8,11]}.	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   There	  are	  at	  least	  seven	  proteins	  required	  for	  C-­‐NHEJ:	  Ku70,	  Ku86,	  the	  DNA	  dependent	   protein	   kinase	   catalytic	   subunit	   (DNA-­‐PKcs),	   Artemis,	   X-­‐ray	   cross	  complementing	   4	   (XRCC4),	   XRCC4-­‐like	   factor	   (XLF)	   and	   DNA	   ligase	   IV	   (LIGIV)	  {reviewed	  by	  [12]}.	   	  The	  basic	  mechanism	  of	  C-­‐NHEJ	  has	  been	  worked	  out	  in	  great	  detail.	   	   Ku70	   and	  Ku86	   form	   a	   heterodimer	   (Ku)	   that	   contains	   an	   internal	   cavity,	  which	  Ku	  uses	  to	  bind	  to	  and	  encircle	  broken	  DNA	  ends	  [13].	  	  Ku,	  besides	  protecting	  DNA	  ends	   from	  exonucleolytic	  attack,	  also	  recruits	  DNA-­‐PKcs,	  a	  phosphoinositol-­‐3-­‐like	   family	   serine/threonine	  protein	  kinase	   [14].	   	  Together,	  Ku70,	  Ku86	  and	  DNA-­‐PKcs	   form	  the	  DNA-­‐dependent	  protein	  kinase	  complex	  (DNA-­‐PK)	  and	  the	  assembly	  of	   this	   trimeric	   complex	  on	   the	   ends	  of	  double-­‐stranded	  DNA	  activates	   the	  kinase	  activity	  of	  DNA-­‐PKcs.	  DNA-­‐PKcs,	   in	   turn,	  phosphorylates	  and	  activates	   the	  nuclease	  Artemis,	  which	   facilitates	  “cleaning	  up”	  of	   the	  ends.	   	  As	  a	   final	  step,	   ligation	  of	   the	  broken	   ends	   is	   catalyzed	   by	   the	   trimeric	   LIGIV	   complex,	   which	   consists	   of	   the	  catalytic	  core,	  DNA	  LIGIV,	  and	  its	  two	  accessory	  factors,	  XLF	  and	  XRCC4.	  	   In	   contrast	   to	   C-­‐NHEJ,	   the	   mechanism,	   the	   regulation,	   and	   the	   factors	  involved	   in	   A-­‐NHEJ	   remain	   elusive.	   	   Mechanistically,	   it	   is	   believed	   that	   during	   A-­‐NHEJ	   both	   broken	   ends	   are	   resected	   5’-­‐to-­‐3’	   on	   one	   strand	   to	   generate	   3’-­‐single-­‐stranded	   overhangs	   containing	   regions	   of	   microhomology	   (generally	   a	   few	  nucleotides),	   which	   are	   then	   used	   to	   mediate	   the	   repair	   event.	   	   Because	   of	   this	  reaction	  pathway,	  deletion	  of	   the	   sequences	  between	   the	  microhomologies	  occurs	  as	  does	  deletion	  of	  one	  of	  the	  blocks	  of	  (micro)homology.	  	  Moreover,	  the	  remaining	  block	  of	  microhomology	  always	  resides	  at	  the	  precise	  site	  of	  repair	  and	  can	  be	  used	  as	  a	  landmark	  to	  define	  such	  repair	  events	  [8,11].	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   A-­‐NHEJ	  was	  not	  thought	  to	  be	  a	  very	  robust	  nor	  a	  particularly	  important	  DNA	  DSB	  repair	  pathway	  because	   it	  could	  usually	  only	  be	  detected	   in	  the	  absence	  of	  C-­‐NHEJ.	  	  Indeed,	  one	  of	  the	  first	  descriptions	  of	  A-­‐NHEJ	  came	  with	  the	  observation	  that	  of	   the	   few	  NHEJ	   DNA	  DSB	   repair	   events	   that	   could	   be	   detected	   in	   Ku86-­‐deficient	  budding	  yeast,	   they	  occurred	  mostly	  between	  short	  direct	  repeats	   [9].	   	  Since	   then,	  there	   have	   been	   similar	   reports	   in	   fission	   yeast	   [15],	   frogs	   [16]	   and	   several	  mammalian	  systems	  [17,18,19,20,21]	  including	  humans	  [22].	  	  The	  significance	  of	  —	  and	   parallel	   interest	   in	  —	  A-­‐NHEJ	   increased	  with	   the	   demonstration	   that	   A-­‐NHEJ	  could	   substitute	   at	   reasonable	   levels	   for	  C-­‐NHEJ	  during	  DNA	  DSB	   repair	   events	   in	  murine	   lymphoid	   class	   switch	   recombination	   [23,24]	   and	   during	   certain	   types	   of	  aberrant	   V(D)J	   recombination	   reactions	   [25].	   	   Moreover,	   A-­‐NHEJ	   has	   been	  implicated	  in	  the	  generation	  of	  large	  deletions	  and	  other	  genomic	  rearrangements	  in	  murine	   cells	   [26,27].	   	   Similarly,	   microhomology	   has	   been	   found	   at	   the	  recombination	   junctions	   of	   radiation-­‐induced	   genomic	   rearrangements	   [28,29]	  implying	  that	  even	  radiation-­‐induced	  DNA	  DSBs	  can	  be	  repaired	  by	  A-­‐NHEJ.	  	  Lastly,	  microhomologies	  are	  frequently	  detected	  at	  breakpoints	  for	  chromosomal	  deletions	  and	   translocations	   in	   human	   cancer	   cells	   [30,31].	   	   These	   observations	   have	  propelled	   many	   laboratories	   to	   identify	   the	   factors	   required	   for	   A-­‐NHEJ.	   	   These	  studies	   have	   implicated	   poly	   (ADP-­‐ribose)	   polymerase-­‐1	   (PARP-­‐1),	   X-­‐ray	   cross	  complementing	  1	   (XRCC1),	  DNA	   ligase	   III	   (LIGIII),	   polynucleotide	  kinase	   (PNK)	  as	  well	   as	   Flap	   endonuclease	   1	   (Fen-­‐1)	   [7,16,32,33,34]	   but	   it	   is	   clear	   that	   additional	  factors	  await	  identification.	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   One	   of	   the	  most	   compelling	   questions	   in	   the	   DNA	   DSB	   repair	   field	   is	   how	  pathway	  choice	   is	  determined.	   	  That	   is,	  once	  a	   chromosome	  breaks,	  how	  does	   the	  cell	  determine	  whether	  HR,	  C-­‐NHEJ	  or	  A-­‐NHEJ	  will	  mediate	  its	  repair?	  	  Since	  each	  of	  these	  repair	  pathways	  produces	  a	  discretely	  distinct	  product,	  including	  some	  which	  have	  been	  implicated	  in	  human	  cancer,	  the	  answer	  to	  this	  question	  seems	  especially	  biologically	   important.	   	   Several	   laboratories	   have	   suggested	   that	   the	   relative	  abundance	  of	  factors,	  binding	  affinities	  for	  DNA	  ends,	  cell	  type	  specificity	  and/or	  cell	  cycle	   phases	  may	   impact	   upon	   this	   decision	   {reviewed	   in	   [35]}.	   	   These	   issues	   are	  complicated	  even	  more	  in	  human	  somatic	  cells	  where	  the	  impact	  of	  loss-­‐of-­‐function	  mutations	  on	  some	  of	  the	  C-­‐NHEJ	  genes	  has	  distinctly	  different	  phenotypes	  than	  are	  observed	   in	   other	   mammals.	   	   In	   particular,	   Ku70	   and	   Ku86	   have	   evolved	   an	  essential	   telomere	  maintenance	   function	   that	   does	   not	   seem	   to	   be	   evident	   in	   any	  other	   mammalian	   systems	   studied	   to	   date	   [1,36,37].	   	   Interestingly,	   Ku	   seems	   to	  exert	   this	   function	   by	   repressing	   the	   HR-­‐mediated	   disassembly	   of	   telomeres	   [2]	  suggesting	   that	   pathway	   choice	   is	   critical	   for	   naturally	   occurring	   double-­‐stranded	  DNA	  ends	  as	  well	  as	  broken	  ones.	  	   To	  begin	  to	  experimentally	  address	  some	  of	  these	  issues	  we	  have	  generated	  a	  series	  of	  human	  somatic	  cell	  lines	  genetically	  engineered	  using	  recombinant	  adeno-­‐associated	   virus	   (rAAV)-­‐mediated	   gene	   targeting	   [38,39,40]	   to	   contain	   reduced	  levels	  of	  the	  C-­‐NHEJ	  factors	  Ku70,	  Ku86,	  DNA-­‐PKcs,	  XLF	  and	  LIGIV.	  	  We	  hypothesized	  that	  in	  the	  presence	  of	  reduced	  or	  no	  C-­‐NHEJ	  activity	  the	  frequency	  and	  regulation	  of	   A-­‐NHEJ	   in	   human	   cells	   could	   be	   assessed.	   	   To	   this	   end	  we	   utilized	   two	   in	   vivo	  plasmid	   end	   joining	   assays	   that	   have	   been	   employed	   to	   study	   end	   joining	   in	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mammalian	  cells	  [34,41,42]	  to	  demonstrate	  that	  null	  mutations	  in	  DNA-­‐PKcs,	  XLF	  or	  LIGIV	  resulted	  in	  a	  severe	  reduction	  in	  the	  frequency	  of	  productive	  DNA	  DSB	  repair.	  	  The	   small	   number	   of	   repair	   events	   that	   did	   occur	   in	   these	   null	   cell	   lines	   were	  hallmarked	  by	   the	  heavy	  usage	  of	  microhomology.	   	   Thus,	   these	   studies	   confirmed	  that	  C-­‐NHEJ	  is	  the	  predominate	  NHEJ	  pathway	  operative	  inside	  human	  somatic	  cells	  and	  in	  its	  absence	  small	  amounts	  of	  A-­‐NHEJ	  can	  be	  detected.	  	  Very	  surprisingly,	  and	  in	   stark	   contrast	   to	   the	   results	  with	  DNA-­‐PKcs,	   XLF	   and	   LIGIV-­‐null	   cell	   lines,	   DNA	  DSB	   repair	   activity	   was	   actually	   slightly	   elevated	   in	   Ku86	   conditionally-­‐null	   cell	  lines.	   	   These	   repair	   events	   appeared,	   once	   again,	   to	   be	   heavily	   biased	   towards	  microhomology-­‐mediated	   repair.	   	   This	   result	   suggested	   that	   Ku86	   actively	  suppresses	  A-­‐NHEJ	  in	  human	  somatic	  cells.	  	  This	  hypothesis	  was	  confirmed	  by	  using	  molecular	  and	  genetic	  approaches	  to	  reduce	  the	  levels	  of	  Ku70	  in	  cell	  lines	  that	  were	  null	  for	  either	  DNA-­‐PKcs	  or	  LIGIV	  and	  which	  resulted	  in	  cell	  lines	  that	  had	  regained	  a	  robust	   DNA	  DSB	   repair	   activity	   that	  was	  mediated	   by	  microhomology.	   	   Together,	  these	  studies	  demonstrate	  that	  Ku	  (Ku70	  and	  Ku86)	  is	  the	  critical	  regulator	  of	  DNA	  DSB	  repair	  pathway	  choice	  in	  human	  somatic	  cells.	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Results	  
Strategy	  and	  cell	  lines	  	   To	  elucidate	  the	  role	  of	  C-­‐NHEJ	  factors	  in	  DNA	  DSB	  repair,	  we	  made	  use	  of	  an	  extrachromosomal	  reporter	  assay	  system	  {[34,42];	  Figure	  1}.	  	  This	  assay	  permits,	  in	  addition	  to	  the	  generation	  of	  defined	  DNA	  DSBs,	  a	  detailed	  follow	  up	  of	  the	  repair	  of	  the	  reporter	  plasmid.	  	  In	  this	  assay,	  end	  joining	  is	  measured	  by	  the	  reconstitution	  of	  green	   fluorescent	   protein	   (GFP)	   expression	   [42].	   	   The	   reporter	   pEGFP-­‐Pem1-­‐Ad2	  consists	   of	   the	  GFP	  gene	  engineered	   such	   that	   it	   is	   interrupted	  by	   a	  2.4	  kb	   intron	  derived	  from	  the	  rat	  Pem1	  gene	  (Figure	  1A).	  	  An	  exon	  derived	  from	  adenovirus	  (Ad)	  has	  been	  introduced	  into	  the	  middle	  of	  the	  intron	  and	  it	  is	  flanked	  on	  both	  sides	  by	  
HindIII	   and	   I-­‐SceI	   restriction	   enzyme	   recognition	   sequences.	   	   In	   un-­‐digested	   or	  partially-­‐digested	  plasmids,	  GFP	  is	  not	  expressed	  because	  the	  Ad	  exon	  is	  efficiently	  incorporated	  into	  the	  GFP	  mRNA	  (Figure	  1C).	   	  Digestion	  of	  the	  plasmid	  either	  with	  
HindIII	   or	   I-­‐SceI	   at	   the	   flanking	   sites	   generates	   a	   linear	   plasmid	   lacking	   the	  adenoviral	   exon	   with	   either	   compatible	   5’-­‐overhanging	   cohesive	   ends	   or	  incompatible	   ends,	   respectively	   (Figure	   1B).	   	   The	  HindIII	   sites	   are	   arranged	   such	  that	   cohesive	   4-­‐bp	   overlapping	   ends	   are	   generated,	   whereas	   the	   I-­‐SceI	   sites	   are	  arranged	   in	   an	   inverted	   orientation,	  which	   demands	   that	   some	   sort	   of	   processing	  must	   occur	   before	   the	   ends	   can	   be	   rejoined.	   	   Thus,	   the	   impact	   of	   loss-­‐of-­‐function	  NHEJ	  gene	  mutations	  on	  these	  aspects	  of	  end	   joining	  can	  be	   individually	  assessed.	  	  Due	   to	   the	   buffering	   capacity	   of	   the	   intron,	   end	   joining	   by	   the	   cellular	   repair	  apparatus	  of	   transfected,	   linearized	  plasmid	  usually	  re-­‐constitutes	  GFP	  expression,	  even	  when	   extensive	   additions	   or	   deletions	   of	   nucleotides	   have	   occurred	   (Figure	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1C).	   	   As	   a	   result,	   a	   wide	   spectrum	   of	   end	   joining	   events	   can	   be	   detected	   and	  quantitated	  by	  FACS	  (fluorescently	  activated	  cell	  sorting).	  	  As	  a	  transfection	  control,	  cells	  are	  always	  co-­‐transfected	  with	  a	  pCherry	  expression	  plasmid,	  and	  the	  data	  are	  expressed	   as	   the	   percentage	   of	   cherry-­‐positive	   cells	   that	   are	   also	   green-­‐positive.	  	  Lastly,	  pEGFP-­‐Pem1-­‐Ad2	  contains	  a	  bacterial	  origin	  of	  replication	  and	  an	  antibiotic	  resistance	   gene	   permitting	   the	   plasmids	   to	   be	   recovered	   from	   human	   cells	   and	  rescued	   in	   E.	   coli.	   	   Consequently,	   the	   structure	   of	   the	   repair	   junctions,	   which	  provides	   mechanistic	   insight	   into	   the	   type	   of	   repair	   that	   was	   utilized,	   can	   be	  identified	  by	  DNA	  sequencing.	  	   This	   assay	   system	   was	   used	   to	   interrogate	   a	   series	   of	   isogenic	   human	  HCT116	  cell	   lines.	   	  HCT116	  is	  a	  human	  adenocarcinoma	  somatic	  tissue	  culture	  cell	  line.	   	   It	   is	  diploid,	   is	  wild-­‐type	   for	  all	  of	   the	  major	  DNA	  DSB	  and	  checkpoint	  genes	  and	  has	  a	  stable	  karyotype	  [40].	  	  The	  derivative	  cell	  lines	  had	  been	  engineered	  using	  rAAV	  gene	  targeting	  to	  be	  reduced	  or	  deficient	   in	   the	  expression	  of	  most	  of	   the	  C-­‐NHEJ	   factors,	   namely:	  Ku70	   [1,43],	  Ku86	   [2,36],	  DNA-­‐PKcs	   [44],	   XLF	   (Fattah	  et	  al.,	  unpublished)	  or	  LIGIV	  (Oh	  et	  al.,	  unpublished).	  	  	  
	  
LIGIV	  is	  the	  only	  C-­‐NHEJ	  gene	  that	  is	  haploinsufficient	  for	  plasmid	  
DNA	  end	  joining	  in	  vivo	  	   When	  HindIII-­‐	  or	  I-­‐SceI-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2	  plasmid	  was	  introduced	  into	   the	   parental	   HCT116	   cell	   line,	   intracellular	   circularization	   allowing	   GFP	  expression	  could	  easily	  be	  detected	  and	  quantitated	  by	   flow	  cytometry	   (Figure	  2).	  	  When	  the	  same	  experiment	  was	  carried	  out	  with	  the	  C-­‐NHEJ	  heterozygous	  cell	  lines,	  
	   	   Fattah	  et	  al.	  
	   131	  
significant	   repair	   activity	   was	   always	   observed	   (Figure	   2).	   	   Averaged	   over	   four	  experiments,	   the	   Ku70,	   Ku86,	   DNA-­‐PKcs	   and	   XLF	   heterozygous	   cell	   lines	   showed	  only	   a	   slightly	   reduced	   ability	   to	   repair	   this	   DNA	   DSB	   that	   was	   not	   significantly	  different	  from	  wild-­‐type	  (Figure	  3).	  	  	  In	  contrast,	  the	  LIGIV+/-­‐	  cell	  line	  possessed	  only	  ~65%	   the	   repair	   capacity	   of	   the	   parental	   cell	   line	   and	   was	   reproducibly	  haploinsufficient	  (Figures	  2	  and	  3).	  	  In	  no	  case	  was	  a	  significant	  difference	  in	  repair	  frequency	   between	   the	   repair	   of	   HindIII-­‐	   or	   I-­‐SceI-­‐plasmid	   observed	   (Figure	   3).	  	  While	  the	  FACS	  analysis	  (Figures	  2	  and	  3)	  measured	  repair	  frequency,	  the	  repaired	  plasmids	   could	   also	   be	   analyzed	   molecularly.	   	   In	   particular,	   the	   HindIII-­‐cleaved	  substrate	  contained	  4	  bp	  compatible	  overhangs	  that	  essentially	  constituted	  a	  stretch	  of	  microhomology	   (Figure	  1B).	   	   If	   these	   sequences	  are	  used	   to	  mediate	   the	   repair	  event,	   they	   generate	   a	   slightly	   smaller	   plasmid	   that	   contains	   a	   single	   HindIII	  restriction	  enzyme	  recognition	   site	  where	   there	  use	   to	  be	   two.	   	  Consequently,	   the	  recovered,	  repaired	  HindIII-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2	  plasmids	  were	  re-­‐digested	  with	   HindIII	   before	   gel	   electrophoresis,	   and	   the	   frequency	   of	   plasmids	   that	   had	  reconstituted	  a	  single	  HindIII	  site	  (“perfect	  joins”)	  was	  determined.	  	  Ku70+/-­‐,	  Ku86+/-­‐	  (Table	   S1),	   DNA-­‐PKcs+/-­‐	   (Table	   S3),	   XLF+/-­‐	   (Table	   S5)	   and	   LIGIV+/-­‐	   (Table	   S7)	   cells	  perfectly	  rejoined	  an	  average	  of	  ~37%	  of	  the	  substrates,	  which	  was	  slightly	  higher	  than	  the	  23%	  perfect	  rejoining	  observed	  in	  wild-­‐type	  cells	  (summarized	  in	  Figure	  S1	  and	  Figure	  6B).	  	  Thus,	  even	  though	  the	  repair	  activity	  was	  not	  substantially	  affected	  by	  the	  loss	  of	  one	  allele	  of	  any	  of	  the	  C-­‐NHEJ	  genes	  tested,	  the	  repair	  profiles	  shifted	  towards	   microhomology-­‐mediated	   joining.	   	   In	   several	   instances,	   perfectly	   joined	  plasmids	  (as	  assessed	  by	  restriction	  digest	  and	  gel	  electrophoresis)	  were	  sequenced	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and	   without	   exception	   the	   existence	   of	   the	   expected	   single	   HindIII	   site	   was	  confirmed	  (data	  not	  shown).	  	  Lastly,	  plasmids	  for	  those	  HindIII-­‐linearized	  substrates	  that	   did	   not	   perfectly	   rejoin	   and	   30	   plasmids	   for	   the	   I-­‐SceI-­‐linearized	   substrate	  (which	  can	  not	  perfectly	  rejoin)	  were	  sequenced.	   	  This	  analysis	  demonstrated	  that	  the	   size	   of	   the	   accompanying	   deletions	   (Figures	   S3	   and	   S4),	   the	   frequency	   of	  microhomology	  usage,	  and	   the	   frequency	  of	   insertions	  was,	  with	  a	   few	   interesting	  exceptions	   (see	   the	   Discussion),	   comparable	   to	   that	   observed	   in	   wild-­‐type	   cells	  (Tables	   S2,	   S4,	   S6	   and	   S8	   and	   Figures	   S1	   and	   S2).	   	   From	   these	   experiments,	   we	  concluded	   that	   the	   reduction	   by	   one	   allele	   of	   most	   C-­‐NHEJ	   factors	   is	   generally	  aphenotypic	   for	  DNA	  end	   joining	  whereas	  LIGIV	   is	  haploinsufficient,	   implying	   that	  LIGIV	  may	  be	  a	  limiting	  C-­‐NHEJ	  factor	  in	  human	  somatic	  cells.	  
	  
The	   absence	   of	   DNA-­‐PKcs,	   XLF	   and	   LIGIV	   greatly	   reduces	   DNA	  
repair	  activity	  
	   In	  rodents,	  cells	  deficient	  in	  any	  of	  the	  C-­‐NHEJ	  components	  are	  generally	  very	  deficient	   in	   joining	   virtually	   all	   types	   of	   DNA	  DSBs	   [3].	   	   To	   test	  whether	   C-­‐NHEJ-­‐deficient	   human	   cells	   are	   also	   impaired	   in	   end	   joining,	   we	   repeated	   the	   above	  experiment	   in	   DNA-­‐PKcs-­‐,	   XLF-­‐	   and	   LIGIV-­‐null	   cell	   lines.	   	   In	   all	   three	   cases,	   the	  frequency	  of	  end	  joining	  was	  greatly	  reduced	  (Figure	  4).	  	  On	  average,	  DNA-­‐PKcs-­‐	  and	  XLF-­‐null	   cell	   lines	   were	   diminished	   by	   an	   order-­‐of-­‐magnitude	   and	   showed	   only	  about	   10%	   the	   repair	   activity	   observed	   in	   the	   parental	   cell	   line	   (Figure	   3).	   	   The	  LIGIV-­‐null	  cell	  line	  was	  always	  the	  most	  profoundly	  affected	  cell	  line	  and	  performed	  end-­‐joining	  only	  a	  few	  percent	  above	  background.	  	  The	  fact	  that	  XLF-­‐null	  cells	  were	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reproducibly	  more	  active	  than	  the	  LIGIV-­‐null	  cells	  is	  consistent	  with	  XLF	  playing	  an	  important,	  but	  not	  essential,	   role	   in	  DNA	  DSB	   ligation.	   	  We	  next	  attempted	  —	  as	  a	  proof-­‐of-­‐principle	  —	  to	  functionally	  rescue	  the	  XLF-­‐null	  line	  to	  confirm	  that	  the	  loss	  of	   end-­‐joining	   activity	   was	   due	   specifically	   to	   the	   respective	   targeted	   knockout	  mutations	   in	   these	   cell	   lines.	   	   A	   XLF	   cDNA	   was	   stably	   introduced	   via	   retroviral	  infection	   into	   the	   XLF-­‐null	   cell	   line,	   and	   a	   subclone	   expressing	  wild-­‐type	   levels	   of	  XLF	   protein	  was	   isolated	   (data	   not	   shown).	   	   This	   cell	   line	   showed	   an	   end-­‐joining	  activity	   that	   was	   90%	   of	   wild-­‐type	   (Figure	   3)	   directly	   demonstrating	   that	   the	  absence	  of	  XLF	  was	  responsible	   for	   the	  phenotype	  of	   the	  null	  cells.	   	   In	  conclusion,	  these	  experiments	  demonstrated	  that	  C-­‐NHEJ	   is	  the	  major	  NHEJ	  repair	  pathway	  in	  human	   somatic	   cells,	   and	   in	   its	   absence	   only	   low	   (albeit	   detectable	   -­‐	   see	   below)	  levels	  of	  end	  joining	  can	  occur.	  	  
The	  absence	  of	  Ku	  changes	  the	  repair	  profile,	  but	  not	  the	  repair	  
activity	  	  	   Primates	  are	  unique	   in	   that,	   in	  contrast	   to	  every	  other	  species	  examined	   to	  date,	  the	  Ku	  genes	  have	  evolved	  to	  become	  essential	  [1,2,36],	  due	  to	  their	  ability	  to	  suppress	  lethal	  HR-­‐mediated	  telomere	  recombination	  [2].	  	  Consequently,	  human	  cell	  lines	   that	   are	   null	   for	   either	   Ku70	   [1]	   or	   Ku86	   [36]	   are	   not	   viable.	   	   We	   have,	  however,	  constructed	  a	  “conditionally-­‐null”	  (Ku86flox/-­‐)	  cell	   line	  for	  Ku86.	   	  This	  cell	  line	  has	  been	  engineered	  through	  rAAV	  gene	  targeting	  technology	  to	  contain	  only	  a	  singly	  functional	  “floxed”	  allele	  of	  Ku86	  [2].	  	  In	  the	  presence	  of	  the	  Cre	  recombinase,	  the	  floxed	  allele	  is	  excised	  and	  the	  cells	  become	  null	  for	  Ku	  expression.	  	  Importantly,	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the	   loss	   of	  Ku86	   is	   essentially	   complete	   in	  4	   to	  5	  days	   and	   although	   the	   cells	  will	  ultimately	  succumb,	  they	  generally	  don’t	  do	  so	  for	  approximately	  2	  weeks	  [2].	  	  Thus,	  the	  day	  4	  to	  day	  14	  window	  was	  used	  to	  assess	  the	  ability	  of	  the	  cells	  to	  perform	  end	  joining.	  	  Consequently,	  Ku86flox/-­‐	  cells	  were	  either	  infected	  with	  a	  control	  adenovirus	  (AdCMV)	   or	   an	   adenovirus	   expressing	   Cre	   (AdCre).	   	   At	   4,	   5	   and	   6	   days	   post-­‐infection,	   a	   portion	   of	   the	   cells	   were	   processed	   for	   Western	   analysis,	   which	  confirmed	   that	   the	   levels	   of	   Ku86	   protein	  were	   greatly	   diminished	   in	   the	   AdCre-­‐treated	  cells	  compared	  to	  the	  control	  AdCMV-­‐treated	  cells	  (Figure	  5A).	  	  The	  levels	  of	  Ku86	   never	   go	   to	   zero	   because	   a	   minor	   portion	   of	   the	   cells	   are	   either	   not	  productively	   infected	   with	   the	   adenoviral	   vector	   and/or	   they	   do	   not	   efficiently	  undergo	  Cre-­‐mediated	  recombination	  [2].	   	  At	  120	  hr	  post	  adenovirus	  infection,	  the	  cells	   were	   transfected	   with	   pEGFP-­‐Pem1-­‐Ad2	   and	   24	   hr	   later	   the	   cells	   were	  analyzed	   by	   FACS	   analysis.	   	   Very	   unexpectedly,	   Ku86flox/-­‐	   +AdCre	   cells	   performed	  end	   joining	   at	   a	   wild-­‐type	   frequency	   (Figure	   5B).	   	   Indeed,	   in	   four	   independent	  experiments	  the	  “Ku86-­‐null”	  cells	  reproducibly	  seemed	  to	  have	  even	  slightly	  higher	  levels	  of	  end	  joining	  activity	  than	  wild-­‐type	  cells,	  regardless	  of	  whether	  HindIII-­‐	  or	  I-­‐
SceI-­‐linearized	  substrates	  were	  used	  (Figure	  3).	  	   We	   were	   perplexed	   by	   this	   result	   until	   we	   considered	   the	   possibility	   that	  although	  the	  frequency	  of	  end-­‐joining	  was	  not	  altered	  in	  Ku86-­‐null	  cells	  the	  repair	  profile	   might	   be.	   	   To	   experimentally	   test	   this	   hypothesis,	   the	   repaired	   HindIII-­‐cleaved	  pEGFP-­‐Pem1-­‐Ad2	  substrate	  plasmids	  were	  recovered	  from	  Ku86-­‐null	  cells	  and	   analyzed	   by	   agarose	   gel	   electrophoresis	   following	   HindIII	   re-­‐digestion	   for	  perfect	   rejoining.	   	   In	   the	   parental	   and	   heterozygous	   cell	   lines	   this	   type	   of	   repair	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event	  was	  observed	   in	   about	  30%	  of	   the	   repaired	  plasmids	   (Figs.	   6A	  and	  6B).	   	   In	  striking	   contrast,	   ~80%	   of	   all	   the	   plasmids	   recovered	   from	   Ku86-­‐null	   cells	   had	  reconstituted	   a	   single	   HindIII	   site	   (Figures	   6A	   and	   6B).	   	   Thus,	   while	   the	   overall	  repair	   frequency	   in	   Ku86-­‐null	   cells	   was	   not	   significantly	   different	   from	  wild-­‐type	  cells,	  the	  repair	  profile	  was	  heavily	  shifted	  to	  one	  that	  utilized	  more	  microhomology.	  	  
Microhomology-­‐mediated	   end	   joining	   also	   dominates	   in	   the	  
absence	  of	  DNA-­‐PKcs,	  XLF	  and	  LIGIV	  	   Although	  end	  joining	  was	  greatly	  reduced	  in	  DNA-­‐PKcs-­‐,	  XLF-­‐	  and	  LIGIV-­‐null	  cell	   lines	  (Figure	  4),	   it	  was	  not	  zero.	   	  Given	  the	  above	  results	  with	  Ku86-­‐null	  cells,	  we	  next	  tested	  whether	  the	  residual	  repair	  in	  these	  other	  C-­‐NHEJ-­‐null	  cell	  lines	  was	  also	  heavily	  biased	  towards	  microhomology.	  	  Indeed,	  although	  there	  were	  far	  fewer	  repair	   events	   in	   these	   three	   cell	   lines	   in	   comparison	   to	  Ku86-­‐null	   cells,	   they	  were	  nonetheless	  predominantly	   (70	   to	  80%)	  mediated	  by	  microhomology	   (Figure	  6B).	  	  Thus,	   DNA-­‐PKcs-­‐,	   XLF-­‐	   and	   LIGIV-­‐null	   cell	   lines	   had	   an	   identical	   repair	   profile	   to	  Ku86-­‐null	  cells	  (Figure	  6B),	  but	  carried	  out	  only	  1	  to	  10%	  as	  many	  repair	  events	  as	  Ku86-­‐null	  cells.	  	  
A-­‐NHEJ	  is	  negatively	  regulated	  by	  Ku	  in	  human	  somatic	  cells	  	   The	  above	  results	  suggested	  that	  Ku	  normally	  actively	  suppresses	  A-­‐NHEJ.	  	  In	  Ku’s	  presence,	  even	  when	  C-­‐NHEJ	   is	   inactivated	  by	  mutations	   in	  DNA-­‐PKcs,	  XLF	  or	  LIGIV,	  A-­‐NHEJ	  is	  apparently	  still	  strongly	  suppressed	  (Figure	  4).	  	  In	  contrast,	  in	  Ku’s	  absence,	  A-­‐NHEJ	  is	  “unleashed”	  and	  rescues	  the	  repair	  activity	  of	  the	  cells	  (Figure	  5).	  	  
	   	   Fattah	  et	  al.	  
	   136	  
Interestingly,	   there	   is	  precedent	   for	   this	  model	   in	   the	   literature.	   	  Thus,	  mouse	  cell	  lines	  deficient	  for	  Ku86	  repair	  I-­‐SceI-­‐induced	  DNA	  DSBs	  with	  a	  frequency	  similar	  to	  that	   of	   wild-­‐type	   cells	   but	   with	   a	   repair	   profile	   that	   is	   biased	   towards	  microhomology	  [45].	  	  Moreover,	  the	  ionizing	  radiation	  sensitivity	  of	  LIGIV-­‐deficient	  chicken	   DT40	   cells	   can	   be	   rescued	   by	   the	   deletion	   of	   Ku70	   [46].	   	   Perhaps	   most	  impressively,	  LIGIV	  deficiency	   in	  the	  mouse	  results	   in	  embryonic	   lethality	  and	  this	  can	   be	   rescued	   by	   the	   deletion	   of	   Ku86	   [47].	   	   Although,	   repair	   profiles	   were	   not	  assessed	   in	   the	   latter	   two	   studies,	   they	   are	   consistent	  with	   the	   absence	   of	  Ku	  de-­‐repressing	  A-­‐NHEJ	  to	  the	  point	  where	  the	  phenotypes	  could	  be	  rescued.	  	   To	  investigate	  if	  this	  paradigm	  could	  be	  extended	  to	  human	  cells	  we	  directly	  tested	  whether	  the	  strong	  repair	  defects	  of	  DNA-­‐PKcs-­‐	  and	  the	  very	  severe	  defects	  of	  LIGIV-­‐null	  cells	  could	  be	  rescued	  by	  reducing	  the	  amount	  of	  Ku	  in	  these	  cell	  lines.	  	  A	  combination	   of	   genetic	   and	   molecular	   approaches	   was	   utilized	   to	   achieve	   a	  significant	  knockdown	  of	  Ku,	  a	  highly	  abundant	  protein.	  	  Thus,	  rAAV	  gene	  targeting	  was	  first	  used	  to	  functionally	  inactivate	  one	  Ku70	  allele	  in	  DNA-­‐PKcs-­‐	  and	  LigIV-­‐null	  cell	  lines.	  	  DNA-­‐PKcs-­‐/-­‐:Ku70+/-­‐	  and	  LIGIV-­‐/-­‐:Ku70+/-­‐	  cell	  lines	  have	  ~50%	  the	  level	  of	  Ku70	  protein	  compared	  to	  wild-­‐type	  cells	  (Figure	  7B;	  [1,43])	  and	  this	  reduction	  in	  Ku	  very	  slightly	  rescued	  the	  repair	  deficiencies	  of	  either	  cell	  line	  (compare	  panel	  5	  with	  panel	  6	  and	  panel	  8	  with	  panel	  9	  in	  Figure	  7A;	  Figure	  7C).	  	  siRNA	  against	  Ku70	  was	   then	   used	   to	   reduce	   the	   level	   of	   Ku	   protein	   to	   ~5%	   of	   wild-­‐type	   (+	   siRNA,	  Figure	   7B).	   	   Impressively,	   DNA-­‐PKcs-­‐/-­‐	   and	   LIGIV-­‐/-­‐	   cells	   showed	   wild-­‐type	   and	  greatly	  enhanced,	   respectively,	  end-­‐joining	  activity	   (compare	  panel	  5	  with	  panel	  7	  and	  panel	  8	  with	  panel	  10	   in	  Figure	  7A;	  Figure	  7C),	  directly	  demonstrating	   that	   a	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reduction	   in	   Ku	   can	   “reanimate”	   a	   cell	   that	   appears	   “dead”	   for	   DNA	   DSB	   repair.	  	  Importantly,	   the	   end	   joining	   occurring	   in	   these	   Ku-­‐reduced	   cell	   lines	   was	  predominately	   microhomology	   mediated	   (Tables	   S3,	   S4,	   S7	   and	   S8).	   	   Moreover,	  these	   data	   provide	   a	   plausible	   molecular	   mechanistic	   explanation	   for	   the	   earlier	  genetic	  results	  obtained	  in	  chickens	  and	  mice.	  
	  
Microhomology-­‐mediated	   A-­‐NHEJ	   predominates	   in	   C-­‐NHEJ	  
deficient	  cells	  	   To	  confirm	  and	  extend	  the	  above	  results,	  we	  utilized	  a	  reporter	  assay	  that	  is	  biased	  towards	  detecting	  A-­‐NHEJ	  events.	  	  pDVG94	  is	  designed	  such	  that	  the	  relative	  efficiency	  of	  C-­‐NHEJ	  versus	  A-­‐NHEJ	  events	  can	  be	  assessed	  [41,48].	  	  When	  pDVG94	  is	  digested	  with	  AfeI	  and	  EcoRV	  it	  results	  in	  a	  blunt-­‐ended	  linear	  substrate	  with	  a	  6-­‐bp	  repeat	  at	  both	  ends	  (Figure	  8A).	  	  C-­‐NHEJ	  can	  rejoin	  these	  ends	  and	  yield	  a	  wide	  variety	   of	   junctions	   but	   A-­‐NHEJ	   almost	   exclusively	   generates	   a	   single	   product	   in	  which	  the	  2	  repeats	  have	  been	  reduced	  to	  1,	  which	  simultaneously	  generates	  a	  novel	  
BstXI	   restriction	   enzyme	   recognition	   site	   (Figure	   8A).	   	   Thus,	   linearized	   pDVG94	  plasmid	  was	  transfected	  into	  the	  mutant	  cell	  lines	  and	  48	  hr	  later	  repaired	  plasmids	  were	  recovered,	  purified	  and	  then	  used	  as	  substrates	  for	  PCR	  using	  a	  5’-­‐radiolabeled	  PCR	  primer	  (Figure	  8B).	  	  The	  relative	  level	  of	  A-­‐NHEJ	  is	  subsequently	  determined	  by	  quantification	   of	   the	   BstXI-­‐digested	   PCR	   products	   where	   a	   180	   bp	   product	  represents	   the	   repaired	   plasmid	   and	   a	   cleaved	   120	   bp	   product	   is	   diagnostic	   of	  microhomology-­‐mediated	  end	  joining	  (Figure	  8B).	   	  The	  parental	  cell	   line,	  Ku86flox/-­‐	  and	   Ku86flox/-­‐	   infected	   with	   AdCMV	   cell	   lines	   carried	   out	   only	   a	   few	   percent	   of	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microhomology-­‐mediated	  end	   joining	   in	  this	  assay	  (Figure	  8C).	   	   In	  contrast,	  Ku86-­‐null	   cells	   showed	  on	  average	  45%	  microhomology	  use	   (Figure	  8C).	   	  Although	   this	  assay	  cannot	  be	  used	  to	  determine	   the	  absolute	   frequency	  of	   the	   individual	  repair	  events,	   it	   confirmed	   that	   in	   the	   absence	   of	   Ku,	   microhomology-­‐mediated	   events	  became	  easily	  detectable.	  	   This	  phenotype	  was	   even	  more	   evident	   in	   the	  DNA-­‐PKcs-­‐	   (Figure	  8D),	   XLF-­‐	  (Figure	   8E)	   and	   LIGIV-­‐	   (Figure	   8F)	   null	   cell	   lines.	   	   In	   the	   absence	   of	   one	   of	   these	  three	   factors,	   the	   frequency	  of	  microhomology-­‐mediated	  end	   joining	  was	  virtually	  100%.	   	   Importantly,	   the	  re-­‐introduction	  of	  a	  wild-­‐type	  DNA-­‐PKcs	  or	  XLF	  cDNA	  into	  their	   respective	   null	   cell	   line,	   partially	   and	   completely,	   respectively,	   reverted	   the	  repair	  events	   to	  a	  C-­‐NHEJ	  spectrum.	   	  Again,	   the	  degree	  of	  repair	  complementation	  was	  directly	  related	  to	  the	  degree	  of	  complementing	  protein	  expression	  achieved	  in	  these	  cell	  lines	  (data	  not	  shown).	  	   These	  experiments	  demonstrated	  that	  in	  the	  presence	  of	  Ku,	  but	  the	  absence	  of	  other	  C-­‐NHEJ	  factors	  that	  virtually	  all	  of	  the	  end	  joining	  in	  human	  cells	  is	  carried	  out	  by	  microhomology-­‐mediated	  processes.	  	  In	  contrast,	  in	  the	  presence	  of	  the	  other	  C-­‐NHEJ	  factors	  but	  in	  the	  absence	  of	  Ku,	  some,	  but	  not	  all,	  of	  the	  end	  joining	  occurs	  using	  microhomology.	  	   	  
Ku	  protects	  DNA	  ends	  from	  degradation	  
	   In	   every	   metabolic	   reaction	   (e.g.,	   DNA	   DSB	   repair,	   V(D)J	   recombination,	  telomere	  maintenance,	  etc.)	  that	  Ku	  participates	  in,	  and	  in	  every	  organism	  that	  such	  reactions	  have	  been	  characterized,	  Ku’s	  absence	  is	  marked	  by	  hyper-­‐resection	  of	  the	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relevant	  DNA	  ends	  [13].	  	  To	  determine	  if	  this	  aspect	  of	  Ku’s	  absence	  is	  conserved	  in	  human	   cells	   extensive	   sequencing	   was	   carried	   out	   of	   pEGFP-­‐Pem1-­‐Ad2	   plasmids	  recovered	  from	  wild	  type	  and	  Ku86-­‐null	  cells.	  	  A	  significant	  increase	  in	  deletion	  size	  in	  Ku86-­‐null	  cells	  compared	  to	  wild-­‐type	  cells	  was	  observed.	  	  In	  wild-­‐type	  cells	  the	  median	   deletion	   size	   was	   595	   bp	   whereas	   in	   Ku86-­‐null	   cells	   it	   was	   1158	   bp	   for	  
HindIII-­‐linearized	   plasmids	   (Table	   S1	   and	   Figure	   S3).	   	   This	   same	   trend	   was	   also	  observed	   in	   I-­‐SceI-­‐linearized	  plasmids	  as	   the	  median	  deletion	  size	  was	  1097	  bp	   in	  Ku86-­‐null	  cells	  in	  comparison	  to	  321	  bp	  in	  wild	  type	  cells	  (Table	  S2	  and	  Figure	  S4).	  	  When	  the	  same	  analysis	  was	  carried	  out	  for	  DNA-­‐PKcs-­‐null	  (Tables	  S3	  and	  S4),	  XLF-­‐null	  (Tables	  S5	  and	  S6)	  and	  LIGIV-­‐null	  (Tables	  S7	  and	  S8)	  cell	  lines	  less	  degradation	  of	  the	  DNA	  ends	  compared	  to	  wild-­‐type	  cells	  was	  observed	  (Figures	  S3	  and	  S4).	  	  In	  summary,	   the	  presence	  or	   absence	  of	  Ku	   in	  human	   somatic	   cells	   carried	  with	   it	   a	  hyper-­‐resection	   phenotype	   that	   was	   identical	   to	   that	   observed	   for	   Ku-­‐dependent	  reactions	  in	  all	  other	  species.	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Discussion	  	   We	  have	  utilized	  rAAV	  knockout	  technology	  to	  construct	  a	  powerful	  reagent:	  a	  series	  of	  isogenic	  human	  cell	  lines	  that	  are	  defective	  for	  genes	  required	  for	  the	  C-­‐NHEJ-­‐mediated	   branch	   of	   DNA	   DSB	   repair.	   	   We	   used	   these	   cell	   lines	   along	   with	  several	   informative	   reporter	   systems	   to	   demonstrate	   that	   wild-­‐type	   human	   cells	  vastly	  prefer	  to	  utilize	  C-­‐NHEJ	  over	  A-­‐NHEJ	  for	  end	  joining	  reactions.	  	  Unexpectedly,	  the	  absence	  of	  the	  proximal	  C-­‐NHEJ	  factor	  Ku,	  resulted	  in	  cells	  that	  still	  carried	  out	  robust	   levels	   of	   end	   joining,	   suggesting	   that	   Ku	   normally	   suppresses	   other	   end	  joining	  pathways.	  	  This	  model	  was	  supported	  by	  the	  construction	  of	  double	  mutant	  cell	  lines,	  which	  demonstrated	  that	  the	  reduction	  of	  Ku	  in	  a	  cell	  that	  was	  incapable	  of	  carrying	  out	  C-­‐NHEJ	  still	  resulted	  in	  high	  levels	  of	  end	  joining.	  	  Thus,	  these	  studies	  demonstrate	   that	   Ku	   is	   the	   critical	   regulator	   for	   determining	   pathway	   choice	   in	  human	  somatic	  cells.	  	  
Ku,	  the	  “mother”	  of	  all	  DNA	  DSB	  repair	  inhibitors?	  Ku	   is	   a	   heavily	   researched	   DNA	   repair	   factor	   and	   the	   majority	   of	   studies	  rightfully	   concentrate	   on	   some	   aspect	   of	   Ku’s	   ability	   to	   positively	   facilitate	   the	  myriad	   of	   repair	   and	   recombination	   reactions	   that	   require	   C-­‐NHEJ.	   	   In	   this	   and	  related	  studies,	  we	  have	  recently	  documented	  that	  Ku	  has	  an	  additional	  and	  hitherto	  underappreciated	   function	  —	   it	   is	   a	   powerful	   inhibitor	   for	   all	   the	   other	  DNA	  DSB	  repair	   pathways.	   	   Specifically,	   we	   have	   demonstrated	   that	   in	   Ku	   is	   an	   essential	  repressor	  of	  HR-­‐mediated	  aberrant	  telomere	  recombination.	   	  In	  the	  absence	  of	  Ku,	  the	   HR	   apparatus	   can	   apparently	   gain	   access	   to	   the	   telomeric	   ends	   and	   generate	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lethal	   telomeric	   shortening	   [2].	   	   Thus,	  Ku	   can	   inhibit	  HR	   specifically	   at	   telomeres.	  	  Moreover,	   in	  a	  study	  that	  characterized	  generalized	  rAAV-­‐mediated	  gene	  targeting	  —	   a	   process	   that	   requires	   HR	   —	   for	   loci	   scattered	   throughout	   the	   genome	   we	  demonstrated	  that	  the	  absence	  of	  Ku	  results	  in	  a	  ~10-­‐fold	  increase	  in	  correct	  gene	  targeting	   [1].	   	   Importantly,	   the	   increase	   in	   correct	   gene	   targeting	   came	   at	   no	  expense	  to	  random	  integrations.	   	  These	  data	  strongly	  suggested	  that	  the	  reduction	  of	   Ku	   in	   human	   somatic	   cells	   de-­‐repressed	   HR	   enough	   to	   facilitate	   much	   higher	  levels	   of	   gene	   targeting	   while	   simultaneously	   allowing	   other	   repair	   pathways	   to	  carry	   out	   random	   integrations	   at	   wild-­‐type	   levels.	   	   This	   conclusion	   is	   completely	  supported	   by	   the	   data	   provided	   in	   this	   present	   study.	   	   Thus,	   here	   we	   have	  documented	   that	   in	   the	   absence	   of	   Ku,	   A-­‐NHEJ	   is	   greatly	   up-­‐regulated.	   	   Together,	  these	  studies	  have	  revealed	   that	  Ku	  can	   inhibit	  HR	  at	   telomeres,	  and	   it	  can	   inhibit	  HR	   and	   A-­‐NHEJ	   throughout	   the	   genome.	   	   Moreover,	   this	   work	   and	   the	   work	   of	  Fattah	   et	   al.	   [1]	   make	   the	   strong	   prediction	   that	   the	   random	   rAAV	   integrations	  observed	  in	  Ku-­‐deficient	  cells	  are	  mediated	  by	  A-­‐NHEJ.	  	  
How	  does	  Ku	  orchestrate	  all	  this	  inhibition?	  Many	   models	   can	   be	   envisioned	   for	   how	   Ku	   suppresses	   A-­‐NHEJ.	   	   One	  possibility	  is	  that	  Ku,	  via	  direct	  protein:protein	  interaction,	  sequesters	  a	  key	  A-­‐NHEJ	  factor	  from	  performing	  its	  function.	  	  In	  a	  Ku-­‐deficient	  cell,	  this	  factor	  would	  be	  free	  to	  facilitate	  A-­‐NHEJ.	  	  A	  good	  candidate	  for	  such	  a	  putative	  factor	  exists.	  	  Thus,	  a	  bevy	  of	   independent	   laboratories	   have	   demonstrated	   that	   PARP-­‐1	   interacts	   with	   Ku	  [49,50,51,52,53].	   	  And	  a	  PARP-­‐1	   interaction	  domain	  has	  been	  defined	   in	   the	  Ku70	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subunit	   at	   AA243-­‐261	   [52].	   	   This	   model	   predicts	   that	   a	   cell	   expressing	   a	   Ku70	  incapable	  of	   interacting	  with	  PARP-­‐1	  (e.g.,	  mutated	  at	  residues	  AA243-­‐261)	  would	  phenocopy	   the	   Ku	   loss-­‐of-­‐function	  mutations	   and	  we	   are	   attempting	   to	   construct	  such	  a	  cell	  line.	  	  A	  second,	  and	  in	  our	  minds,	  likelier	  possibility,	  is	  that	  Ku	  controls	  A-­‐NHEJ	  by	   regulating	  access	   to	   the	   substrate;	  namely,	   a	  dsDNA	  end.	   	  We	  prefer	   this	  model	  because	  not	  only	  does	  Ku	  repress	  A-­‐NHEJ	  but	  it	  also	  represses	  HR	  at	  internal	  loci	   [1]	   and	   at	   telomeres	   [2].	   	   While	   it	   is	   possible	   that	   Ku	   mediates	   all	   of	   this	  repression	  by	  physically	  binding	  to	  and	  inhibiting/sequestering	  a	  different	  protein	  or	   proteins	   for	   each	   reaction,	   it	   seems	   simpler	   if	   Ku	   simultaneously	   regulates	   all	  three	   processes	   by	   regulating	   access	   to	   the	   substrate	   for	   all	   of	   these	   pathways:	  double-­‐stranded	  DNA	  ends.	   	  Specifically,	  we	  propose	  that	  in	  order	  to	  be	  channeled	  into	   a	   particular	   pathway	   (HR,	   A-­‐NHEJ	   or	   C-­‐NHEJ),	   that	   pathway’s	   DNA	   binding	  factor	  (probably	  RAD52,	  PARP-­‐1	  and	  Ku,	  respectively)	  needs	  to	  bind	  onto	  the	  ends	  of	  the	  break	  and	  subsequently	  recruit	  their	  pathway’s	  associated	  factors.	  	  We	  posit	  that	   Ku	   generally	   gets	   to	   the	   ends	   of	   a	   dsDNA	   break	   faster	   and/or	   with	   higher	  affinity	  than	  RAD52	  or	  PARP-­‐1	  and	  once	  there	  it	  blocks	  their	  access,	  such	  that	  repair	  is	   fated	   to	   occur	   by	   C-­‐NHEJ.	   	   This	   model	   is	   by	   no	   means	   novel	   and	   has	   been	  proposed	  by	  a	  myriad	  of	  investigators	  and	  was	  broached	  at	  least	  a	  decade	  ago	  [54],	  although	  it	  still	  remains	  largely	  untested.	  	  In	  this	  regard,	  a	  cell	  line	  that	  expressed	  a	  double-­‐stranded	  DNA	  end	  binding	  Ku	  mutant	  would	  be	  predicted	  to	  be	  incapable	  of	  repressing	  either	  HR	  or	  A-­‐NHEJ	  and	  the	  construction	  of	  such	  a	  cell	  line	  is	  underway.	  	  Lastly,	   this	   model,	   in	   particular,	   could	   explain	   the	   differences	   between	   mice	   and	  humans.	  	  In	  mice,	  the	  levels	  of	  Ku/DNA-­‐PK	  are	  much	  lower	  than	  they	  are	  in	  humans	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and	  consequently	  there	  might	  be	  a	  “fair	  fight”	  between	  Ku,	  Rad52	  and	  PARP-­‐1	  over	  who	  gets	  to	  a	  broken	  end.	  	  In	  contrast,	  in	  human	  cells	  where	  the	  levels	  of	  Ku/DNA-­‐PK	   are	   about	   50-­‐fold	   higher	   [13,55],	   Ku	   has	   become	   the	   “bully”	   and	   essentially	  dominates	  pathway	  choice.	  	  
Is	  there	  evidence	  for	  yet	  another	  sub-­‐pathway	  of	  NHEJ?	  In	  this	  study	  we	  have	  interrogated	  our	  mutant	  cell	  lines	  with	  two	  structurally	  similar,	   but	   fundamentally	   different,	   types	   of	  DNA	   ends.	   	   In	   one	   of	   them	   (HindIII-­‐linearized	   pEGFP-­‐Pem1-­‐Ad2)	   a	   region	   of	   pre-­‐existing	   microhomology	   was	  presented	   to	   the	   cell.	   	   In	   the	   other	   (I-­‐SceI-­‐linearized	   pEGFP-­‐Pem1-­‐Ad2	   and	  linearized	   pDVG94)	   some	   processing	   by	   the	   cell	   was	   required	   to	   reveal	   the	  microhomology.	   	   Microhomology-­‐mediated	   end	   joining	   of	   the	   HindIII-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2	  plasmid	  could	  be	  detected	  in	  the	  wild-­‐type	  parental	  cells	  (Figure	  2	   and	   Tables	   S1,	   S3,	   S5	   and	   S7).	   	   This	   perfect	   end	   joining	   increased	   in	   Ku	  heterozygotes	   and	   became	   the	   predominate	   reaction	   product	   in	  Ku-­‐	   reduced/null	  cell	  lines.	  	  These	  results	  can	  be	  most	  simply	  interpreted	  if	  Ku	  inhibits	  A-­‐NHEJ	  and	  as	  the	  level	  of	  Ku	  is	  reduced	  the	  levels	  of	  A-­‐NHEJ	  reciprocally	  rise.	  	  The	  data	  generated	  using	  the	  two	  repair	  substrates	  that	  required	  processing	  suggests	  that	  this	  model	  is,	  however,	  over-­‐simplified.	   	  Thus,	  as	   the	   level	  of	  Ku	  was	  reduced	   in	   the	  various	  cell	  lines	   the	   frequency	  of	  microhomology-­‐mediated	  end	   joining	   increased	  with	   I-­‐SceI-­‐linearized	   pEGFP-­‐Pem1-­‐Ad2	   and	   linearized	   pDVG94,	   but	   so	   did	   other	   end	   joining	  activities.	  	  This	  was	  most	  evident	  in	  the	  experiments	  using	  pDVG94	  where	  ~55%	  of	  the	   repaired	   plasmids	   in	   a	   Ku-­‐null	   cell	   did	   not	   use	   microhomology	   to	   repair	   the	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plasmid	   (Figure	   8C).	   	   Sequencing	   of	   these	   events	   and	   those	   derived	   from	   I-­‐SceI-­‐linearized	   pEGFP-­‐Pem1-­‐Ad2	   did	   not	   reveal	   any	   novel	   repair	   signatures	   and	  most	  events	  looked	  indistinguishable	  from	  typical	  C-­‐NHEJ	  products	  (Table	  S2).	  	  Together,	  these	  studies	  suggest	  that	  there	  may	  be	  at	  least	  one	  additional	  NHEJ	  pathway	  that	  is	  distinguishable	   from	  C-­‐NHEJ	  and	  A-­‐NHEJ	  by	   its	   lack	  of	   requirement	   for	  Ku	  and	   its	  lack	  of	  microhomology	  use,	  respectively.	  	  	  Needless	  to	  say,	  these	  products	  could	  also	  be	   accounted	   for	   by	   A-­‐NHEJ	   if	   it	   does	   not	   have	   an	   absolute	   requirement	   for	  microhomology.	  	  The	  construction	  of	  humans	  cell	  lines	  that	  are	  doubly	  defective	  for	  C-­‐NHEJ	  and	  A-­‐NHEJ	  should	  genetically	  address	  this	  issue.	  	  
The	  power	  of	  rAAV-­‐mediated	  human	  somatic	  cell	  genetics	  Advances	  in	  the	  DNA	  DSB	  repair	  field	  have	  come	  predominately	  from	  studies	  on	   yeast	   and	   genetically	   modified	   mice.	   	   There	   are	   instances,	   C-­‐NHEJ	   foremost	  among	   them,	   however,	   where	   the	   phenotypes	   of	   yeast	   and	   mice	   mutants	   do	   not	  accurately	   recapitulate	   the	   corresponding	  phenotypes	  observed	   in	  humans.	   	   Since	  ultimately	  we	  wish	  to	  apply	  what	  we	  have	  learned	  in	  model	  systems	  to	  the	  study	  of	  humans	   in	   the	   clinic,	   a	   potentially	   more	   appropriate	   model	   system	   is	   the	   use	   of	  human	  somatic	  cells	  in	  culture.	  	  There	  are,	  of	  course,	  attendant	  limitations	  to	  using	  human	  cells	  in	  culture	  and	  the	  requisite	  caution	  needs	  to	  be	  taken	  in	  extrapolating	  cell	  culture	  results	  to	  patients	  in	  the	  clinic.	  	  It	  is,	  however,	  also	  reasonable	  to	  expect	  that	  the	  physiology	  of	  human	  cells	  in	  culture	  may	  reflect	  more	  accurately	  the	  basic	  biochemical	   process	   of	   human	   patients	   than,	   say,	   rodent	   cells	   in	   vivo	   might.	   	   The	  strength	   of	   the	   rodent	   system	   stems	   predominately	   from	   the	   ability	   to	   make	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targeted	   alterations	   of	   individual	   genes	   using	   the	   technology	   of	   HR	   [56].	   	   This	  technology	   exists	   for	   human	   somatic	   cells	   as	  well	   [39,40,57].	   	   Overall,	   at	   least	   73	  different	  genes	  have	  been	   functionally	   inactivated	   in	  a	   total	  of	  43	  different	  human	  somatic	  cell	  lines	  {[40]	  and	  unpublished	  data}.	  	  To	  our	  knowledge,	  however,	  this	  is	  one	   of	   the	   first	   reports	   of	   the	   systematic	   inactivation	   of	   a	   large	   number	   of	   genes	  involved	   in	   a	   single	   pathway.	   	   Importantly,	   we	   have	   shown	   that	   it	   is	   possible	   to	  make	  simple	  knockouts,	   conditional	  knockouts	  and	  double	  mutant	  human	  somatic	  cell	   lines	  with	   relative	   ease.	   	   The	   general	   utility	   of	   rAAV-­‐mediated	   gene	   targeting	  may	  thus	  be	  of	  interest	  for	  investigators	  working	  on	  biological	  problems	  that	  cannot	  be	  adequately	  modeled	  in,	  for	  example,	  the	  mouse.	  	  
	   	   Fattah	  et	  al.	  
	   146	  
Materials	  and	  Methods	  
Cell	  culture	  The	  human	  wild-­‐type	  HCT116	  cell	  line	  and	  its	  derivatives	  were	  cultured	  in	  McCoy’s	  5A	  medium	  containing	  10%	  fetal	  bovine	  serum,	  100	  U/ml	  penicillin,	  and	  100	  U/ml	  streptomycin	   in	   a	   humidified	   incubator	  with	   5%	   CO2	   at	   37	   oC.	   	   Cell	   lines	   derived	  from	  correct	  gene	  targeting	  were	  propagated	  under	  G418	  (1	  mg/ml)	  selection.	  	  Cell	  lines	   carrying	   exogenous	   cDNA	  expression	  vectors	   (either	  XLF	  or	  DNA-­‐PKcs)	  were	  grown	  in	  2	  mg/ml	  of	  puromycin.	  	  
Cell	  lines	  The	  wild-­‐type	  human	  HCT116	  cell	  line	  was	  obtained	  from	  the	  ATCC.	  	  The	  derivative	  Ku70+/-­‐	   [43],	  Ku86+/-­‐	   [36],	  Ku86flox/-­‐	   [2],	  DNA-­‐PKcs+/-­‐	  and	  DNA-­‐PKcs-­‐/-­‐	   [44]	  cell	   lines	  have	   been	   described.	   	   Derivatives	   of	   Ku70+/-­‐	   cells	   treated	   with	   Ku70	   RNAi	  (SMARTPool	   oligonucleotides;	   Dharmacon)	   or	   stably	   expressing	   shRNA	   vectors	  directed	  against	  Ku70	  have	  also	  been	  described	  [1].	  	  The	  XLF+/-­‐	  and	  XLF-­‐/-­‐	  (Fattah	  et	  
al.,	  manuscript	  in	  preparation)	  and	  the	  LIGIV+/-­‐	  and	  LIGIV-­‐/-­‐	  (Oh	  et	  al.,	  manuscript	  in	  preparation)	  cell	  lines	  were	  generated	  by	  rAAV	  gene	  targeting.	  	  Similarly,	  compound	  mutant	   cell	   lines	   (e.g.,	   Ku70+/-­‐:LIGIV-­‐/-­‐)	   were	   generated	   using	   the	   rAAV	   targeting	  technology	  described	  elsewhere	  [40].	  	  	  
Treatment	  of	  Ku86flox/-­‐	  cells	  with	  Cre	  To	  generate	  Ku86-­‐null	  cells,	  the	  Ku86flox/-­‐	  	  cells	  were	  plated	  onto	  a	  6-­‐well	  plate	  at	  a	  density	  of	  5	  X	  104	  cells	  per	  well	  and	  allowed	  to	  attach	  for	  18	  hr.	  	  Adenoviral	  infection	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was	  carried	  out	  by	  adding	  2	  ml	  of	  fresh	  media	  containing	  5	  X	  108	  virus	  particles	  of	  either	  a	  control	  (AdCMV)	  or	  experimental	  (AdCre)	  adenoviral	  stock	  to	  each	  well	  [2].	  	  After	   4	   days	   (96	   hr)	   of	   incubation	   the	   cells	  were	   re-­‐plated	   into	   6-­‐well	   plates	   and	  allowed	   to	   incubate	   for	   another	   24	   hr	   before	   the	   cells	   were	   transfected	   with	  linearized	  NHEJ	  substrates	  (see	  below).	  	  Flow	  cytometry	  was	  then	  carried	  out	  after	  an	  additional	  incubation	  for	  24	  hr.	  	  
The	  end-­‐joining	  assay,	  transfection	  and	  FACS	  analysis	  The	   in	   vivo	   end-­‐joining	   reporter	   plasmid	   pEGFP-­‐Pem1-­‐Ad2	   (Figure	   1)	   has	   been	  described	  [34,42].	  	  Prior	  to	  transfection,	  the	  pEGFP-­‐Pem1-­‐Ad2	  plasmid	  was	  digested	  with	  HindIII	  or	  I-­‐SceI	  (NEB)	  for	  8	  to	  12	  hr	  to	  generate	  different	  types	  of	  DNA	  ends.	  	  A	  pCherry	  plasmid	  (Clontech)	  was	  co-­‐transfected	  with	  linearized	  pEGFP-­‐Pem1-­‐Ad2	  as	  a	  control	  of	   transfection	  efficiency.	   	  The	  cell	   line	  under	  analysis	  was	  subcultured	  a	  day	   before	   transfection	   and	   was	   ~60	   to	   70%	   confluent	   for	   transfection.	  	  Transfections	  were	  performed	  using	  Lipofectamine	  2000	  (Invitrogen)	  according	  to	  manufacture’s	   instructions.	   	   Green	   (EGFP)	   and	   red	   (Cherry)	   fluorescence	   was	  measured	   by	   fluorescence-­‐activated	   flow	   cytometry	   (FACS)	   24	   hr	   later	   [34].	   	   For	  FACS	   analysis	   cells	   were	   harvested,	   washed	   in	   1X	   PBS	   and	   fixed	   using	   2%	  paraformaldehyde.	  FACS	  analysis	  was	  performed	  on	  a	  FACSCalibur	  instrument	  (BD	  Biosciences).	   	   For	   the	   HCT116	   cell	   line	   a	   red-­‐versus-­‐green	   standard	   curve	   was	  derived	  with	  varying	  amount	  of	  cherry	  and	  green	  plasmids	  to	  avoid	  measurements	  near	  the	  plateau	  region.	  	  The	  values	  of	  repaired	  events	  is	  reported	  as	  a	  ratio	  of	  cells	  that	  were	   double	   positive	   for	   red	   and	   green	   fluorescence	   over	   total	   cells	   that	   are	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only	   positive	   for	   red	   fluorescence.	   	   This	   ratio	   normalizes	   the	   repair	   events	   to	   the	  transfection	   controls.	   	   The	   values	   for	   all	   the	   mutants	   are	   reported	   as	   a	   percent	  repair	  of	  wild-­‐type	  cells.	  	  
Plasmid	  rescue	  The	  repaired	  NHEJ	  reporter	  pEGFP-­‐Pem1-­‐Ad2	  substrates	  were	  rescued	  from	  human	  cells	  using	  a	  Qiagen	  mini-­‐preparation	  protocol,	  transformed	  into	  E.	  coli	  (TOP10)	  and	  colonies	   carrying	   the	   repaired	  plasmids	  were	   selected	  on	  LB	  plates	   containing	  30	  mg/ml	  of	  kanamycin.	  	  The	  fidelity	  of	  NHEJ	  repair	  events	  was	  examined	  by	  digesting	  the	  plasmid	  DNA	  from	  individual	  colonies	  with	  the	  restriction	  enzyme	  HindIII	  prior	  to	  agarose	  gel	  electrophoresis.	  	  Precise	  junctional	  information	  was	  obtained	  by	  DNA	  sequencing	  using	   a	   variety	   of	   primers	   (sequences	   available	   upon	   request)	   located	  upstream	  and	  downstream	  of	   the	  Ad2	   exon	   sequence.	   	   Those	   events	   that	   had	  not	  restored	   the	   original	   restriction	   site	  were	   always	   analyzed	   by	   sequencing.	   	   For	   I-­‐
SceI-­‐digested	   substrate,	   all	   the	   repair	   products	   were	   directly	   sequenced,	   as	  incompatible	  I-­‐SceI	  sites	  should	  not	  restore	  the	  original	  restriction	  site(s).	  	  
Microhomology	  assay	  The	   microhomology	   assay	   was	   performed	   as	   described	   [41].	   	   In	   brief,	   2.5	   mg	   of	  
EcoRV-­‐	  (NEB)	  and	  AfeI-­‐	  (NEB)	  digested	  plasmid	  pDVG94	  were	  transfected	  into	  cells	  that	  were	  ~60%	  confluent,	  in	  6	  well	  plates,	  using	  Lipofectamine	  2000	  (Invitrogen)	  according	   to	  manufacturer’s	   instruction.	   	  The	   transfection	  efficiencies	  of	  wild-­‐type	  HCT116	   and	   the	   derivative	  mutant	   cell	   lines	   were	   determined	   using	   the	   plasmid	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pEGFP-­‐Pem1	   as	   described	   above.	   	   After	   transfection	   (48	   hr),	   plasmid	   DNA	   was	  recovered	   using	   a	  modified	   Qiagen	  mini-­‐preparation	   protocol.	   	   Repaired	   pDVG94	  plasmid	  was	  PCR	  amplified	  using	  primer	  FM30	  and	  a	  5’-­‐radiolabeled	  primer	  DAR5	  [41].	   	  The	  PCR	  product	  was	  digested	  with	  BstXI	  (NEB).	  Restriction	  fragments	  were	  separated	   by	   electrophoresis	   along	   with	   undigested	   PCR	   product	   in	   a	   6%	  polyacrylamide	  gel	   in	  TBE	  buffer.	   	  The	  gel	  was	  subsequently	  dried	  and	  exposed	  to	  film.	   	   The	   bands	   representing	   the	   undigested	   (180	   bp)	   or	   digested	   (120	   bp)	   PCR	  products	  were	  quantified	  using	  ImageQuant	  software.	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Figure	  Legends	  Figure	  1.	  Reporter	  substrate	  for	  analysis	  of	  NHEJ	  	  	  A	   cartoon	   of	   the	   reporter	   construct	   (pEGFP-­‐Pem1-­‐Ad2).	   	   (A)	   The	   construct	   is	  essentially	   a	   GFP	   cassette	   whose	   expression	   is	   driven	   by	   CMV	   promoter	   and	  terminated	   by	   the	   SV40	   polyA	   sequence.	   	   “G”	   is	   separated	   from	   “FP”	   by	   a	   2.4	   kb	  intron	  containing	  an	  exon	  (Ad)	  from	  adenovirus	  that	  is	  flanked	  by	  HindIII	  and	  I-­‐SceI	  restriction	   sites.	   	   Splice	  donor	   (SD)	   and	   splice	   acceptor	   (SA)	   sites	   are	   shown.	   	   (B)	  Restriction	   sites	   used	   to	   introduce	   DNA	   DSBs.	   Digestion	   with	   HindIII	   generates	  compatible	  cohesive	  ends.	   	  Because	   I-­‐SceI	  has	  a	  nonpalindromic	  18-­‐bp	  recognition	  site,	  cleavage	  of	  the	  two	  inverted	  I-­‐SceI	  sites	  generates	  incompatible	  ends.	  	  (C)	  Due	  to	   the	  presence	  of	   the	  Ad-­‐exon	   into	   the	  middle	  of	   the	  Pem1	   intron,	   the	  Ad	  exon	   is	  efficiently	  spliced	  into	  the	  middle	  of	  the	  GFP	  ORF,	  inactivating	  the	  GFP	  activity	  and	  thus	  making	   the	   starting	   substrate	  GFP	  negative.	   	   Both	   sides	   of	   the	  Ad	   exon	  have	  
HindIII/I-­‐SceI	   restriction	   sites.	   	   Cleavage	   with	   either	   of	   these	   endonucleases	  removes	  the	  Ad	  exon	  and	  upon	  successful	  intracellular	  plasmid	  circularization	  GFP	  expression	  is	  restored	  and	  can	  be	  quantitated	  by	  flow	  cytometry.	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Figure	  2.	  	  NHEJ	  in	  the	  parental	  HCT116	  and	  C-­‐NHEJ	  mutant	  (heterozygous)	  cell	  lines	  	  The	   indicated	   cell	   lines	   were	   transfected	   with	   HindIII-­‐	   (Top	   panels)	   or	   I-­‐SceI-­‐(Bottom	  panels)	   linearized	  pEGFP-­‐Pem1-­‐Ad2	   together	  with	  a	   supercoiled	  pCherry	  plasmid	   (to	  monitor	   transfection	   efficiency).	   	   The	   number	   in	   the	   top	   right	   corner	  corresponds	  to	  the	  percentage	  of	  cells	  that	  turned	  green	  after	  24	  hr	  as	  a	  percentage	  of	  the	  cells	  productively	  transfected.	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Figure	  3.	  	  The	  impact	  of	  C-­‐NHEJ	  mutations	  on	  end	  joining	  	  	  Four	   independent	   experiments	   comparable	   to	   those	   depicted	   in	   Figures	   2	   and	   4	  were	  performed	  and	  the	  average	  percent	  repair	  relative	  to	  wild	  type	  is	  shown	  with	  the	  standard	  deviation.	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Figure	  4.	  	  The	  loss	  of	  C-­‐NHEJ	  greatly	  reduces	  end	  joining	  	  	  The	   indicated	   cell	   lines	   were	   transfected	   with	   HindIII-­‐	   (Top	   panels)	   or	   I-­‐SceI-­‐	  (Bottom	   panels)	   linearized	   pEGFP-­‐Pem1-­‐Ad2	   plasmid	   together	   with	   a	   pCherry	  plasmid.	   	  The	  cells	  were	  analyzed	  by	  FACS	  24	  hr	  post	  transfection.	   	  The	  number	  of	  cells	  that	  were	  doubly	  EGFP	  (horizontal)	  and	  pCherry	  (vertical)	  positive	  versus	  the	  number	   that	  were	   pCherry	   positive	  was	   determined.	   	   For	   a	   given	   experiment	   the	  data	  are	  shown	  as	  percent	  repair	  in	  the	  upper	  right-­‐hand	  corner	  of	  each	  plot.	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Figure	  5.	  	  Ku86-­‐null	  cells	  show	  wild-­‐type	  levels	  of	  end	  joining	  activity	  	  	  (A)	  Western	  blot	  analysis	  shows	  that	  the	  expression	  of	  Cre	  (AdCre)	  in	  Ku86flox/-­‐	  cells	  results	  in	  the	  reduction	  of	  Ku86	  expression.	  	  AdCMV	  is	  a	  negative	  control	  adenoviral	  vector.	   	   (B)	   the	   indicated	   cell	   lines	   were	   transfected	   with	   either	   HindIII-­‐	   (Top	  panels)	   or	   I-­‐SceI-­‐	   (bottom	   panels)	   linearized	   pEGFP-­‐Pem1-­‐Ad2	   plasmid.	   	   All	  symbols	  are	  as	  in	  Figure	  4.	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Figure	  6.	  	  The	  absence	  of	  Ku86	  results	  in	  predominately	  microhomology-­‐based	  end	  joining	  	  	  (A)	  HindIII-­‐linearized	   pEGFP-­‐Pem1-­‐Ad2	   plasmids	  were	   recovered	   from	   either	  WT	  HCT116,	  Ku86+/-­‐	  or	  Ku86-­‐/-­‐	  cells,	  propagated	  through	  E.	  coli	  and	  then	  analyzed	  for	  retention	   of	   a	   single	   HindIII	   restriction	   site	   (“perfect	   rejoining”)	   by	   HindIII	  restriction	  enzyme	  digestion	  analysis.	  	  The	  asterisks	  indicate	  those	  plasmids	  where	  perfect	  rejoining	  occurred.	   	  (B)	  The	  results	  of	   four	  or	  more	  experiments	  similar	  to	  those	  depicted	  in	  (A)	  were	  combined	  and	  summarized.	  	  N.B.	  The	  re-­‐expression	  of	  a	  WT	  DNA-­‐PKcs	  or	  XLF	  cDNA	  (+cDNA)	   in	   their	   respective	  null	   cell	   lines	   reduced	   the	  frequency	   of	   perfect	   rejoining	   back	   to	  WT	   levels,	   confirming	   the	   specificity	   of	   the	  effect.	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Figure	   7.	   	   The	   reduction	   of	   Ku	   results	   in	   elevated	   levels	   of	   end	   joining	   in	   C-­‐NHEJ	  mutant	  cell	  lines	  	  	  (A)	  FACS	  profiles	  using	  the	  pEGFP-­‐Pem1-­‐Ad2	  reporter	  substrate	  are	  shown	  for	  the	  indicated	   cell	   lines.	   	   The	   profiles	   for	   the	   Top	   and	   Bottom	   panels	   were	   generated	  using	   HindIII-­‐	   and	   I-­‐SceI-­‐linearized	   plasmids,	   respectively.	   	   The	   percent	   of	   the	  substrate	   that	  was	  repaired	   is	  shown	  in	  the	  right-­‐hand	  corner	  of	  each	  profile.	   	   (B)	  Western	  blot	  analyses	  demonstrate	  a	  reduction	  in	  Ku	  protein	  levels.	  	  Western	  blots	  for	  extracts	  derived	  from	  the	  indicated	  cell	  lines	  are	  shown	  using	  antibodies	  against	  either	  Ku86,	   Ku70	   or	   (as	   a	   loading	   control)	   tubulin	   (Tub).	   	   Each	   of	   the	   blots	  was	  quantitated	  using	  a	  phosphoimager	  and	  the	  level	  of	  a	  particular	  Ku	  subunit	  relative	  to	  the	  amount	  expressed	   in	  the	  parental	  cell	   line	   is	   indicated	  below	  each	  blot.	   	   (C)	  Four	   independent	   experiments	   comparable	   to	   those	   depicted	   in	   panel	   A	   were	  performed	  and	  the	  average	  percent	  repair	  is	  shown	  with	  the	  standard	  deviation.	  	   	  
	   	   Fattah	  et	  al.	  
	   163	  
Figure	  8.	   	   Independent	  confirmation	  of	  microhomology-­‐mediated	  end	   joining	   in	  C-­‐NHEJ	  mutant	  cell	  lines	  	  	  (A)	   	  Reporter	  substrate	  biased	  for	  use	  by	  microhomology-­‐directed	  NHEJ	  (A-­‐NHEJ).	  	  The	  reporter	  has	  been	  designed	  such	  that	  cleavage	  with	  Eco47III	  and	  EcoRV	  results	  in	  a	  blunt-­‐ended	  linear	  substrate	  with	  6-­‐bp	  direct	  repeats	  (boxes)	  at	  both	  ends.	  	  C-­‐NHEJ	   joining	  will	   result	   in	   the	   retention	  of	   some	  of	   both	   repeats	  whereas	  A-­‐NHEJ	  should	   generate	   a	   single	   repeat,	   which	   is	   a	   substrate	   for	   BstXI.	   	   This	   figure	   is	  excerpted	  from	  Verkaik	  et	  al.,	  2002,	  Eur.	  J.	  Immunol.,	  32:701.	  	  (B)	  The	  experimental	  scheme	  for	  analysis	  of	  the	  plasmids	  recovered	  from	  transfected	  cells.	  	  The	  plasmids	  were	  subjected	  to	  PCR	  using	  one	  radiolabeled	  (asterisk)	  primer.	  	  The	  PCR	  products	  were	   then	   subjected	   to	   BstXI	   restriction	   enzyme	   digestion.	   	   (C-­‐F)	   Left	   Panels:	  Autoradiograms	   of	   representative	   microhomology	   assays	   using	   the	   indicated	   cell	  lines.	  	  The	  size	  of	  the	  primary	  PCR	  product	  (180	  bp)	  and	  the	  BstXI	  cleavage	  product	  (120	  bp)	  are	  indicated.	  	  Right	  Panels:	  	  Three	  independent	  experiments	  similar	  to	  the	  ones	  shown	  on	  the	  left	  were	  quantitated	  with	  a	  phosphoimager	  and	  averaged.	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Supporting	  Figure	  Legends	  Supporting	  Figure	  S1.	  Repair	  efficiency	  of	  heterozygous	  cell	  lines.	  The	  indicated	  cell	  lines	  were	  transfected	  with	  HindIII-­‐	  (Top	  panels)	  or	  I-­‐SceI-­‐	  (Bottom	  panels)	  linearized	  pEGFP-­‐Pem1-­‐	  Ad2	  together	  with	  a	  supercoiled	  pCherry	  plasmid	  (to	  monitor	  transfection	  efficiency).	  The	  number	  in	  the	  top	  right	  corner	  corresponds	  to	  the	  percentage	  of	  cells	  that	  turned	  green	  after	  24	  hr	  as	  a	  percentage	  of	  the	  cells	  productively	  transfected.	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Supporting	   Figure	   S2.	   Repair	   junction	   analysis	   of	  HindIII	   -­‐	   linearized	   plasmids	   for	  perfect	  joins.	  The	   data	   presented	   individually	   in	   Tables	   S1,	   S3,	   S5,	   and	   S7	   using	   the	   HindIII-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2-­‐lenearized	  plasmid	  was	  consolidated	  into	  4	  categories:	  perfect	   joins	   (dark	   rectangles),	   imperfect	   joins	   (light	   gray	   rectangles),	  microhomology	   (white	   rectangles),	   and	   insertions	   (dark	   gray	   rectangles)	   and	   is	  presented	  as	  the	  percentage	  of	  total	  events	  for	  each	  of	  the	  indicated	  cell	  lines.	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Supporting	   Figure	   S3.	   Repair	   junction	   analysis	   of	   I-­‐SceI	   -­‐	   linearized	   plasmids	   for	  perfect	  joins.	  The	  data	  presented	  individually	  in	  Tables	  S2,	  S4,	  S6,	  and	  S8	  using	  the	  I-­‐SceI-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2-­‐lenearized	  plasmid	  was	  consolidated	  into	  3	  categories:	  imperfect	  joins	  (light	  gray	  rectangles),	  microhomology	  (white	  rectangles)	  and	  insertions	  (dark	  gray	  rectangles)	  and	  is	  presented	  as	  the	  percentage	  of	  total	  events	  for	  each	  of	  the	  indicated	  cell	  lines.	  N.B.	  Perfect	  joining	  is	  not	  possible	  with	  this	  substrate.	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Supporting	   Figure	   S4.	   Sequence	   analysis	   of	   repair	   junctions	   of	  HindIII	   -­‐	   linearized	  plasmids	  for	  deletions.	  The	  data	  presented	  individually	  in	  Tables	  S1,	  S3,	  S5,	  and	  S7	  using	  the	  HindIII-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2-­‐lenearized	  plasmid	  was	  analyzed	  only	  for	  deletions.	  Each	  dot	  represents	  an	  individual	  data	  point	  and	  some	  dots	  overlap.	  The	  mean	  (dark	  rectangle)	  and	  the	  median	  (gray	  rectangle)	  are	  shown	  for	  each	  of	  the	  indicated	  cell	  lines.	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Supporting	   Figure	   S5.	   Sequence	   analysis	   of	   repair	   junctions	   of	  HindIII	   -­‐	   linearized	  plasmids	  for	  deletions.	  The	  data	  presented	  individually	  in	  Tables	  S2,	  S4,	  S6,	  and	  S8	  using	  the	  I-­‐SceI-­‐linearized	  pEGFP-­‐Pem1-­‐Ad2-­‐lenearized	  plasmid	  was	  analyzed	  only	  for	  deletions.	  Each	  dot	  represents	  an	  individual	  data	  point	  and	  some	  dots	  overlap.	  The	  mean	  (dark	  rectangle)	  and	  the	  median	  (gray	  rectangle)	  are	  shown	  for	  each	  of	  the	  indicated	  cell	  lines.	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   S2.	   Sequence	   analysis	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Final	  Discussion	  
	  
CtIP,	  EXO1,	  and	  DNA2	  are	  essential	  genes	  in	  human	  cells	  	  	   DNA	  resection	  is	  a	  highly	  conserved	  biological	  process	  that	  generates	  ssDNA	  from	  dsDNA,	  and	  is	  catalyzed	  by	  nucleases.	  	  DNA	  resection	  is	  a	  critical	  process	  that	  links	  DNA	  damage	   to	   cell	   cycle	   checkpoint	   activation,	  which	   is	   key	   to	   the	   survival	  and	  fitness	  of	  an	  organism1.	  	  Furthermore,	  DNA	  resection	  is	  required	  for	  HR2	  and	  for	  generating	   the	   ssDNA	   that	   forms	   protective	   t-­‐loops	   at	   the	   ends	   of	   telomeres3.	  	  Notably,	   hypomorphic	   CtIP	  mutations	   in	   humans	   have	   been	   identified	   in	   patients	  with	   Seckel	   or	   Jawad	   syndrome	   who	   suffer	   from	   microcephaly	   and	   growth	  retardation4.	   	   The	   majority	   of	   studies	   on	   human	   CtIP,	   EXO1	   and	   DNA2	   have	  depended	  on	  siRNA	  knockdowns	  and	  only	  addressed	  gene	  function	  in	  the	  context	  of	  DSB	   repair	   responding	   to	   exogenous	   DNA	   damaging	   agents5-­‐12.	   	   Although	   these	  studies	  have	  significantly	  contributed	  to	  the	  field,	  they	  fail	  to	  address	  if	  these	  genes	  are	   essential	   in	   human	   cells	   and	   if	   so	   what	   their	   essential	   function(s)	   in	   an	  unperturbed	   cell	   may	   be.	   	   Therefore,	   we	   constructed	   CtIPF/-­‐:CreERt2,	   EXO1F/-­‐:CreERt2,	   and	   DNA2F/-­‐/-­‐:CreERt2	   conditionally-­‐null	   human	   somatic	   HCT116	   cell	  lines	  that	  are	  also	  equipped	  with	  a	  CreERt2,	  tamoxifen-­‐inducible	  system.	  	  	   My	  initial	  postulation	  was	  that	  CtIP	  and	  EXO1	  would	  not	  be	  essential	  genes	  because	   humans	   with	   hypomorphic	   CtIP	  mutations	   and	   EXO1	   knockout	   mice	   are	  viable.	   	   With	   this	   information,	   it	   seemed	   safe	   to	   assume	   that	   human	   cells	   would	  survive	  without	  CtIP	  or	  EXO1,	  and	  I	  attempted	  to	  construct	  CtIP-­‐/-­‐	  and	  EXO1-­‐/-­‐	  null	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human	  cell	  lines	  as	  models	  for	  my	  study.	  	  After	  targeting	  the	  first	  allele,	  my	  attempts	  to	  target	  the	  second	  allele	  of	  either	  CtIP	  or	  EXO1	  only	  resulted	  in	  retargeting	  of	  the	  initially	   targeted	   allele	   such	   that	   one	   WT	   allele	   always	   remained.	   	   The	   strong	  disequilibrium	  in	   favor	  of	  retargeting	  strongly	  suggested	  that	  CtIP	  and	  EXO1	  were	  essential.	  	  Therefore,	  I	  had	  to	  reconfigure	  my	  approach	  and	  construct	  conditionally-­‐null	   cell	   lines	   for	   these	   genes.	   	  With	   the	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cell	  lines,	   I	   found	  that	   these	  cells	  could	  not	  survive	   in	   the	  presence	  of	   tamoxifen.	   	  This	  data	  was	  completely	  consistent	  with	  my	  initial	  observation	  that	  CtIP	  and	  EXO1	  are	  essential	  genes.	  	  	  We	   and	   our	   collaborators,	   Dr.	   Judith	   Campbell	   and	   Sheila	   Stewart	   of	  California	   Institute	   of	   Technology	   and	   Washington	   University	   in	   St.	   Louis,	  respectively,	  greatly	  desired	  a	  DNA2-­‐null	  cell	   line	  for	  similar	  studies.	   	  Learning	  the	  fates	  of	  my	  CtIP-­‐	  and	  EXO1-­‐	  gene	  targeting	  studies,	  I	  decided	  to	  directly	  construct	  a	  DNA2	   conditionally-­‐null	   cell	   line.	   	   Unfortunately,	   I	  was	   delayed	   in	   generating	   this	  cell	  line	  because	  DNA2	  turned	  our	  to	  be	  triploid	  in	  the	  HCT116	  cell	  line.	  	  HCT116	  is	  often	  used	  for	  gene	  targeting	  studies	  because	  it	  is	  diploid,	  but	  it	  does	  carry	  several	  small	   chromosomal	   duplications.	   	   Unfortunately	   the	   DNA2	   locus	   falls	   into	   one	   of	  these	  intervals.	  Ultimately,	   I	   constructed	  a	  DNA2F/-­‐/-­‐:CreERt2	  cell	   line.	   	  Like	  CtIP	  and	  EXO1,	  DNA2	  conditionally-­‐null	  cells	  did	  not	  proliferate	  in	  the	  presence	  of	  tamoxifen.	  	  Due	  to	   the	   delay	   in	   cell	   line	   construction,	   I	   was	   not	   able	   to	   investigate	   DNA2	   as	  extensively	  as	  CtIP	  and	  EXO1.	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The	  HCT116	  cell	   line	   is	  mismatch	  repair	  deficient	  due	  to	  a	  null	  mutation	   in	  MLH113.	   	  This	  raised	  a	  concern	  that	  the	  lethality	  of	  CtIP	  and	  EXO	  may	  be	  synthetic	  with	  MLH1,	  which	  would	  mean	  any	  data	  produced	  from	  this	  study	  would	  be	  cell	  line	  specific	   and	   less	   generally	   biologically,	   relevant.	   	   Therefore,	   I	   constructed	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cell	   lines	   that	   stably	   expressed	   a	   complementing	  wild-­‐type	  MLH1	  cDNA.	   	  With	  these	  cells,	  I	  was	  able	  to	  show	  that	  MLH1-­‐expressing	  HCT116	   cells	   still	   cannot	   survive	   without	   CtIP	   and	   EXO1.	   	   Additionally,	   I	   have	  preliminary	   data	   demonstrating	   that	   DNA2	   is	   also	   not	   synthetically	   lethal	   with	  MLH1.	   	   In	   toto,	   CtIP	   or	   EXO1	   is	   clearly	   not	   synthetically	   lethal	   with	   the	   absence	  MLH1,	  and	  consequently	  any	  results	  are	  not	  cell	  line	  specific.	  	  	  My	   novel	   findings	   show	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	   essential	   genes	   in	  human	   cells.	   	   This	   data	   clearly	   suggest	   that	   either	   DNA	   resection	   is	   an	   essential	  activity	  in	  human	  cells	  or	  that	  CtIP,	  EXO1	  and	  DNA2	  have	  other	  functions	  required	  to	  keep	  cells	  alive.	   	  While	   it	   is	   clear	   that	   the	   inactivation	  of	  CtIP,	  EXO1,	  and	  DNA2	  with	  tamoxifen	  results	  in	  cell	  death,	  an	  advantage	  of	  my	  experimental	  system	  is	  that	  the	   cells	   die	   slowly	   and	   a	   generous	   window	   of	   time	   was	   available	   for	   me	   to	  investigate	  the	  novel	  phenotypes.	  	  The	   inactivation	   of	   CtIP	   and	   EXO1	  with	   tamoxifen,	   resulted	   in	   very	   similar	  severe	   phenotypes.	   	   In	   general,	   I	   acquired	   data	   after	   1,	   3,	   5,	   and/or	   7	   days	   after	  tamoxifen	  treatment	  such	  that	  a	  temporal	  view	  of	  the	  phenotypes	  could	  be	  acquired	  after	   the	   inactivation	   of	   expression	   CtIP	   or	   EXO1.	   	   Importantly,	   the	   findings	   here	  were	  observed	  in	  unperturbed	  cells	  without	  any	  exposure	  to	  DNA	  damaging	  agents.	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The	  essential	  functions	  of	  CtIP	  and	  EXO1	  After	  inactivating	  CtIP	  and	  EXO1,	  I	  initially	  found	  that	  p53	  levels	  were	  highly	  elevated,	  which	   is	   consistent	  with	  many	   studies	   that	   show	   that	   CtIP	   and	   EXO1	   is	  required	   for	  genome	  stability5,9,10.	   	  Extending	   this	  study,	   I	   found	  elevated	   levels	  of	  chromosomal	  breaks,	  fragmentations,	  radial	  chromosomes,	  and	  extreme	  aneuploidy	  in	   CtIP-­‐	   and	   EXO1-­‐null	   cells.	   	   Furthermore,	   during	   the	   analysis	   we	   noticed	  many	  fusion	   events	   but	   their	   complex	   structures	  were	   too	   difficult	   to	   analyze	   and	   thus	  they	  were	  omitted	  from	  the	  dataset.	  	  The	  more	  compelling	  aspect	  of	  our	  study	  is	  the	  CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cells	   were	   never	   exposed	   to	   DNA	   damaging	  agents.	  	  It	  is	  clear	  that	  the	  genetic	  inactivation	  of	  CtIP	  or	  EXO1	  triggers	  severe	  DNA	  damage	  in	  an	  unperturbed	  cell.	  In	  unperturbed	  cells,	  DNA	  replication	  is	  the	  major	  source	  of	  DNA	  damage14,15,	  which	   led	   me	   to	   hypothesize	   that	   the	   loss	   of	   CtIP	   and	   EXO1	   was	   affecting	   DNA	  replication	  such	  that	  it	  leads	  to	  severe	  DNA	  damage.	  	  Therefore,	  I	  carried	  out	  several	  DNA	  replication	  assays	  to	  test	  my	  hypothesis.	  With	  the	  EdU	  incorporation	  assay,	   I	  was	  able	  to	  acquire	  a	  temporal	  view	  of	  cell-­‐cycle	  profiles	  after	   inactivating	  CtIP	  or	  EXO1	  with	   tamoxifen.	   	   I	   found	  that	   the	  inactivation	  of	  CtIP	   and	  EXO1	   triggered	   continuous	  DNA	   replication	   initiation	   and	  DNA	   synthesis.	   	   The	   continuous	   DNA	   synthesis	   resulted	   in	   extremely	   high	   DNA	  content,	   which	   was	   consistent	   with	   the	   aneuploid	   cells	   found	   in	   the	   karyotype	  analysis.	  	  Extending	  this	  study,	  I	  performed	  DNA	  fiber	  assays	  on	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  to	  measure	  DNA	  replication	  tract	  lengths	  as	  a	  measure	  of	  DNA	  replication	  fork	  progression	   or	   velocity.	   	   The	   inactivation	   of	   CtIP	   and	   EXO1	   resulted	   in	   severely	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shortened	  replication	  tract	  lengths	  over	  time.	  	  These	  findings	  strongly	  indicated	  that	  CtIP	   and	   EXO1	   are	   directly	   involved	   in	   DNA	   replication.	   	   In	   retrospect,	   this	   is	  probably	  not	  surprising	  since	  CtIP	  and	  EXO1	  have	  a	  PIP	  box	  domain	  that	   interacts	  with	  PCNA.	  From	   the	   immunofluorescence	   and	   chromatin	   fractionation	   experiments,	   I	  found	  that	  the	  inactivation	  of	  CtIP	  and	  EXO1	  triggered	  severe	  DNA	  replication	  fork	  stalling.	  	  These	  stalled	  forks	  eventually	  collapsed	  into	  DSBs	  that	  were	  then	  repaired	  by	  NHEJ.	  	  In	  these	  cells	  I	  found	  elevated	  levels	  of	  FANCD2	  and	  RPA	  nuclear	  foci,	  and	  chromatin	  recruitment.	  	  Additionally,	  I	  also	  found	  that	  modified	  PCNA	  accumulated	  to	   extremely	   high	   levels	   over	   time	   in	   the	   chromatin	   fractions.	   	   Together,	   these	  observations	  indicate	  that	  the	  inactivation	  of	  CtIP	  and	  EXO1	  strongly	  triggers	  stalled	  replication	   forks	   that	   persist	   over	   days	   because	   they	   cannot	   restart.	   	   Indeed,	   the	  high	   levels	   of	   γH2AX	   foci	   is	   consistent	   with	   the	   conclusion	   that	   the	   stalled	  replication	  forks	  are	  not	  resolved	  and	  collapse	  into	  DSBs.	  	  In	  addition,	  the	  persistent	  53BP1	   nuclear	   foci	   and	   chromatin	   recruitment	   strongly	   suggests	   that	   NHEJ	   is	  actively	   repairing	   these	   DSBs,	   which,	   in	   turn,	   that	   results	   in	   the	   aberrant	  chromosomes	   seen	   in	   the	   karyotype	   analysis.	   	   Further	   corroborating	  my	   findings,	  the	   loss	  of	  CtIP	  and	  EXO1	   triggered	   the	  phosphorylation	  of	  CHK2T68	  and	  ATMS1981.	  	  These	   modified	   proteins	   are	   hallmarks	   of	   an	   activated	   checkpoint	   and	   strongly	  suggests	  that	  DSBs	  are	  activating	  the	  ATM-­‐CHK2	  pathway,	  which	  can	  be	  a	  promoter	  of	  NHEJ	  repair16.	  	  	  Finally,	  I	  analyzed	  WCE	  and	  chromatin	  fractions	  by	  western	  analysis.	   	   I	  was	  able	  make	  several	  novel	  findings.	  	  I	  found	  that	  CtIP	  and	  EXO1	  are	  co-­‐regulated	  such	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that	   inactivating	   either	   of	   these	   genes	   results	   in	   the	  down	   regulation	   of	   the	   other	  one.	  	  Interestingly,	  the	  inactivation	  of	  CtIP	  or	  EXO1	  also	  triggered	  the	  degradation	  of	  FANCD2,	   BRCA2,	   Rad51,	   and	   CHK1.	   	   The	   degradation	   of	   these	   proteins	   is	   a	   novel	  finding,	   and	   shows	   that	   DNA	   resection	   connects	   the	   HR	   and	   FA	   pathways.	  	  Moreover,	  this	  data	  shows	  that	  the	  lack	  of	  DNA	  resection	  effectively	  disables	  the	  FA,	  HR,	  and	  ATR-­‐CHK1	  pathways.	  	  	  All	  of	  these	  findings	  are	  connected	  to	  to	  each	  other	  by	  previous	  studies:	  1)	  CHK1-­‐,	   and	   BRCA2-­‐	   deficient	   cells	   increase	   DNA	   replication	   initiation	   and	   have	  severely	   short	   replication	   tracts17Daboussi:2008kr},	   2)	   chronic	   genotoxic	   stress	  leads	   to	   CHK1	   degradation18,	   3)	   In	   HR-­‐compromised	   cells	   53BP1	   promotes	   NHEJ	  repair	  of	  DSBs,	  which	  leads	  to	  aberrant	  chromosomes19.	  Collectively,	   the	   data	   I	   have	   generated	   show	   that	   CtIP	   and	   EXO1	   are	  intimately	  involved	  in	  DNA	  replication.	  	  In	  unperturbed	  cells,	  DNA	  replication	  forks	  eventually	   run	   into	   repetitive	   regions	   that	   cause	   them	   to	   stall.	   	   The	   ATR-­‐CHK1	  pathway	   is	   activated	  which	   in	   turn	   stabilizes	   the	   stalled	   forks	   and	   recruit	   factors	  that	   restart	   the	  stalled	   forks	   (e.g.	  FANCD2,	  BRCA2,	  and	  Rad51).	   	  CtIP	  and	  EXO	  are	  closely	  associated	  to	  the	  replication	  forks,	  presumably	  through	  docking	  onto	  PCNA.	  	  The	  close	  proximity	  of	  CtIP	  and	  EXO1	  permits	  swifter	  end	  resection	  on	  the	  stalled	  forks,	   which	   creates	   access	   for	   FANCD2,	   BRCA2	   and	   Rad51	   to	   restart	   the	   stalled	  forks	  in	  timely	  manner.	  	  	  However,	   in	   the	   absence	   of	   CtIP	   and	   EXO1,	   stalled	   replication	   forks	   are	  unable	  to	  restart	  because	  the	  FANCD2,	  BRCA2	  and	  Rad51	  cannot	  access	  the	  stalled	  forks.	  	  As	  the	  stalled	  forks	  persist	  over	  time,	  CHK1	  is	  under	  constant	  activation	  that	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leads	  to	  its	  rapid	  degradation,	  with	  insufficient	  time	  for	  recovery.	   	  As	  a	  result,	  ATR	  cannot	  stabilize	  the	  stalled	  forks	  without	  CHK1	  and	  the	  forks	  are	  now	  susceptible	  to	  collapse.	   	   Moreover,	   since	   the	   absence	   of	   CtIP	   and	   EXO1	   lead	   to	   degradation	   of	  BRCA2	  and	  Rad51,	  the	  HR	  pathway	  is	  also	  essentially	  non-­‐functional;	  therefore,	  the	  cell	   is	   left	  to	  repair	  DSBs	  with	  NHEJ	  as	  mirrored	  with	  the	  elevated	  levels	  of	  53BP1	  nuclear	  foci.	  
	  
	  
DNA2	  is	  also	  co-­‐regulated	  with	  CtIP	  and	  EXO1	  CtIP	   initiates	  DSB	   resection	  with	  minimal	   processing	   of	   the	  DNA	  ends,	   and	  then	  EXO1	  and	  DNA2	  are	   recruited	   for	   the	   subsequent	   extensive	   resection,	  which	  generates	  the	  long	  stretches	  of	  ssDNA	  for	  HR.	  	  It	  has	  been	  clear	  that	  these	  nucleases	  participate	  in	  the	  same	  pathway;	  however,	  it	  has	  never	  been	  shown	  how	  these	  three	  genes	  genetically	  interact	  in	  human	  cells.	  The	   CtIPF/-­‐:CreERt2	   and	   EXO1F/-­‐:CreERt2	   cell	   lines	   have	   proven	   to	   be	  powerful	  human	  cell	  genetic	  models.	  	  With	  them,	  I	  was	  able	  to	  determine	  the	  fates	  of	  cells	   in	   the	   absence	   of	   CtIP	   or	   EXO1,	   and	   to	   determine	   the	   genetic	   interaction	  between	  CtIP	   and	  EXO1.	   	  However,	   the	   addition	   of	   the	  DNA2F/-­‐/-­‐:CreERt2	   cell	   line	  allowed	  me	  to	  shed	  even	  more	  light	  on	  how	  this	  trio	  of	  nucleases	  genetically	  interact	  with	  each	  other.	  With	  the	  DNA2F/-­‐/-­‐:CreERt2	  cell	  line,	  I	  was	  able	  to	  show	  that	  CtIP,	  EXO1,	  and	  DNA2	   are	   co-­‐regulated;	   the	   inactivation	   of	   any	   one	   of	   the	   3	   genes	   results	   in	   the	  downregulation	  of	  the	  other	  2	  genes.	  	  Furthermore,	  I	  also	  found	  that	  the	  inactivation	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of	   DNA2	   also	   results	   in	   the	   degradation	   of	   FANCD2,	   BRCA2,	   Rad51,	   and	   CHK1.	  	  Therefore,	  the	  3	  nucleases	  coordinately	  regulate	  HR	  and	  FA.	  	  	  Since	  these	  phenotypes	  have	  never	  been	  observed	  before,	  we	  thought	  that	  it	  would	  important	  to	  recapitulate	  these	  findings	  in	  another	  cell	  line.	  	  In	  collaboration	  with	  Dr.	   Jung	  Eun	   from	   the	  Sobeck	   laboratory,	  Dr.	  Eun	  knocked	  down	  CtIP,	  EXO1,	  and	   DNA2	   in	   the	   GM637	   cell	   line	   (immortalized,	   human	   fibroblast20)	  with	   siRNA.	  	  She	  also	  found	  that	  CtIP,	  EXO1,	  and	  DNA2	  are	  co-­‐regulated;	  and	  the	  three	  nucleases	  also	  coordinately	  regulate	  FANCD2.	  	  These	  results	  are	  consistent	  with	  my	  findings	  in	  the	  HCT116	  cell	  line	  and	  emphasize	  that	  the	  coordinate	  regulation	  of	  FANCD2	  is	  not	  specific	  to	  the	  HCT116	  cell	  line.	  In	  conclusion,	  I	  have	  constructed	  three	  genetic	  models	  in	  order	  to	  study	  the	  roles	   of	   DNA	   resection	   in	   human	   cells.	   	   I	   found	   that	   CtIP,	   EXO1,	   and	   DNA2	   are	  epistatic,	   and	   that	   they	   are	   essential	   genes	   in	   human	   cells.	   	   Furthermore,	   I	  demonstrated	   that	   CtIP	   and	   EXO1	   are	   required	   for	   normal	   DNA	   replication	   fork	  progression.	  	  In	  their	  absence,	  DNA	  replication	  forks	  inevitably	  stall	  with	  no	  means	  of	  restarting	  and	  eventually	  collapse	  into	  DSBs.	  	  In	  order	  to	  survive,	  the	  cell	  relies	  on	  the	  remaining	  DSB	  repair	  pathway,	  NHEJ,	  which	  results	  in	  the	  formation	  of	  aberrant	  chromosomes.	  Collaborating	   with	   Dr.	   Farjana	   Fattah,	   a	   previous	   graduate	   student	   in	   our	  laboratory,	  we	  utilized	  a	  series	  of	  isogenic	  mutant	  cell	  lines	  that	  were	  disrupted	  for	  Ku,	   DNA-­‐PKcs,	   XLF,	   and	   LIGIV	   (C-­‐NHEJ	   factors)	   to	   investigate	   their	   impact	   on	   the	  spectrum	   of	   end-­‐joining	   repair	   in	   human	   somatic	   cells.	   	   This	   investigation	   was	  facilitated	  by	  well-­‐characterized	   in	  vivo	   end-­‐joining	  plasmid	   assays21	   to	  determine	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the	  overall	  end	  joining	  competence	  of	  a	  cell;	  and	  another	  end-­‐joining	  plasmid-­‐based	  assay,	   which	   measured	   microhomology	   usage	   in	   the	   repair	   junction22.	   	   In	   the	  absence	   of	   DNA-­‐PKcs,	   XLF,	   and	   LIGIV	   end-­‐joining	   activity	   was	   severely	  compromised;	  and	  sequencing	  of	  the	  plasmids	  were	  rescued	  from	  cells	  revealed	  that	  the	  A-­‐NHEJ	  pathway	  predominantly	  uses	  microhomology	  for	  repair.	   	  Furthermore,	  our	   experiments	   showed	   that	   Ku	   is	   the	  master	   regulator	   of	  NHEJ	   pathway	   choice	  and	   is	   important	   for	   protecting	   DNA	   ends	   from	   degradation.	   	   In	   conclusion,	   this	  work	  helped	  elucidate	  how	  A-­‐NHEJ	  is	  regulated	  in	  human	  somatic	  cells.	  
	  
	  
Future	  Directions	  	  
Characterization	  of	  DNA2-­‐null	  cells	  Since	   the	   construction	   of	   the	   DNA2F/-­‐/-­‐	   cell	   line	   was	   delayed,	   their	  characterization	   is	   still	   incomplete	   and	   this	   should	   be	   the	   next	   priority.	   	   The	  remaining	   experiments	   required	   to	   achieve	   a	   similar	   depth	   of	   characterization	   as	  the	  CtIP-­‐	  and	  EXO1-­‐null	  cells	  are:	  1)	  growth	  curves	  and	  MLH1	  complementation,	  2)	  EdU	   incorporation	   assay,	   3)	   karyotype	   analysis,	   4)	   DNA	   fiber	   assays,	   5)	  immunofluorescence,	   and	   6)	   western	   analysis	   of	   WCE	   and	   chromatin	   fractions.	  	  Accomplishing	   these	   experiments	  will	   paint	   a	   stronger	   picture	   of	   how	   this	   trio	   of	  nucleases	  functions	  in	  a	  cell.	  	  	  
Complementation	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The	  next	  experiment	  for	  these	  studies	  is	  clearly	  to	  rescue	  the	  phenotypes	  of	  CtIP-­‐,	  EXO1-­‐,	  and	  DNA2-­‐null	  cells.	  	  I	  have	  made	  multiple	  attempts	  to	  complement	  the	  CtIPF/-­‐:CreERt2	  and	  EXO1F/-­‐:CreERt2	  cell	  lines	  with	  CtIP	  and	  EXO1	  either	  (EXO1a	  or	  EXO1b)	   cDNA	   expression	   vectors	   driven	   by	   a	   CAG	   promoter,	   respectively.	  	  Unfortunately	   my	   efforts	   have	   never	   been	   successful,	   as	   the	   cells	   do	   not	   survive	  after	  inactivating	  CtIP	  or	  EXO1.	  	  This	  is	  likely	  due	  to	  poor	  or	  unregulated	  expression	  of	  the	  rescuing	  cDNAs.	  	  The	  next	  strategy	  should	  be	  to	  try	  other	  expression	  vectors	  and/or	   rescue	   the	  mutant	   cell	   lines	   by	   knocking	   back	   in	   a	   functional	   copy	   of	   the	  relevant	  gene.	  	  	  
Structure:	  function	  analyses	  There	  are	  no	  known	  patients	  with	  EXO1	  or	  DNA2	  mutations.	  	  However,	  there	  do	  exist	  patients	  with	  CtIP	  truncation	  mutations	  (Seckel	  and	  Jawad	  syndromes)	  that	  suffer	   from	   developmental	   abnormalities4.	   	   Generating	   knock-­‐in	   models	   of	   these	  patient	  mutations	  in	  the	  HCT116	  cell	  line	  would	  potentially	  allow	  us	  to	  understand	  the	   structure	   and	   function	   of	   CtIP	   in	   DNA	   replication,	   and	   its	   role	   in	   human	  development.	  	  	  	  
Are	   CtIP,	   EXO1,	   and	   DNA2	   involved	   in	   telomeric	   G-­‐overhang	  
synthesis?	  Several	   studies	   have	   implicated	   CtIP,	   EXO1,	   and	   DNA2	   are	   involved	   in	   telomere	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maintenance2,3,23.	   	   In	  yeast,	  SAE2	  (CtIP	   in	  humans),	  EXO1	  and	  DNA2	  have	  all	  been	  implicated	   in	  maintaining	  the	   length	  of	   telomeres.	   	  A	  recent	  study	   in	  mice	  showed	  that	   EXO1	   is	   responsible	   for	   generation	   of	   G-­‐overhangs	   that	   are	   required	   in	  telomeres	   to	   form	   the	   t-­‐loop	   complex,	  which	   protects	   the	   ends	   of	   chromosomes3.	  	  However,	   there	   have	   been	   no	   reports	   of	   human	   CtIP,	   EXO1,	   and	   DNA2	   being	  involved	  in	  maintaining	  telomere	  length	  or	  G-­‐overhang	  derivation.	  	  	  In	  collaboration	  with	  graduate	  student	  in	  our	  laboratory,	  Adam	  Harvey,	  we	  have	   preliminary	   data	   showing	   that	   CtIP-­‐,	   EXO1-­‐,	   and	   DNA2-­‐null	   cells	   have	  shortened	  telomeres;	  however,	  these	  cells	  also	  have	  high	  levels	  of	  DSBs.	  	  Since	  DSBs	  that	  occur	   in	   the	   telomeres	   can	  present	   themselves	   as	   shortened	   telomeres,	   these	  data	   must	   be	   viewed	   as	   very	   preliminary.	   	   Interestingly,	   however,	   we	   also	   have	  preliminary	   data	   showing	   that	   EXO1	   (but	   not	   CtIP	   nor	   DNA2)	   may	   generate	  telomeric	  3’	  G-­‐overhangs	  in	  human	  cells.	  	  These	  findings	  clearly	  need	  to	  be	  pursued	  and	   if	   they	   can	   be	   authenticated	   they	   would	   expand	   the	   functional	   repertoire	   of	  EXO1	  in	  human	  cell.	  	  
Are	   CtIP	   and	   EXO1	   required	   for	   DNA	   replication	   through	  
repetitive	  regions?	  The	  genomic	  landscape	  of	  human	  cell	  is	  wrought	  with	  obstacles	  for	  a	  moving	  replication	  fork.	  	  To	  determine	  if	  CtIP	  and	  EXO1	  are	  required	  to	  restart	  these	  stalled	  replication	   forks,	   we	   will	   use	   a	   technique	   called	   single	   molecule	   analysis	   of	  replicated	  DNA	  (SMARD)27.	   	  SMARD	  couples	  Southern	  blotting	  techniques	  with	  the	  DNA	  fiber	  assay,	  which	  allows	  the	  visualization	  of	  DNA	  replication	  tracts	  at	  the	  locus	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of	  interest.	  	  If	  the	  replication	  tract	  lengths	  of	  repetitive	  regions	  in	  CtIP-­‐	  or	  EXO1-­‐null	  cells	  are	  significantly	  different	  from	  wild-­‐type	  cells	  (with	  the	  appropriate	  controls),	  it	   would	   strengthen	   a	   model	   where	   CtIP	   and	   EXO1	   are	   required	   for	   proper	   DNA	  replication	  in	  repetitive	  regions.	  	  	  
Analysis	  of	  protein	  dynamics	  of	  replication	  forks	   in	  the	  absence	  
of	  CtIP,	  EXO1,	  or	  DNA2	  via	  iPOND	  I	  have	  found	  that	  the	   loss	  of	  CtIP	  or	  EXO1	  results	   in	  DNA	  replication-­‐related	  damage	  and	  the	  rapid	  degradation	  of	  FANCD2,	  BRCA2,	  Rad51,	  and	  CHK1.	  	  To	  further	  understand	   the	   pattern	   of	   recruitment	   of	   these	   factors	   to	   the	   replication	   forks	   in	  CtIP-­‐	  and	  EXO1-­‐null	  cells,	  I	  plan	  to	  isolate	  proteins	  on	  nascent	  DNA	  (iPOND)24-­‐26	  to	  monitor	  changes	  occurring	  at	  the	  replication	  fork.	  	  During	  DNA	  replication,	  EdU	  will	  be	   incorporated	   into	   the	  nascent	  strand.	   	  After	  a	  determined	  EdU	   incubation	  time,	  the	  cells	  are	  fixed	  with	  paraformaldehyde	  to	  crosslink	  the	  proteins	  on	  to	  the	  nascent	  strands	   containing	   EdU.	   	   Subsequently,	   EdU	   is	   covalently	   linked	   to	   alkyne-­‐Biotin	  molecules	  via	  a	  “click”	  reaction	  followed	  by	  lysis	  and	  sonication24.	  	  The	  proteins	  are	  then	   purified	   through	   a	   streptavidin	   column	   and	   can	   be	   analyzed	   by	   western	  analysis.	   	   Performing	   iPOND	   analysis	   in	   a	   time	   course	   after	   inactivating	   CtIP	   and	  EXO1	   with	   tamoxifen	   will	   provide	   insightful	   data	   on	   the	   evolution	   of	   replication	  forks	   in	   the	   absence	   of	   CtIP	   and	   EXO1.
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